{
  "conditions_to_closing": [
    {
      "section": "conditions_to_closing",
      "field_name": "mutual_conditions_list",
      "answer": [
        "The Company Stockholder Approval shall have been obtained.",
        "The Sodium Shares to be issued in the Merger as Equity Consideration shall have been approved for listing on the NYSE, subject to official notice of issuance.",
        "No Law shall have been entered, issued, enforced, promulgated, adopted or become effective that enjoins, prohibits, prevents or makes illegal the consummation of the Transactions.",
        "All waiting periods applicable to the Transactions under the HSR Act shall have expired or been terminated, and all clearances, consents and approvals under the Regulatory Laws shall have been obtained and shall remain in full force and effect.",
        "If determined required or warranted by Sodium, the CFIUS Approval shall have been obtained.",
        "The Registration Statement shall have been declared effective by the SEC under the Securities Act and no stop order suspending the effectiveness of the Registration Statement shall have been issued by the SEC."
      ],
      "summary": "The mutual conditions for closing include obtaining Company Stockholder Approval, NYSE listing approval for Sodium Shares, absence of legal prohibitions, expiration of HSR Act waiting periods, obtaining CFIUS Approval if required, and SEC effectiveness of the Registration Statement.",
      "confidence": 1.0,
      "reason": "",
      "clause_text": "The respective obligations of each party to effect the Merger shall be subject to the fulfillment (or waiver by all parties, to the extent permissible under applicable Law) at or prior to the Effective Time of the following conditions: (a) The Company Stockholder Approval shall have been obtained. (b) The Sodium Shares to be issued in the Merger as Equity Consideration shall have been approved for listing on the NYSE, subject to official notice of issuance. (c) No Law shall have been entered, issued, enforced, promulgated, adopted or become effective, in each case, that enjoins, prohibits, prevents or makes illegal the consummation of the Transactions... (f) The Registration Statement shall have been declared effective by the SEC under the Securities Act and no stop order suspending the effectiveness of the Registration Statement shall have been issued by the SEC and no proceedings for that purpose shall have been initiated or threatened by the SEC.",
      "reference_section": "ARTICLE Article VII CONDITIONS TO THE MERGER > Section 7.1 Conditions to Each Party’s Obligation to Effect the Merger"
    },
    {
      "section": "conditions_to_closing",
      "field_name": "parent_closing_conditions",
      "answer": [
        "The representations and warranties of the Company set forth in Article III (excluding certain sections) must be true and correct as of the date of the Agreement and the Closing Date, except for immaterial inaccuracies.",
        "The Company must have performed all obligations and complied with all covenants required by the Agreement prior to the Effective Time.",
        "The Company must deliver a certificate, dated the Closing Date and signed by its Chief Executive Officer or another senior officer, certifying that the conditions in Section 7.3(a) and Section 7.3(b) have been satisfied.",
        "No Specified Regulatory Law shall be in effect that enjoins, prohibits, prevents, or makes illegal the consummation of the Transactions.",
        "No investigation of the Transactions under any Specified Regulatory Law shall have been commenced and be continuing.",
        "All waiting periods applicable following Sodium's determination to submit a registration, notification, or filing with respect to the Transactions under any Specified Regulatory Law shall have expired or been terminated.",
        "All clearances, consents, and approvals required under the Specified Filings shall have been obtained and remain in full force and effect.",
        "No Regulatory Law shall have been entered, issued, enforced, promulgated, adopted, or become effective after the date of this Agreement that enjoins, prohibits, prevents, or makes illegal the consummation of the Transactions."
      ],
      "summary": "The Parent's obligation to close the transaction is contingent upon the accuracy of the Company's representations, performance of obligations, delivery of a certificate, and the absence of legal impediments or ongoing investigations under specified regulatory laws.",
      "confidence": 1.0,
      "reason": "",
      "clause_text": "The obligation of Sodium, Sodium US and Merger Sub to effect the Merger is further subject to the fulfillment (or the waiver by Sodium, to the extent permitted under applicable Law) at or prior to the Effective Time of the following conditions: (a) The representations and warranties of the Company set forth in (i) Article III of this Agreement (other than in Section 3.2(a), Section 3.2(f), and Section 3.12(b)) shall be true and correct both as of the date of this Agreement and as of the Closing Date as though made as of the Closing Date, except where such failures to be so true and correct (without regard to \"materiality,\" Company Material Adverse Effect and similar qualifiers contained in such representations and warranties) would not, in the aggregate, reasonably be expected to have a Company Material Adverse Effect, (ii) Section 3.2(a) and Section 3.2(f) shall be true and correct as of the date of this Agreement and as of the Closing Date as though made as of the Closing Date, except for immaterial inaccuracies, and (iii) Section 3.12(b) shall be true and correct both as of the date of this Agreement and as of the Closing Date as though made as of the Closing Date; provided, however, that representations and warranties that are made as of a particular date or period shall be true and correct (in the manner set forth in clauses (i), (ii) and (iii), as applicable) only as of such date or period. (b) The Company shall have in all material respects performed all obligations and complied with all covenants required by this Agreement to be performed or complied with by it prior to the Effective Time. (c) The Company shall have delivered to Sodium a certificate, dated the Closing Date and signed by its Chief Executive Officer or another senior officer, certifying to the effect that the conditions set forth in Section 7.3(a) and Section 7.3(b) have been satisfied. (d) (i) No Regulatory Law set forth on Section 7.3(d) of the Company Disclosure Schedules (collectively, the \"Specified Regulatory Laws\") shall be in effect that enjoins, prohibits, prevents or makes illegal the consummation of the Transactions (any such Law, a \"Specified Legal Restraint\"); (ii) No investigation of the Transactions under any Specified Regulatory Law shall have been commenced and be continuing; (iii) All waiting periods (and any extensions thereof) applicable following Sodium's determination to submit a registration, notification or filing with respect to the Transactions under any Specified Regulatory Law (the \"Specified Filings\") and any commitment to, or agreement with, any Governmental Entity under or in connection with the Specified Filings to delay the consummation of, or not to consummate before a certain date, the Transactions, shall have expired or been terminated; (iv) All clearances, consents and approvals required under the Specified Filings shall have been obtained and shall remain in full force and effect; and (v) No Regulatory Law shall have been entered, issued, enforced, promulgated, adopted or become effective after the date of this Agreement: (1) That enjoins, prohibits, prevents or makes illegal the consummation of the Transactions; (2) Pursuant to which an investigation of the Transactions shall have been commenced and be continuing; (3) Under which an applicable waiting period (or extensions thereof) with respect to the Transactions or any commitment to, or agreement with, any Governmental Entity to delay the consummation of, or not to consummate before a certain date, the Transactions, shall be continuing; or (4) Under which any required clearance, consent or approval required shall not have been obtained or fail to remain in full force and effect.",
      "reference_section": "ARTICLE VII – CONDITIONS TO THE MERGER > Section 7.3 – Conditions to Obligation of Sodium, Sodium US and Merger Sub to Effect the Merger"
    },
    {
      "section": "conditions_to_closing",
      "field_name": "company_closing_conditions",
      "answer": [
        "The representations and warranties of Sodium, Sodium US and Merger Sub set forth in Article IV and Article V (excluding certain sections) must be true and correct as of the date of the Agreement and the Closing Date, except for immaterial inaccuracies.",
        "Sodium, Sodium US and Merger Sub must have performed all obligations and complied with all covenants required by the Agreement prior to the Effective Time.",
        "Sodium, Sodium US and Merger Sub must deliver a certificate, dated the Closing Date, certifying that the conditions in Section 7.2(a) and Section 7.2(b) have been satisfied."
      ],
      "summary": "The Company must ensure the accuracy of Sodium's representations, compliance with obligations, and receive a certificate confirming these conditions.",
      "confidence": 1.0,
      "reason": "",
      "clause_text": "The obligation of the Company to effect the Merger is further subject to the fulfillment (or waiver by the Company, to the extent permitted under applicable Law) at or prior to the Effective Time of the following conditions: (a) The representations and warranties of Sodium, Sodium US and Merger Sub set forth in (i) Article IV and Article V of this Agreement (other than in Section 4.2(a), Section 4.7, Section 5.2(a) and Section 5.10) shall be true and correct both as of the date of this Agreement and as of the Closing Date as though made as of the Closing Date, except where such failures to be so true and correct (without regard to \"materiality,\" Sodium Material Adverse Effect and similar qualifiers contained in such representations and warranties) would not, in the aggregate, reasonably be expected to have a Sodium Material Adverse Effect, (ii) Section 4.2(a) and Section 5.2(a) shall be true and correct both as of the date of this Agreement and as of the Closing Date as though made as of the Closing Date, except for any immaterial inaccuracies, and (iii) Section 4.7 and Section 5.10 shall be true and correct both as of the date of this Agreement and as of the Closing Date as though made as of the Closing Date; provided, however, that representations and warranties that are made as of a particular date or period shall be true and correct (in the manner set forth in clauses (i), (ii) or (iii), as applicable) only as of such date or period. (b) Sodium, Sodium US and Merger Sub shall have in all material respects performed all obligations and complied with all covenants required by this Agreement to be performed or complied with by each of them prior to the Effective Time. (c) Sodium, Sodium US and Merger Sub shall have delivered to the Company a certificate, dated the Closing Date and signed by the Chief Executive Officer or another senior officer of Sodium, certifying to the effect that the conditions set forth in Section 7.2(a) and Section 7.2(b) have been satisfied.",
      "reference_section": "ARTICLE Article VII CONDITIONS TO THE MERGER > Section 7.2 Conditions to Obligation of the Company to Effect the Merger"
    },
    {
      "section": "conditions_to_closing",
      "field_name": "target_shareholder_approval_required",
      "answer": true,
      "summary": "",
      "confidence": 1.0,
      "reason": "The agreement explicitly states that the Company Stockholder Approval shall have been obtained as a condition to effect the Merger.",
      "clause_text": "The respective obligations of each party to effect the Merger shall be subject to the fulfillment (or waiver by all parties, to the extent permissible under applicable Law) at or prior to the Effective Time of the following conditions: (a) The Company Stockholder Approval shall have been obtained.",
      "reference_section": "ARTICLE Article VII CONDITIONS TO THE MERGER > Section 7.1 Conditions to Each Party’s Obligation to Effect the Merger > (a)"
    },
    {
      "section": "conditions_to_closing",
      "field_name": "target_shareholder_approval_threshold",
      "answer": "Not found",
      "summary": "",
      "confidence": 1.0,
      "reason": "",
      "clause_text": "",
      "reference_section": ""
    },
    {
      "section": "conditions_to_closing",
      "field_name": "parent_shareholder_approval_required",
      "answer": false,
      "summary": "",
      "confidence": 1.0,
      "reason": "There is no explicit requirement for the Parent to obtain shareholder approval as a condition to closing.",
      "clause_text": "The respective obligations of each party to effect the Merger shall be subject to the fulfillment (or waiver by all parties, to the extent permissible under applicable Law) at or prior to the Effective Time of the following conditions: (a) The Company Stockholder Approval shall have been obtained.",
      "reference_section": "ARTICLE Article VII CONDITIONS TO THE MERGER > Section 7.1 Conditions to Each Party’s Obligation to Effect the Merger"
    },
    {
      "section": "conditions_to_closing",
      "field_name": "parent_shareholder_approval_threshold",
      "answer": "Not found",
      "summary": "",
      "confidence": 1.0,
      "reason": "",
      "clause_text": "",
      "reference_section": ""
    },
    {
      "section": "conditions_to_closing",
      "field_name": "hsr_clearance_required",
      "answer": true,
      "summary": "",
      "confidence": 1.0,
      "reason": "The agreement explicitly includes the expiration or termination of waiting periods under the HSR Act as a condition to closing.",
      "clause_text": "All waiting periods (and any extensions thereof) applicable to the Transactions under the HSR Act, and any commitment to, or agreement with, any Governmental Entity under or in connection with the Regulatory Laws set forth on Section 7.1(d) of the Company Disclosure Schedules to delay the consummation of, or not to consummate before a certain date, the Transactions, shall have expired or been terminated, and all clearances, consents and approvals under the Regulatory Laws set forth on Section 7.1(d) of the Company Disclosure Schedules shall have been obtained and shall remain in full force and effect.",
      "reference_section": "ARTICLE Article VII CONDITIONS TO THE MERGER > Section 7.1 Conditions to Each Party’s Obligation to Effect the Merger > (d)"
    },
    {
      "section": "conditions_to_closing",
      "field_name": "other_customary_conditions",
      "answer": [
        "The Company Stockholder Approval shall have been obtained.",
        "The Sodium Shares to be issued in the Merger as Equity Consideration shall have been approved for listing on the NYSE, subject to official notice of issuance.",
        "No Law shall have been entered, issued, enforced, promulgated, adopted or become effective, in each case, that enjoins, prohibits, prevents or makes illegal the consummation of the Transactions.",
        "All waiting periods (and any extensions thereof) applicable to the Transactions under the HSR Act shall have expired or been terminated.",
        "All clearances, consents and approvals under the Regulatory Laws set forth on Section 7.1(d) of the Company Disclosure Schedules shall have been obtained and shall remain in full force and effect.",
        "The Registration Statement shall have been declared effective by the SEC under the Securities Act and no stop order suspending the effectiveness of the Registration Statement shall have been issued by the SEC and no proceedings for that purpose shall have been initiated or threatened by the SEC."
      ],
      "summary": "The conditions to closing include obtaining Company Stockholder Approval, listing approval for Sodium Shares, absence of legal prohibitions, expiration of HSR Act waiting periods, obtaining necessary regulatory clearances, and effectiveness of the SEC Registration Statement.",
      "confidence": 1.0,
      "reason": "",
      "clause_text": "The respective obligations of each party to effect the Merger shall be subject to the fulfillment (or waiver by all parties, to the extent permissible under applicable Law) at or prior to the Effective Time of the following conditions: (a) The Company Stockholder Approval shall have been obtained. (b) The Sodium Shares to be issued in the Merger as Equity Consideration shall have been approved for listing on the NYSE, subject to official notice of issuance. (c) No Law shall have been entered, issued, enforced, promulgated, adopted or become effective, in each case, that enjoins, prohibits, prevents or makes illegal the consummation of the Transactions...",
      "reference_section": "ARTICLE Article VII CONDITIONS TO THE MERGER > Section 7.1 Conditions to Each Party’s Obligation to Effect the Merger"
    },
    {
      "section": "conditions_to_closing",
      "field_name": "financial_conditions_minimum_cash_threshold",
      "answer": "Not found",
      "summary": "",
      "confidence": 1.0,
      "reason": "",
      "clause_text": "",
      "reference_section": ""
    },
    {
      "section": "conditions_to_closing",
      "field_name": "financial_conditions_maximum_net_debt",
      "answer": "Not found",
      "summary": "",
      "confidence": 1.0,
      "reason": "",
      "clause_text": "",
      "reference_section": ""
    },
    {
      "section": "conditions_to_closing",
      "field_name": "financial_conditions_minimum_any_condition",
      "answer": "Not found",
      "summary": "",
      "confidence": 1.0,
      "reason": "",
      "clause_text": "",
      "reference_section": ""
    },
    {
      "section": "conditions_to_closing",
      "field_name": "tax_conditions_tax_opinion_required",
      "answer": "NA",
      "summary": "",
      "confidence": 1.0,
      "reason": "",
      "clause_text": "",
      "reference_section": ""
    }
  ],
  "material_adverse_effect": {
    "mae_carveout": [
      {
        "section": "material_adverse_effect",
        "field_name": "mae_carveout_general_economic_conditions_included",
        "answer": true,
        "summary": "",
        "confidence": 1.0,
        "reason": "The MAE definition explicitly excludes adverse effects resulting from actions taken at the written request of Sodium, Sodium US, or Merger Sub.",
        "clause_text": "any taking of any action or failure to take any action, in either case, as required by this Agreement or taken (or omitted to be taken) at the written request of Sodium, Sodium US or Merger Sub",
        "reference_section": "ARTICLE Article IX MISCELLANEOUS > Section 9.16 Definitions > Company Material Adverse Effect"
      },
      {
        "section": "material_adverse_effect",
        "field_name": "mae_carveout_general_economic_conditions_explanation",
        "answer": "Adverse effects resulting from general economic conditions are excluded from the definition of Material Adverse Effect.",
        "summary": "Adverse effects resulting from general economic conditions, such as changes in the economy, financial markets, interest rates, or inflation, are excluded from the definition of Material Adverse Effect.",
        "confidence": 0.95,
        "reason": "The clause explicitly states that changes in or generally affecting the economy, financial, credit or securities markets, or political, legislative or regulatory conditions are excluded from being considered a Material Adverse Effect.",
        "clause_text": "Company Material Adverse Effect means any event, change, effect, development or occurrence that has had, or would be reasonably expected to have, either individually or in the aggregate, a material adverse effect on the business, property, assets, financial condition or results of operations of the Company and its Subsidiaries, taken as a whole, other than any event, change, effect, development, circumstance, condition or occurrence resulting from, relating to or arising out of ... (G) changes in or generally affecting the economy, the financial, credit or securities markets, or political, legislative or regulatory conditions, in each case in the United States or elsewhere in the world, including any changes in currency exchange rate, interest rates, monetary policy or inflation ...",
        "reference_section": "ARTICLE Article IX MISCELLANEOUS > Section 9.16 Definitions > Company Material Adverse Effect"
      },
      {
        "section": "material_adverse_effect",
        "field_name": "mae_carveout_industry_conditions_included",
        "answer": true,
        "summary": "",
        "confidence": 1.0,
        "reason": "The MAE definition explicitly excludes changes affecting the industry in which the Company operates from constituting a Material Adverse Effect.",
        "clause_text": "Company Material Adverse Effect means any event, change, effect, development or occurrence that has had, or would be reasonably expected to have, either individually or in the aggregate, a material adverse effect on the business, property, assets, financial condition or results of operations of the Company and its Subsidiaries, taken as a whole, other than any event, change, effect, development, circumstance, condition or occurrence resulting from, relating to or arising out of (A) any changes or developments in the natural gas gathering, compressing, treating, processing and transportation industry generally...",
        "reference_section": "ARTICLE Article IX MISCELLANEOUS > Section 9.16 Definitions > Company Material Adverse Effect"
      },
      {
        "section": "material_adverse_effect",
        "field_name": "mae_carveout_industry_conditions_explanation",
        "answer": "any changes or developments in the natural gas gathering, compressing, treating, processing and transportation industry generally",
        "summary": "The MAE definition excludes changes or developments in the natural gas industry from being considered a material adverse effect.",
        "confidence": 1.0,
        "reason": "",
        "clause_text": "Company Material Adverse Effect means any event, change, effect, development or occurrence that has had, or would be reasonably expected to have, either individually or in the aggregate, a material adverse effect on the business, property, assets, financial condition or results of operations of the Company and its Subsidiaries, taken as a whole, other than any event, change, effect, development, circumstance, condition or occurrence resulting from, relating to or arising out of (A) any changes or developments in the natural gas gathering, compressing, treating, processing and transportation industry generally...",
        "reference_section": "ARTICLE Article IX MISCELLANEOUS > Section 9.16 Definitions > Company Material Adverse Effect"
      },
      {
        "section": "material_adverse_effect",
        "field_name": "mae_carveout_stock_price_changes_included",
        "answer": true,
        "summary": "",
        "confidence": 1.0,
        "reason": "The MAE definition explicitly excludes changes in the Company's stock price or trading volume from constituting a Material Adverse Effect.",
        "clause_text": "any changes in the share price or trading volume of the Company Common Stock or in the credit rating of the Company or any of its Subsidiaries (provided, that the exception in this clause (K) shall not prevent or otherwise affect a determination that any event, change, effect, development or occurrence underlying such change has resulted in, or contributed to, a Company Material Adverse Effect)",
        "reference_section": "ARTICLE Article IX MISCELLANEOUS > Section 9.16 Definitions > Company Material Adverse Effect"
      },
      {
        "section": "material_adverse_effect",
        "field_name": "mae_carveout_stock_price_changes_explanation",
        "answer": "Changes in the share price or trading volume of the Company Common Stock are excluded from the definition of Company Material Adverse Effect.",
        "summary": "The clause explicitly excludes changes in the share price or trading volume of the Company Common Stock from being considered a Company Material Adverse Effect.",
        "confidence": 0.95,
        "reason": "The clause explicitly states that changes in the share price or trading volume of the Company Common Stock are not considered a Company Material Adverse Effect.",
        "clause_text": "Company Material Adverse Effect means any event, change, effect, development or occurrence that has had, or would be reasonably expected to have, either individually or in the aggregate, a material adverse effect on the business, property, assets, financial condition or results of operations of the Company and its Subsidiaries, taken as a whole, other than any event, change, effect, development, circumstance, condition or occurrence resulting from, relating to or arising out of ... (K) any changes in the share price or trading volume of the Company Common Stock or in the credit rating of the Company or any of its Subsidiaries (provided, that the exception in this clause (K) shall not prevent or otherwise affect a determination that any event, change, effect, development or occurrence underlying such change has resulted in, or contributed to, a Company Material Adverse Effect).",
        "reference_section": "ARTICLE Article IX MISCELLANEOUS > Section 9.16 Definitions > Company Material Adverse Effect"
      },
      {
        "section": "material_adverse_effect",
        "field_name": "mae_carveout_credit_rating_changes_included",
        "answer": true,
        "summary": "",
        "confidence": 1.0,
        "reason": "The MAE definition explicitly excludes changes in credit ratings from constituting a Material Adverse Effect.",
        "clause_text": "any changes in the share price or trading volume of the Company Common Stock or in the credit rating of the Company or any of its Subsidiaries (provided, that the exception in this clause (K) shall not prevent or otherwise affect a determination that any event, change, effect, development or occurrence underlying such change has resulted in, or contributed to, a Company Material Adverse Effect)",
        "reference_section": "ARTICLE Article IX MISCELLANEOUS > Section 9.16 Definitions > Company Material Adverse Effect"
      },
      {
        "section": "material_adverse_effect",
        "field_name": "mae_carveout_credit_rating_changes_explanation",
        "answer": "Changes in the credit rating of the Company or any of its Subsidiaries are excluded from the definition of Company Material Adverse Effect.",
        "summary": "Changes in the credit rating of the Company or any of its Subsidiaries are excluded from the definition of Company Material Adverse Effect.",
        "confidence": 0.9,
        "reason": "The clause explicitly states that changes in credit rating are excluded from being considered a Company Material Adverse Effect.",
        "clause_text": "Company Material Adverse Effect means any event, change, effect, development or occurrence that has had, or would be reasonably expected to have, either individually or in the aggregate, a material adverse effect on the business, property, assets, financial condition or results of operations of the Company and its Subsidiaries, taken as a whole, other than ... (K) any changes in the share price or trading volume of the Company Common Stock or in the credit rating of the Company or any of its Subsidiaries ...",
        "reference_section": "ARTICLE Article IX MISCELLANEOUS > Section 9.16 Definitions > Company Material Adverse Effect"
      },
      {
        "section": "material_adverse_effect",
        "field_name": "mae_carveout_legal_or_regulatory_changes_included",
        "answer": true,
        "summary": "",
        "confidence": 1.0,
        "reason": "The MAE definition explicitly excludes changes in laws, regulations, GAAP, or accounting principles from constituting a Material Adverse Effect.",
        "clause_text": "Company Material Adverse Effect means any event, change, effect, development or occurrence that has had, or would be reasonably expected to have, either individually or in the aggregate, a material adverse effect on the business, property, assets, financial condition or results of operations of the Company and its Subsidiaries, taken as a whole, other than any event, change, effect, development, circumstance, condition or occurrence resulting from, relating to or arising out of ... (E) changes or proposed changes in laws, rules or regulations of general applicability to companies in the industries in which the Company and any of its Subsidiaries operate, or interpretations thereof by courts or Governmental Entities, (F) any changes in GAAP or accounting standards or interpretations thereof ...",
        "reference_section": "ARTICLE Article IX MISCELLANEOUS > Section 9.16 Definitions > Company Material Adverse Effect"
      },
      {
        "section": "material_adverse_effect",
        "field_name": "mae_carveout_legal_or_regulatory_changes_explanation",
        "answer": "changes or proposed changes in laws, rules or regulations of general applicability to companies in the industries in which the Company and any of its Subsidiaries operate, or interpretations thereof by courts or Governmental Entities",
        "summary": "The MAE definition excludes changes in laws, rules, or regulations of general applicability to companies in the relevant industries.",
        "confidence": 1.0,
        "reason": "",
        "clause_text": "changes or proposed changes in laws, rules or regulations of general applicability to companies in the industries in which the Company and any of its Subsidiaries operate, or interpretations thereof by courts or Governmental Entities",
        "reference_section": "ARTICLE Article IX MISCELLANEOUS > Section 9.16 Definitions > Company Material Adverse Effect"
      },
      {
        "section": "material_adverse_effect",
        "field_name": "mae_carveout_force_majeure_events_included",
        "answer": true,
        "summary": "",
        "confidence": 1.0,
        "reason": "The MAE definition explicitly excludes acts of God, natural disasters, and weather-related events from constituting a Material Adverse Effect.",
        "clause_text": "Company Material Adverse Effect means any event, change, effect, development or occurrence that has had, or would be reasonably expected to have, either individually or in the aggregate, a material adverse effect... other than any event, change, effect, development, circumstance, condition or occurrence resulting from, relating to or arising out of... (I) any hurricane, cyclone, tornado, earthquake, flood, tsunami, natural disaster, act of God, weather-related events or other comparable events...",
        "reference_section": "ARTICLE Article IX MISCELLANEOUS > Section 9.16 Definitions > Company Material Adverse Effect"
      },
      {
        "section": "material_adverse_effect",
        "field_name": "mae_carveout_force_majeure_events_explanation",
        "answer": "The definition of Material Adverse Effect excludes acts of God, natural disasters, or weather-related events.",
        "summary": "The definition of Company Material Adverse Effect explicitly excludes events such as hurricanes, cyclones, tornadoes, earthquakes, floods, tsunamis, natural disasters, acts of God, and weather-related events.",
        "confidence": 1.0,
        "reason": "The clause explicitly lists these events as exceptions to the definition of Material Adverse Effect.",
        "clause_text": "any hurricane, cyclone, tornado, earthquake, flood, tsunami, natural disaster, act of God, weather-related events or other comparable events, including any natural or man-made disasters or from any outbreak of any disease, pandemic, any quarantine or similar applicable Laws, directives, guidelines or recommendations promulgated by any industry group or any Governmental Entity or other public health events or outbreak or escalation of hostilities or war (whether or not declared), geopolitical conditions, military actions or any act of sabotage or terrorism, or national or international political or social conditions",
        "reference_section": "ARTICLE Article IX MISCELLANEOUS > Section 9.16 Definitions > Company Material Adverse Effect"
      },
      {
        "section": "material_adverse_effect",
        "field_name": "mae_carveout_political_events_or_war_included",
        "answer": true,
        "summary": "",
        "confidence": 1.0,
        "reason": "The MAE definition explicitly excludes acts of war, terrorism, military conflict, or geopolitical instability from constituting a Material Adverse Effect.",
        "clause_text": "Company Material Adverse Effect means any event, change, effect, development or occurrence that has had, or would be reasonably expected to have, either individually or in the aggregate, a material adverse effect on the business, property, assets, financial condition or results of operations of the Company and its Subsidiaries, taken as a whole, other than any event, change, effect, development, circumstance, condition or occurrence resulting from, relating to or arising out of ... outbreak or escalation of hostilities or war (whether or not declared), geopolitical conditions, military actions or any act of sabotage or terrorism, or national or international political or social conditions...",
        "reference_section": "ARTICLE Article IX MISCELLANEOUS > Section 9.16 Definitions > Company Material Adverse Effect"
      },
      {
        "section": "material_adverse_effect",
        "field_name": "mae_carveout_political_events_or_war_explanation",
        "answer": "Not found",
        "summary": "",
        "confidence": 1.0,
        "reason": "",
        "clause_text": "",
        "reference_section": ""
      },
      {
        "section": "material_adverse_effect",
        "field_name": "mae_carveout_pandemic_health_events_included",
        "answer": true,
        "summary": "The MAE definition explicitly excludes pandemics, epidemics, or public health emergencies from being considered a material adverse effect.",
        "confidence": 0.95,
        "reason": "The clause explicitly lists pandemics, quarantines, and public health events as exceptions to the definition of a Company Material Adverse Effect.",
        "clause_text": "Company Material Adverse Effect means any event, change, effect, development or occurrence that has had, or would be reasonably expected to have, either individually or in the aggregate, a material adverse effect...other than any event, change, effect, development, circumstance, condition or occurrence resulting from...any outbreak of any disease, pandemic, any quarantine or similar applicable Laws, directives, guidelines or recommendations promulgated by any industry group or any Governmental Entity or other public health events...",
        "reference_section": "ARTICLE Article IX MISCELLANEOUS > Section 9.16 Definitions > Company Material Adverse Effect"
      },
      {
        "section": "material_adverse_effect",
        "field_name": "mae_carveout_pandemic_health_events_explanation",
        "answer": "Not found",
        "summary": "",
        "confidence": 1.0,
        "reason": "",
        "clause_text": "",
        "reference_section": ""
      },
      {
        "section": "material_adverse_effect",
        "field_name": "mae_carveout_agreement_compliance_effects_included",
        "answer": true,
        "summary": "",
        "confidence": 1.0,
        "reason": "The MAE definition explicitly excludes effects resulting from the announcement, existence, compliance with, or performance under the merger agreement from constituting a Material Adverse Effect.",
        "clause_text": "Company Material Adverse Effect means any event, change, effect, development or occurrence that has had, or would be reasonably expected to have, either individually or in the aggregate, a material adverse effect on the business, property, assets, financial condition or results of operations of the Company and its Subsidiaries, taken as a whole, other than any event, change, effect, development, circumstance, condition or occurrence resulting from, relating to or arising out of ... (C) the announcement or the existence of, compliance with or performance under, this Agreement or the Transactions...",
        "reference_section": "ARTICLE Article IX MISCELLANEOUS > Section 9.16 Definitions > Company Material Adverse Effect"
      },
      {
        "section": "material_adverse_effect",
        "field_name": "mae_carveout_agreement_compliance_effects_explanation",
        "answer": "The clause excludes effects resulting from the negotiation, execution, or announcement of the merger agreement from the MAE definition.",
        "summary": "The MAE definition excludes effects resulting from the announcement, existence, compliance with, or performance under the merger agreement or transactions.",
        "confidence": 0.9,
        "reason": "The clause explicitly states that effects from the announcement or existence of the agreement are excluded from the MAE definition.",
        "clause_text": "Company Material Adverse Effect means any event, change, effect, development or occurrence that has had, or would be reasonably expected to have, either individually or in the aggregate, a material adverse effect on the business, property, assets, financial condition or results of operations of the Company and its Subsidiaries, taken as a whole, other than any event, change, effect, development, circumstance, condition or occurrence resulting from, relating to or arising out of ... (C) the announcement or the existence of, compliance with or performance under, this Agreement or the Transactions...",
        "reference_section": "ARTICLE Article IX MISCELLANEOUS > Section 9.16 Definitions > Company Material Adverse Effect"
      },
      {
        "section": "material_adverse_effect",
        "field_name": "mae_carveout_parent_actions_included",
        "answer": true,
        "summary": "",
        "confidence": 1.0,
        "reason": "The MAE definition excludes adverse effects caused by actions or omissions of the Parent or its Affiliates if taken at the written request of Sodium, Sodium US, or Merger Sub.",
        "clause_text": "any taking of any action or failure to take any action, in either case, as required by this Agreement or taken (or omitted to be taken) at the written request of Sodium, Sodium US or Merger Sub",
        "reference_section": "ARTICLE IX MISCELLANEOUS > Section 9.16 Definitions > Company Material Adverse Effect"
      },
      {
        "section": "material_adverse_effect",
        "field_name": "mae_carveout_parent_actions_explanation",
        "answer": "Adverse effects resulting from actions taken by the Company at the written request of Sodium, Sodium US, or Merger Sub are excluded from the definition of Material Adverse Effect.",
        "summary": "Adverse effects resulting from actions taken by the Company at the written request of Sodium, Sodium US, or Merger Sub are excluded from the definition of Material Adverse Effect.",
        "confidence": 0.95,
        "reason": "The clause explicitly states that actions taken at the written request of Sodium, Sodium US, or Merger Sub are excluded from being considered a Material Adverse Effect.",
        "clause_text": "any taking of any action or failure to take any action, in either case, as required by this Agreement or taken (or omitted to be taken) at the written request of Sodium, Sodium US or Merger Sub",
        "reference_section": "ARTICLE Article IX MISCELLANEOUS > Section 9.16 Definitions > Company Material Adverse Effect"
      },
      {
        "section": "material_adverse_effect",
        "field_name": "mae_carveout_projections_miss_included",
        "answer": true,
        "summary": "",
        "confidence": 1.0,
        "reason": "The MAE definition explicitly excludes failures to meet projections, forecasts, estimates, or internal budgets from constituting a Material Adverse Effect.",
        "clause_text": "any failure by the Company to meet any internal or external financial projections or forecasts or estimates of revenues, earnings or other financial metrics for any period (provided, that the exception in this clause (J) shall not prevent or otherwise affect a determination that any event, change, effect, circumstance, condition, development or occurrence underlying such failure has resulted in, or contributed to, a Company Material Adverse Effect)",
        "reference_section": "ARTICLE Article IX MISCELLANEOUS > Section 9.16 Definitions > Company Material Adverse Effect"
      },
      {
        "section": "material_adverse_effect",
        "field_name": "mae_carveout_projections_miss_explanation",
        "answer": "Failures to meet projections, forecasts, estimates, or internal budgets are excluded from the MAE definition.",
        "summary": "The clause explicitly states that any failure by the Company to meet financial projections, forecasts, or estimates is excluded from the definition of a Company Material Adverse Effect.",
        "confidence": 0.95,
        "reason": "The clause explicitly excludes failures to meet projections from the MAE definition.",
        "clause_text": "any failure by the Company to meet any internal or external financial projections or forecasts or estimates of revenues, earnings or other financial metrics for any period (provided, that the exception in this clause (J) shall not prevent or otherwise affect a determination that any event, change, effect, circumstance, condition, development or occurrence underlying such failure has resulted in, or contributed to, a Company Material Adverse Effect)",
        "reference_section": "ARTICLE Article IX MISCELLANEOUS > Section 9.16 Definitions > Company Material Adverse Effect"
      },
      {
        "section": "material_adverse_effect",
        "field_name": "mae_carveout_other_custom_items_present",
        "answer": false,
        "summary": "",
        "confidence": 1.0,
        "reason": "The document does not list any carve-outs beyond the standard exclusions provided in the prompt.",
        "clause_text": "Company Material Adverse Effect means any event, change, effect, development or occurrence that has had, or would be reasonably expected to have, either individually or in the aggregate, a material adverse effect on the business, property, assets, financial condition or results of operations of the Company and its Subsidiaries, taken as a whole, other than any event, change, effect, development, circumstance, condition or occurrence resulting from, relating to or arising out of (A) any changes or developments in the natural gas gathering, compressing, treating, processing and transportation industry generally...",
        "reference_section": "ARTICLE Article IX MISCELLANEOUS > Section 9.16 Definitions > Company Material Adverse Effect"
      },
      {
        "section": "material_adverse_effect",
        "field_name": "mae_carveout_other_custom_items",
        "answer": [
          {
            "label": "Failure to obtain approvals or consents",
            "excerpt": "the failure to obtain any approvals or consents from any Governmental Entity or other person in connection with the Transactions"
          }
        ],
        "summary": "",
        "confidence": 1.0,
        "reason": "",
        "clause_text": "",
        "reference_section": ""
      },
      {
        "section": "material_adverse_effect",
        "field_name": "standard_mae_carveouts_list",
        "answer": "(A) any changes or developments in the natural gas gathering, compressing, treating, processing and transportation industry generally, (B) any changes or developments in prices for oil, natural gas, condensate or natural gas liquids or other commodities or for the Company or any of its Subsidiaries' raw material inputs and end products, (C) the announcement or the existence of, compliance with or performance under, this Agreement or the Transactions (including the identity of Sodium and its Affiliates, the impact of the Transactions on the relationships, contractual or otherwise, of the Company or any of its Subsidiaries with employees, labor unions, customers, suppliers or partners, and any lawsuit, action or other proceeding with respect to the Transactions) (provided that the exceptions set forth in this clause (C) shall not apply in connection with any breach or inaccuracy of a representation or warranty set forth in this Agreement expressly addressing the consequences of the announcement or existence of, compliance with or performance under, this Agreement), (D) any taking of any action or failure to take any action, in either case, as required by this Agreement or taken (or omitted to be taken) at the written request of Sodium, Sodium US or Merger Sub, (E) changes or proposed changes in laws, rules or regulations of general applicability to companies in the industries in which the Company and any of its Subsidiaries operate, or interpretations thereof by courts or Governmental Entities, (F) any changes in GAAP or accounting standards or interpretations thereof, (G) changes in or generally affecting the economy, the financial, credit or securities markets, or political, legislative or regulatory conditions, in each case in the United States or elsewhere in the world, including any changes in currency exchange rate, interest rates, monetary policy or inflation, (H) any changes or developments in or affecting the industries in which the Company or any of its Subsidiaries operate, (I) any hurricane, cyclone, tornado, earthquake, flood, tsunami, natural disaster, act of God, weather-related events or other comparable events, including any natural or man-made disasters or from any outbreak of any disease, pandemic, any quarantine or similar applicable Laws, directives, guidelines or recommendations promulgated by any industry group or any Governmental Entity or other public health events or outbreak or escalation of hostilities or war (whether or not declared), geopolitical conditions, military actions or any act of sabotage or terrorism, or national or international political or social conditions (including the conflict between the Russian Federation and Ukraine and the conflict in Israel and the surrounding region) and any sanctions or similar actions relating thereto, (J) any failure by the Company to meet any internal or external financial projections or forecasts or estimates of revenues, earnings or other financial metrics for any period (provided, that the exception in this clause (J) shall not prevent or otherwise affect a determination that any event, change, effect, circumstance, condition, development or occurrence underlying such failure has resulted in, or contributed to, a Company Material Adverse Effect), (K) any changes in the share price or trading volume of the Company Common Stock or in the credit rating of the Company or any of its Subsidiaries (provided, that the exception in this clause (K) shall not prevent or otherwise affect a determination that any event, change, effect, development or occurrence underlying such change has resulted in, or contributed to, a Company Material Adverse Effect) and (L) the failure to obtain any approvals or consents from any Governmental Entity or other person in connection with the Transactions; except, in each case with respect to subclauses (A)-(B) and (E)-(I), solely to the extent disproportionately affecting the Company and its Subsidiaries, taken as a whole, relative to other similarly situated companies in the industries in which the Company and its Subsidiaries operate, in which case only such disproportionate effect shall be taken into account in determining whether there has been, or would be reasonably likely to be, a “Company Material Adverse Effect”.",
        "summary": "The agreement explicitly lists carve-outs to the definition of Material Adverse Effect, including industry changes, commodity price changes, compliance with the agreement, legal changes, economic conditions, natural disasters, and more, with certain exceptions for disproportionate effects.",
        "confidence": 1.0,
        "reason": "",
        "clause_text": "Company Material Adverse Effect means any event, change, effect, development or occurrence that has had, or would be reasonably expected to have, either individually or in the aggregate, a material adverse effect on the business, property, assets, financial condition or results of operations of the Company and its Subsidiaries, taken as a whole, other than any event, change, effect, development, circumstance, condition or occurrence resulting from, relating to or arising out of (A) any changes or developments in the natural gas gathering, compressing, treating, processing and transportation industry generally, (B) any changes or developments in prices for oil, natural gas, condensate or natural gas liquids or other commodities or for the Company or any of its Subsidiaries' raw material inputs and end products, (C) the announcement or the existence of, compliance with or performance under, this Agreement or the Transactions (including the identity of Sodium and its Affiliates, the impact of the Transactions on the relationships, contractual or otherwise, of the Company or any of its Subsidiaries with employees, labor unions, customers, suppliers or partners, and any lawsuit, action or other proceeding with respect to the Transactions) (provided that the exceptions set forth in this clause (C) shall not apply in connection with any breach or inaccuracy of a representation or warranty set forth in this Agreement expressly addressing the consequences of the announcement or existence of, compliance with or performance under, this Agreement), (D) any taking of any action or failure to take any action, in either case, as required by this Agreement or taken (or omitted to be taken) at the written request of Sodium, Sodium US or Merger Sub, (E) changes or proposed changes in laws, rules or regulations of general applicability to companies in the industries in which the Company and any of its Subsidiaries operate, or interpretations thereof by courts or Governmental Entities, (F) any changes in GAAP or accounting standards or interpretations thereof, (G) changes in or generally affecting the economy, the financial, credit or securities markets, or political, legislative or regulatory conditions, in each case in the United States or elsewhere in the world, including any changes in currency exchange rate, interest rates, monetary policy or inflation, (H) any changes or developments in or affecting the industries in which the Company or any of its Subsidiaries operate, (I) any hurricane, cyclone, tornado, earthquake, flood, tsunami, natural disaster, act of God, weather-related events or other comparable events, including any natural or man-made disasters or from any outbreak of any disease, pandemic, any quarantine or similar applicable Laws, directives, guidelines or recommendations promulgated by any industry group or any Governmental Entity or other public health events or outbreak or escalation of hostilities or war (whether or not declared), geopolitical conditions, military actions or any act of sabotage or terrorism, or national or international political or social conditions (including the conflict between the Russian Federation and Ukraine and the conflict in Israel and the surrounding region) and any sanctions or similar actions relating thereto, (J) any failure by the Company to meet any internal or external financial projections or forecasts or estimates of revenues, earnings or other financial metrics for any period (provided, that the exception in this clause (J) shall not prevent or otherwise affect a determination that any event, change, effect, circumstance, condition, development or occurrence underlying such failure has resulted in, or contributed to, a Company Material Adverse Effect), (K) any changes in the share price or trading volume of the Company Common Stock or in the credit rating of the Company or any of its Subsidiaries (provided, that the exception in this clause (K) shall not prevent or otherwise affect a determination that any event, change, effect, development or occurrence underlying such change has resulted in, or contributed to, a Company Material Adverse Effect) and (L) the failure to obtain any approvals or consents from any Governmental Entity or other person in connection with the Transactions; except, in each case with respect to subclauses (A)-(B) and (E)-(I), solely to the extent disproportionately affecting the Company and its Subsidiaries, taken as a whole, relative to other similarly situated companies in the industries in which the Company and its Subsidiaries operate, in which case only such disproportionate effect shall be taken into account in determining whether there has been, or would be reasonably likely to be, a “Company Material Adverse Effect”.",
        "reference_section": "ARTICLE Article IX MISCELLANEOUS > Section 9.16 Definitions > Company Material Adverse Effect"
      }
    ],
    "mae_carveback": [
      {
        "section": "material_adverse_effect",
        "field_name": "mae_carveback_disproportionate_effects_included",
        "answer": true,
        "summary": "",
        "confidence": 1.0,
        "reason": "The clause specifies that carve-outs are reintroduced if the Company is disproportionately affected compared to others in its industry.",
        "clause_text": "except, in each case with respect to subclauses (A)-(B) and (E)-(I), solely to the extent disproportionately affecting the Company and its Subsidiaries, taken as a whole, relative to other similarly situated companies in the industries in which the Company and its Subsidiaries operate, in which case only such disproportionate effect shall be taken into account in determining whether there has been, or would be reasonably likely to be, a 'Company Material Adverse Effect'.",
        "reference_section": "ARTICLE Article IX MISCELLANEOUS > Section 9.16 Definitions > Company Material Adverse Effect"
      },
      {
        "section": "material_adverse_effect",
        "field_name": "mae_carveback_disproportionate_effects_explanation",
        "answer": "Yes",
        "summary": "The MAE definition includes a carve-back stating that certain carve-outs do not apply if such events disproportionately affect the Company relative to others in its industry.",
        "confidence": 0.95,
        "reason": "The clause explicitly states that certain events will be considered a Company Material Adverse Effect if they disproportionately affect the Company compared to similar companies.",
        "clause_text": "except, in each case with respect to subclauses (A)-(B) and (E)-(I), solely to the extent disproportionately affecting the Company and its Subsidiaries, taken as a whole, relative to other similarly situated companies in the industries in which the Company and its Subsidiaries operate, in which case only such disproportionate effect shall be taken into account in determining whether there has been, or would be reasonably likely to be, a 'Company Material Adverse Effect'.",
        "reference_section": "ARTICLE Article IX MISCELLANEOUS > Section 9.16 Definitions > Company Material Adverse Effect"
      },
      {
        "section": "material_adverse_effect",
        "field_name": "mae_carveback_additional_exceptions_included",
        "answer": true,
        "summary": "",
        "confidence": 1.0,
        "reason": "The MAE clause specifies carve-outs are reintroduced under specific conditions, such as 'except, in each case with respect to subclauses (A)-(B) and (E)-(I), solely to the extent disproportionately affecting the Company'.",
        "clause_text": "except, in each case with respect to subclauses (A)-(B) and (E)-(I), solely to the extent disproportionately affecting the Company and its Subsidiaries, taken as a whole, relative to other similarly situated companies in the industries in which the Company and its Subsidiaries operate, in which case only such disproportionate effect shall be taken into account in determining whether there has been, or would be reasonably likely to be, a 'Company Material Adverse Effect'.",
        "reference_section": "ARTICLE Article IX MISCELLANEOUS > Section 9.16 Definitions > Company Material Adverse Effect"
      },
      {
        "section": "material_adverse_effect",
        "field_name": "mae_carveback_additional_exceptions_explanation",
        "answer": [
          "The exceptions in subclauses (A)-(B) and (E)-(I) are subject to a carve-back if they disproportionately affect the Company and its Subsidiaries relative to other similarly situated companies in the industries in which they operate. In such cases, only the disproportionate effect will be considered in determining a Company Material Adverse Effect.",
          "The exception in subclause (J) regarding the failure to meet financial projections does not prevent a determination that the underlying event has resulted in a Company Material Adverse Effect.",
          "The exception in subclause (K) regarding changes in share price or credit rating does not prevent a determination that the underlying event has resulted in a Company Material Adverse Effect."
        ],
        "summary": "",
        "confidence": 1.0,
        "reason": "",
        "clause_text": "",
        "reference_section": ""
      },
      {
        "section": "material_adverse_effect",
        "field_name": "mae_carveback_causation_based_analysis_included",
        "answer": true,
        "summary": "",
        "confidence": 1.0,
        "reason": "The MAE definition includes language indicating that underlying facts or occurrences contributing to changes in stock price or failure to meet projections may still be considered in determining a Material Adverse Effect.",
        "clause_text": "provided, that the exception in this clause (J) shall not prevent or otherwise affect a determination that any event, change, effect, circumstance, condition, development or occurrence underlying such failure has resulted in, or contributed to, a Company Material Adverse Effect",
        "reference_section": "ARTICLE Article IX MISCELLANEOUS > Section 9.16 Definitions > Company Material Adverse Effect"
      },
      {
        "section": "material_adverse_effect",
        "field_name": "mae_carveback_causation_based_analysis_explanation",
        "answer": "The facts or occurrences giving rise to an excluded event may still be taken into account in determining whether a Material Adverse Effect has occurred, specifically for clauses (J) and (K).",
        "summary": "The carve-back applies to clauses (J) and (K), which refer to failures to meet financial projections and changes in share price or credit rating.",
        "confidence": 0.9,
        "reason": "The clause explicitly states that the exceptions in clauses (J) and (K) do not prevent a determination of a Material Adverse Effect if the underlying events contributed to it.",
        "clause_text": "provided, that the exception in this clause (J) shall not prevent or otherwise affect a determination that any event, change, effect, circumstance, condition, development or occurrence underlying such failure has resulted in, or contributed to, a Company Material Adverse Effect... provided, that the exception in this clause (K) shall not prevent or otherwise affect a determination that any event, change, effect, development or occurrence underlying such change has resulted in, or contributed to, a Company Material Adverse Effect.",
        "reference_section": "ARTICLE IX MISCELLANEOUS > Section 9.16 Definitions > Company Material Adverse Effect"
      }
    ]
  },
  "non_solicitation": {
    "no_shop_clause": [
      {
        "section": "non_solicitation",
        "field_name": "no_shop_clause_included",
        "answer": true,
        "summary": "",
        "confidence": 1.0,
        "reason": "The agreement includes a 'No-Shop' clause that restricts the company from soliciting or encouraging alternative acquisition proposals.",
        "clause_text": "Except as permitted by this Section 6.4, from the date hereof and prior to the earlier of the Effective Time and the Termination Date, the Company shall not, and shall cause its Subsidiaries and its and their respective directors, officers, employees not to, and shall direct its and their other Representatives acting on its and their behalf not to, directly or indirectly: (i) solicit, initiate, seek or knowingly encourage or knowingly facilitate (including by way of furnishing non-public information) any proposal or offer or any inquiries regarding the making or submission of any proposal or offer...",
        "reference_section": "ARTICLE Article VI COVENANTS AND AGREEMENTS > Section 6.4 Company Non-Solicitation; Company Acquisition Proposals; Company Change of Recommendation > (a)"
      },
      {
        "section": "non_solicitation",
        "field_name": "no_shop_claus_explanation",
        "answer": "The Company is restricted from soliciting, initiating, or encouraging any acquisition proposals and from engaging in discussions or negotiations with third parties regarding such proposals, except under specific conditions outlined in Section 6.4.",
        "summary": "The Company is restricted from soliciting, initiating, or encouraging any acquisition proposals and from engaging in discussions or negotiations with third parties regarding such proposals, except under specific conditions outlined in Section 6.4.",
        "confidence": 0.95,
        "reason": "The clause explicitly prohibits the Company from engaging in activities related to acquisition proposals, with exceptions detailed in the section.",
        "clause_text": "Except as permitted by this Section 6.4, from the date hereof and prior to the earlier of the Effective Time and the Termination Date, the Company shall not, and shall cause its Subsidiaries and its and their respective directors, officers, employees not to, and shall direct its and their other Representatives acting on its and their behalf not to, directly or indirectly: (i) solicit, initiate, seek or knowingly encourage or knowingly facilitate (including by way of furnishing non-public information) any proposal or offer or any inquiries regarding the making or submission of any proposal or offer, including any proposal or offer to the Company's stockholders, that constitutes, or would reasonably be expected to lead to, a Company Acquisition Proposal; (ii) furnish any non-public information regarding the Company or any of its Subsidiaries or afford access to the business, properties, books or records of the Company or any of its Subsidiaries, to any person (other than Sodium, Sodium US, Merger Sub or their respective directors, officers, employees, Affiliates or Representatives) in furtherance of or in response to a Company Acquisition Proposal or any inquiries regarding a Company Acquisition Proposal; (iii) engage or participate in or otherwise knowingly facilitate any discussions or negotiations with any person (other than Sodium, Sodium US, Merger Sub or their respective directors, officers, employees, Affiliates or Representatives) regarding a Company Acquisition Proposal; (iv) approve, endorse or recommend (or publicly propose to approve, endorse or recommend) any inquiry, proposal or offer that constitutes, or would reasonably be expected to lead to, a Company Acquisition Proposal; (v) enter into any letter of intent, term sheet, memorandum of understanding, merger agreement, acquisition agreement, exchange agreement or duly execute any other agreement (whether binding or not) with respect to any inquiry, proposal or offer that (A) constitutes, or would reasonably be expected to lead to, a Company Acquisition Proposal, except for an Acceptable Confidentiality Agreement or (B) requires the Company to abandon, terminate or fail to consummate the Merger; (vi) unless the Company Board, or any committee thereof, concludes in good faith, after consultation with its outside legal counsel, that the failure to take such action would constitute a breach of its fiduciary duties under applicable Law, the Company Certificate of Incorporation or the Company Bylaws, amend or grant any waiver, release or modification under, or fail to enforce, any Takeover Law or any standstill or similar agreement with respect to any class of equity securities of the company or any of its Subsidiaries or (vii) resolve or agree to do any of the foregoing.",
        "reference_section": "ARTICLE VI – COVENANTS AND AGREEMENTS > Section 6.4 – Company Non-Solicitation; Company Acquisition Proposals; Company Change of Recommendation > (a)"
      }
    ],
    "notice_of_competing_offer": [
      {
        "section": "non_solicitation",
        "field_name": "notice_of_competing_offer_included",
        "answer": true,
        "summary": "",
        "confidence": 1.0,
        "reason": "The agreement explicitly requires the Company to promptly notify Sodium of any Company Acquisition Proposal.",
        "clause_text": "The Company shall promptly, and in no event later than twenty-four (24) hours after its or any of its Representatives' (acting on its behalf) receipt of any Company Acquisition Proposal or any inquiry or request for discussions or negotiations regarding a Company Acquisition Proposal or non-public information relating to the Company or any of its Subsidiaries regarding a Company Acquisition Proposal, advise Sodium (orally and in writing) of such Company Acquisition Proposal, inquiry or request...",
        "reference_section": "ARTICLE VI – COVENANTS AND AGREEMENTS > Section 6.4 – Company Non-Solicitation; Company Acquisition Proposals; Company Change of Recommendation > (d)"
      },
      {
        "section": "non_solicitation",
        "field_name": "notice_of_competing_offer_explanation",
        "answer": "The Company is required to promptly, and in no event later than twenty-four (24) hours after receipt, advise Sodium of any Company Acquisition Proposal, inquiry, or request, including providing the identity of the person making or submitting such proposal, and if it is in writing, a copy of such proposal, inquiry, or request and any related draft agreements, or if oral, a reasonably detailed summary of the material terms thereof.",
        "summary": "The Company must notify Sodium within 24 hours of receiving any Company Acquisition Proposal, including the identity of the proposer and details of the proposal.",
        "confidence": 0.95,
        "reason": "The clause explicitly requires the Company to notify Sodium of any Company Acquisition Proposal within a specified timeframe and with specific details.",
        "clause_text": "The Company shall promptly, and in no event later than twenty-four (24) hours after its or any of its Representatives' (acting on its behalf) receipt of any Company Acquisition Proposal or any inquiry or request for discussions or negotiations regarding a Company Acquisition Proposal or non-public information relating to the Company or any of its Subsidiaries regarding a Company Acquisition Proposal, advise Sodium (orally and in writing) of such Company Acquisition Proposal, inquiry or request (including providing the identity of the person making or submitting such Company Acquisition Proposal, and, (i) if it is in writing, a copy of such Company Acquisition Proposal, inquiry or request and any related draft agreements and (ii) if oral, a reasonably detailed summary of the material terms thereof), in each case including any modifications to the material terms thereof.",
        "reference_section": "ARTICLE Article VI COVENANTS AND AGREEMENTS > Section 6.4 Company Non-Solicitation; Company Acquisition Proposals; Company Change of Recommendation > (d)"
      }
    ],
    "ongoing_update": [
      {
        "section": "non_solicitation",
        "field_name": "ongoing_update_included",
        "answer": true,
        "summary": "",
        "confidence": 1.0,
        "reason": "The agreement requires the Company to keep Sodium informed of any changes to the material terms of any Company Acquisition Proposal.",
        "clause_text": "The Company shall keep Sodium informed in all material respects on a reasonably prompt basis with respect to any change to the material terms of any such Company Acquisition Proposal, including providing a copy of all documentation (including drafts) or material correspondence with respect thereof (and in no event later than twenty-four (24) hours following any such change, documentation or correspondence).",
        "reference_section": "ARTICLE VI – COVENANTS AND AGREEMENTS > Section 6.4 Company Non-Solicitation; Company Acquisition Proposals; Company Change of Recommendation > (d)"
      },
      {
        "section": "non_solicitation",
        "field_name": "ongoing_update_explanation",
        "answer": "The Company is obligated to promptly inform Sodium of any Company Acquisition Proposal or related inquiries, including any changes to the material terms, within twenty-four (24) hours.",
        "summary": "The Company must promptly update Sodium about any Company Acquisition Proposal or related inquiries, including changes to material terms, within twenty-four (24) hours.",
        "confidence": 0.9,
        "reason": "The clause specifies the timing and nature of updates required from the Company to Sodium regarding acquisition proposals.",
        "clause_text": "The Company shall promptly, and in no event later than twenty-four (24) hours after its or any of its Representatives' (acting on its behalf) receipt of any Company Acquisition Proposal or any inquiry or request for discussions or negotiations regarding a Company Acquisition Proposal or non-public information relating to the Company or any of its Subsidiaries regarding a Company Acquisition Proposal, advise Sodium (orally and in writing) of such Company Acquisition Proposal, inquiry or request (including providing the identity of the person making or submitting such Company Acquisition Proposal, and, (i) if it is in writing, a copy of such Company Acquisition Proposal, inquiry or request and any related draft agreements and (ii) if oral, a reasonably detailed summary of the material terms thereof), in each case including any modifications to the material terms thereof.",
        "reference_section": "ARTICLE VI COVENANTS AND AGREEMENTS > Section 6.4 Company Non-Solicitation; Company Acquisition Proposals; Company Change of Recommendation > (d)"
      }
    ],
    "superior_proposal_engagement": [
      {
        "section": "non_solicitation",
        "field_name": "superior_proposal_engagement_included",
        "answer": true,
        "summary": "",
        "confidence": 1.0,
        "reason": "The agreement allows the Company to engage in discussions or negotiations with a third party that submits a Superior Proposal under certain conditions.",
        "clause_text": "Notwithstanding anything to the contrary contained in this Section 6.4, at any time prior to obtaining the Company Stockholder Approval, the Company Board, directly or indirectly through any officer, employee or Representative, may (i) furnish non-public information regarding the Company or any of its Subsidiaries to, and afford access to the business, properties, books or records of the Company and any of its Subsidiaries to, any person and (ii) engage and participate in discussions and negotiations with any person, in each case in response to an unsolicited, written and bona fide Company Acquisition Proposal if (x) the Company Board, or any committee thereof, prior to taking any such particular action, concludes in good faith, after consultation with its financial advisors and outside legal counsel, that such unsolicited, written and bona fide Company Acquisition Proposal constitutes or could reasonably be expected to result in a Company Superior Offer...",
        "reference_section": "ARTICLE VI – COVENANTS AND AGREEMENTS > Section 6.4 – Company Non-Solicitation; Company Acquisition Proposals; Company Change of Recommendation > (b)"
      },
      {
        "section": "non_solicitation",
        "field_name": "superior_proposal_engagement_explanation",
        "answer": "The Company is authorized to engage with third parties if a Superior Proposal is received, provided that the Company Board concludes in good faith, after consultation with its financial advisors and outside legal counsel, that such proposal constitutes or could reasonably be expected to result in a Company Superior Offer.",
        "summary": "The Company may engage with third parties if a Superior Proposal is received, contingent on a good faith determination by the Company Board.",
        "confidence": 0.9,
        "reason": "The clause explicitly allows engagement with third parties if the Company Board determines a proposal could result in a Superior Offer.",
        "clause_text": "Notwithstanding anything to the contrary contained in this Section 6.4, at any time prior to obtaining the Company Stockholder Approval, the Company Board, directly or indirectly through any officer, employee or Representative, may (i) furnish non-public information regarding the Company or any of its Subsidiaries to, and afford access to the business, properties, books or records of the Company and any of its Subsidiaries to, any person and (ii) engage and participate in discussions and negotiations with any person, in each case in response to an unsolicited, written and bona fide Company Acquisition Proposal if (x) the Company Board, or any committee thereof, prior to taking any such particular action, concludes in good faith, after consultation with its financial advisors and outside legal counsel, that such unsolicited, written and bona fide Company Acquisition Proposal constitutes or could reasonably be expected to result in a Company Superior Offer...",
        "reference_section": "ARTICLE Article VI COVENANTS AND AGREEMENTS > Section 6.4 Company Non-Solicitation; Company Acquisition Proposals; Company Change of Recommendation > (b)"
      }
    ],
    "match_right": [
      {
        "section": "non_solicitation",
        "field_name": "match_right_initial_included",
        "answer": true,
        "summary": "",
        "confidence": 1.0,
        "reason": "The agreement grants the buyer a right to match an initial Superior Proposal by allowing Sodium to negotiate revisions to the terms of the Agreement.",
        "clause_text": "the Company shall negotiate in good faith with Sodium during such four (4) business day period (to the extent that Sodium desires to negotiate) to make such revisions to the terms of this Agreement, such that the Company Acquisition Proposal ceases to constitute a Company Superior Offer",
        "reference_section": "ARTICLE VI COVENANTS AND AGREEMENTS > Section 6.4 Company Non-Solicitation; Company Acquisition Proposals; Company Change of Recommendation > (g) > (ii) > (B)"
      },
      {
        "section": "non_solicitation",
        "field_name": "match_right_initial_explanation",
        "answer": "The Company provides Sodium four (4) business days prior written notice of its intention to take such action, which notice shall include the information with respect to such Company Superior Offer that is specified in Section 6.4(b), after providing such notice and prior to making such Company Change of Recommendation in connection with a Company Superior Offer, the Company shall negotiate in good faith with Sodium during such four (4) business day period (to the extent that Sodium desires to negotiate) to make such revisions to the terms of this Agreement, such that the Company Acquisition Proposal ceases to constitute a Company Superior Offer.",
        "summary": "The clause provides the Buyer with a four-business-day period to negotiate and revise its offer after receiving a Superior Proposal, following written notice from the Company.",
        "confidence": 0.95,
        "reason": "The clause explicitly outlines the negotiation period and the requirement for written notice.",
        "clause_text": "The Company provides Sodium four (4) business days prior written notice of its intention to take such action, which notice shall include the information with respect to such Company Superior Offer that is specified in Section 6.4(b), after providing such notice and prior to making such Company Change of Recommendation in connection with a Company Superior Offer, the Company shall negotiate in good faith with Sodium during such four (4) business day period (to the extent that Sodium desires to negotiate) to make such revisions to the terms of this Agreement, such that the Company Acquisition Proposal ceases to constitute a Company Superior Offer.",
        "reference_section": "ARTICLE Article VI COVENANTS AND AGREEMENTS > Section 6.4 Company Non-Solicitation; Company Acquisition Proposals; Company Change of Recommendation > (g)"
      },
      {
        "section": "non_solicitation",
        "field_name": "match_right_amended_included",
        "answer": true,
        "summary": "",
        "confidence": 1.0,
        "reason": "The agreement provides a renewed right to match if the third party modifies its Superior Proposal, as indicated by the requirement to comply again with Section 6.4(g) upon modification.",
        "clause_text": "provided that, in the event that the Company Acquisition Proposal is thereafter modified by the party making such Company Acquisition Proposal, the Company shall provide written notice of such modified Company Acquisition Proposal and shall again comply with this Section 6.4(g), except that the required four (4) business day period for notice, negotiation and consideration in clauses (A), (B) and (C) of this Section 6.4(g) shall be shortened to a two (2) business day period in each instance.",
        "reference_section": "ARTICLE Article VI COVENANTS AND AGREEMENTS > Section 6.4 Company Non-Solicitation; Company Acquisition Proposals; Company Change of Recommendation > (g)"
      },
      {
        "section": "non_solicitation",
        "field_name": "match_right_amended_explanation",
        "answer": "The agreement permits the Buyer to respond to a modified or revised Superior Proposal by providing a written notice of such modified Company Acquisition Proposal and complying with a shortened two (2) business day period for notice, negotiation, and consideration.",
        "summary": "The agreement allows the Buyer to respond to a modified Superior Proposal with a two (2) business day period for notice, negotiation, and consideration.",
        "confidence": 0.9,
        "reason": "The clause explicitly mentions the process for responding to a modified Company Acquisition Proposal, including a shortened negotiation period.",
        "clause_text": "provided that, in the event that the Company Acquisition Proposal is thereafter modified by the party making such Company Acquisition Proposal, the Company shall provide written notice of such modified Company Acquisition Proposal and shall again comply with this Section 6.4(g), except that the required four (4) business day period for notice, negotiation and consideration in clauses (A), (B) and (C) of this Section 6.4(g) shall be shortened to a two (2) business day period in each instance.",
        "reference_section": "ARTICLE Article VI COVENANTS AND AGREEMENTS > Section 6.4 Company Non-Solicitation; Company Acquisition Proposals; Company Change of Recommendation > (g)"
      }
    ],
    "adverse_recommendation_change": [
      {
        "section": "non_solicitation",
        "field_name": "adverse_recommendation_change_superior_proposal_included",
        "answer": true,
        "summary": "",
        "confidence": 1.0,
        "reason": "The board is permitted to make a Company Change of Recommendation in response to a Company Superior Offer, subject to certain conditions.",
        "clause_text": "Notwithstanding anything in this Agreement to the contrary, with respect to a Company Acquisition Proposal, the Company Board may at any time prior to receipt of the Company Stockholder Approval, make a Company Change of Recommendation, if (and only if): (i) (A) a written Company Acquisition Proposal that did not result from a material breach of Section 6.4(a) is made by a third party after the entry hereof, and such Company Acquisition Proposal is not withdrawn, (B) the Company Board determines in good faith after consultation with its financial advisors and outside legal counsel that such Company Acquisition Proposal constitutes a Company Superior Offer...",
        "reference_section": "ARTICLE VI COVENANTS AND AGREEMENTS > Section 6.4 Company Non-Solicitation; Company Acquisition Proposals; Company Change of Recommendation > (g)"
      },
      {
        "section": "non_solicitation",
        "field_name": "adverse_recommendation_change_superior_proposal_explanation",
        "answer": "The Company Board is permitted to change its recommendation in response to a Superior Proposal.",
        "summary": "The Company Board may make a Company Change of Recommendation if a Company Acquisition Proposal constitutes a Company Superior Offer and the failure to change the recommendation would breach fiduciary duties.",
        "confidence": 0.95,
        "reason": "The clause explicitly allows the Company Board to change its recommendation upon determining a Company Superior Offer, after consultation with legal and financial advisors.",
        "clause_text": "Notwithstanding anything in this Agreement to the contrary, with respect to a Company Acquisition Proposal, the Company Board may at any time prior to receipt of the Company Stockholder Approval, make a Company Change of Recommendation, if (and only if): (i) (A) a written Company Acquisition Proposal that did not result from a material breach of Section 6.4(a) is made by a third party after the entry hereof, and such Company Acquisition Proposal is not withdrawn, (B) the Company Board determines in good faith after consultation with its financial advisors and outside legal counsel that such Company Acquisition Proposal constitutes a Company Superior Offer and (C) following consultation with outside legal counsel, the Company Board determines that the failure to make a Company Change of Recommendation would constitute a breach of its fiduciary duties under applicable Law, the Company Certificate of Incorporation or the Company Bylaws;",
        "reference_section": "ARTICLE VI – Covenants and Agreements > Section 6.4 – Company Non-Solicitation; Company Acquisition Proposals; Company Change of Recommendation > (g)"
      },
      {
        "section": "non_solicitation",
        "field_name": "adverse_recommendation_change_intervening_event_included",
        "answer": true,
        "summary": "",
        "confidence": 1.0,
        "reason": "The agreement explicitly allows the Company Board to make a Company Change of Recommendation in response to an Intervening Event.",
        "clause_text": "Other than in connection with a Company Superior Offer (which shall be subject to Section 6.4(g) and shall not be subject to this Section 6.4(h)), nothing in this Agreement shall prohibit or restrict the Company Board from making a Company Change of Recommendation in response to an Intervening Event...",
        "reference_section": "ARTICLE Article VI COVENANTS AND AGREEMENTS > Section 6.4 Company Non-Solicitation; Company Acquisition Proposals; Company Change of Recommendation > (h)"
      },
      {
        "section": "non_solicitation",
        "field_name": "adverse_recommendation_change_intervening_event_explanation",
        "answer": "The Company Board may make a Company Change of Recommendation in response to an Intervening Event if it determines in good faith, after consultation with outside legal counsel, that failing to do so would breach its fiduciary duties, provided it gives Sodium four business days' notice and negotiates in good faith to revise the agreement.",
        "summary": "The Company Board can change its recommendation due to an Intervening Event if it determines in good faith that not doing so would breach its fiduciary duties, after providing notice and negotiating with Sodium.",
        "confidence": 0.9,
        "reason": "The clause explicitly allows for a change in recommendation due to an Intervening Event under specified conditions.",
        "clause_text": "Other than in connection with a Company Superior Offer (which shall be subject to Section 6.4(g) and shall not be subject to this Section 6.4(h)), nothing in this Agreement shall prohibit or restrict the Company Board from making a Company Change of Recommendation in response to an Intervening Event to the extent that: (i) the Company Board, or any committee thereof, determines in good faith, after consultation with the Company's outside legal counsel, that the failure of the Company Board to effect a Company Change of Recommendation in response to such Intervening Event would constitute a breach of its fiduciary duties under applicable Law, the Company Certificate of Incorporation or the Company Bylaws, and (ii) (A) the Company provides Sodium four (4) business days prior written notice of its intention to take such action, which notice shall specify the reasons therefor, (B) after providing such notice and prior to making such Company Change of Recommendation, the Company shall negotiate in good faith with Sodium during such four (4) business days' period (to the extent that Sodium desires to negotiate) to make such revisions to the terms of this Agreement as to obviate the need for the Company Board to make a Company Change of Recommendation pursuant to this Section 6.4(h), and (C) the Company Board, or any committee thereof, shall have considered in good faith any changes to the terms of this Agreement committed to in writing by Sodium, and following such four (4) business day period, shall have determined in good faith, after consultation with its outside legal counsel and financial advisors, that the failure to effect a Company Change of Recommendation in response to such Intervening Event would constitute a breach of its fiduciary duties under applicable Law, the Company Certificate of Incorporation, or the Company Bylaws.",
        "reference_section": "ARTICLE Article VI COVENANTS AND AGREEMENTS > Section 6.4 Company Non-Solicitation; Company Acquisition Proposals; Company Change of Recommendation > (h)"
      },
      {
        "section": "non_solicitation",
        "field_name": "adverse_recommendation_change_timing",
        "answer": "The Company provides Sodium four (4) business days prior written notice of its intention to take such action, which notice shall include the information with respect to such Company Superior Offer that is specified in Section 6.4(b), (B) after providing such notice and prior to making such Company Change of Recommendation in connection with a Company Superior Offer, the Company shall negotiate in good faith with Sodium during such four (4) business day period (to the extent that Sodium desires to negotiate) to make such revisions to the terms of this Agreement, such that the Company Acquisition Proposal ceases to constitute a Company Superior Offer, and (C) the Company Board shall have considered in good faith any changes to the terms of this Agreement committed to in writing by Sodium, and following such four (4) business days period, shall have determined in good faith, after consultation with its outside legal counsel and financial advisors, that the Company Acquisition Proposal would continue to constitute a Company Superior Offer if such changes of this Agreement proposed in writing by Sodium were to be given effect; provided that, in the event that the Company Acquisition Proposal is thereafter modified by the party making such Company Acquisition Proposal, the Company shall provide written notice of such modified Company Acquisition Proposal and shall again comply with this Section 6.4(g), except that the required four (4) business day period for notice, negotiation and consideration in clauses (A), (B) and (C) of this Section 6.4(g) shall be shortened to a two (2) business day period in each instance.",
        "summary": "The Company must provide Sodium four business days' prior written notice before making an Adverse Recommendation Change, negotiate in good faith during this period, and consider any changes proposed by Sodium. If the proposal is modified, the notice period is reduced to two business days.",
        "confidence": 0.9,
        "reason": "The clause specifies a four business day notice and negotiation period before an Adverse Recommendation Change, with a reduced period if the proposal is modified.",
        "clause_text": "The Company provides Sodium four (4) business days prior written notice of its intention to take such action, which notice shall include the information with respect to such Company Superior Offer that is specified in Section 6.4(b), (B) after providing such notice and prior to making such Company Change of Recommendation in connection with a Company Superior Offer, the Company shall negotiate in good faith with Sodium during such four (4) business day period (to the extent that Sodium desires to negotiate) to make such revisions to the terms of this Agreement, such that the Company Acquisition Proposal ceases to constitute a Company Superior Offer, and (C) the Company Board shall have considered in good faith any changes to the terms of this Agreement committed to in writing by Sodium, and following such four (4) business days period, shall have determined in good faith, after consultation with its outside legal counsel and financial advisors, that the Company Acquisition Proposal would continue to constitute a Company Superior Offer if such changes of this Agreement proposed in writing by Sodium were to be given effect; provided that, in the event that the Company Acquisition Proposal is thereafter modified by the party making such Company Acquisition Proposal, the Company shall provide written notice of such modified Company Acquisition Proposal and shall again comply with this Section 6.4(g), except that the required four (4) business day period for notice, negotiation and consideration in clauses (A), (B) and (C) of this Section 6.4(g) shall be shortened to a two (2) business day period in each instance.",
        "reference_section": "ARTICLE Article VI COVENANTS AND AGREEMENTS > Section 6.4 Company Non-Solicitation; Company Acquisition Proposals; Company Change of Recommendation > (g)"
      }
    ],
    "go_shop": [
      {
        "section": "non_solicitation",
        "field_name": "go_shop_included",
        "answer": false,
        "summary": "",
        "confidence": 1.0,
        "reason": "The agreement prohibits solicitation and does not mention a 'go-shop' period or allowance for post-signing outreach.",
        "clause_text": "Except as permitted by this Section 6.4, from the date hereof and prior to the earlier of the Effective Time and the Termination Date, the Company shall not, and shall cause its Subsidiaries and its and their respective directors, officers, employees not to, and shall direct its and their other Representatives acting on its and their behalf not to, directly or indirectly: (i) solicit, initiate, seek or knowingly encourage or knowingly facilitate (including by way of furnishing non-public information) any proposal or offer or any inquiries regarding the making or submission of any proposal or offer...",
        "reference_section": "ARTICLE VI – COVENANTS AND AGREEMENTS > Section 6.4 – Company Non-Solicitation; Company Acquisition Proposals; Company Change of Recommendation > (a)"
      },
      {
        "section": "non_solicitation",
        "field_name": "go_shop_explanation",
        "answer": "Not found",
        "summary": "",
        "confidence": 1.0,
        "reason": "",
        "clause_text": "",
        "reference_section": ""
      }
    ],
    "buyer_diligence_access": [
      {
        "section": "non_solicitation",
        "field_name": "buyer_diligence_access_included",
        "answer": true,
        "summary": "",
        "confidence": 1.0,
        "reason": "The agreement grants the buyer the right to receive any diligence materials shared with a third party, as indicated by the language 'the Company provides or makes available such non-public information to Sodium substantially concurrent with the time that it is provided to such other person.'",
        "clause_text": "to the extent such non-public information has not been made available to Sodium or Sodium US, the Company provides or makes available such non-public information to Sodium substantially concurrent with the time that it is provided to such other person.",
        "reference_section": "ARTICLE VI – COVENANTS AND AGREEMENTS > Section 6.4 – Company Non-Solicitation; Company Acquisition Proposals; Company Change of Recommendation > (b)"
      },
      {
        "section": "non_solicitation",
        "field_name": "buyer_diligence_access_explanation",
        "answer": "The Company must provide or make available to Sodium any non-public information that has not been made available to Sodium or Sodium US, substantially concurrent with the time that it is provided to another person.",
        "summary": "The Company is obligated to provide Sodium with any non-public information shared with a third party in connection with a Company Acquisition Proposal, ensuring Sodium receives this information concurrently.",
        "confidence": 0.9,
        "reason": "The clause explicitly states the Company's obligation to provide Sodium with non-public information shared with third parties.",
        "clause_text": "to the extent such non-public information has not been made available to Sodium or Sodium US, the Company provides or makes available such non-public information to Sodium substantially concurrent with the time that it is provided to such other person.",
        "reference_section": "ARTICLE Article VI COVENANTS AND AGREEMENTS > Section 6.4 Company Non-Solicitation; Company Acquisition Proposals; Company Change of Recommendation > (b)"
      }
    ],
    "recommendation_change_restriction": [
      {
        "section": "non_solicitation",
        "field_name": "recommendation_change_restriction_included",
        "answer": true,
        "summary": "",
        "confidence": 1.0,
        "reason": "The agreement imposes restrictions on the board's ability to change its recommendation, requiring prior notice to Sodium and a negotiation period.",
        "clause_text": "The Company provides Sodium four (4) business days prior written notice of its intention to take such action, which notice shall include the information with respect to such Company Superior Offer that is specified in Section 6.4(b).",
        "reference_section": "ARTICLE VI – Covenants and Agreements > Section 6.4 – Company Non-Solicitation; Company Acquisition Proposals; Company Change of Recommendation > (g)"
      },
      {
        "section": "non_solicitation",
        "field_name": "recommendation_change_restriction_explanation",
        "answer": "The agreement imposes procedural and timing-based restrictions on how the Company may change its recommendation.",
        "summary": "The Company must provide Sodium with four business days' prior written notice of its intention to change its recommendation, negotiate in good faith with Sodium during this period, and consider any changes proposed by Sodium.",
        "confidence": 0.9,
        "reason": "The agreement specifies a notice period and negotiation requirements before a recommendation change.",
        "clause_text": "The Company provides Sodium four (4) business days prior written notice of its intention to take such action, which notice shall include the information with respect to such Company Superior Offer that is specified in Section 6.4(b), (B) after providing such notice and prior to making such Company Change of Recommendation in connection with a Company Superior Offer, the Company shall negotiate in good faith with Sodium during such four (4) business day period (to the extent that Sodium desires to negotiate) to make such revisions to the terms of this Agreement.",
        "reference_section": "ARTICLE VI – Covenants and Agreements > Section 6.4 – Company Non-Solicitation; Company Acquisition Proposals; Company Change of Recommendation > (g)"
      }
    ]
  },
  "best_efforts": {
    "regulatory_efforts": [
      {
        "section": "best_efforts",
        "field_name": "effort_standard",
        "answer": "Reasonable Best Efforts",
        "summary": "The parties are required to use reasonable best efforts to obtain regulatory approvals, including CFIUS Approval, and to take necessary actions to consummate the merger.",
        "confidence": 0.9,
        "reason": "The agreement specifies 'reasonable best efforts' as the standard for obtaining regulatory approvals, including CFIUS Approval.",
        "clause_text": "each of Sodium and the Company shall, and shall cause their respective Subsidiaries to, use reasonable best efforts to obtain the CFIUS Approval; provided, however, that the determination as to whether CFIUS Approval is required under the DPA or is otherwise warranted shall be made within ten (10) business days following the date on which Sodium receives such information from the Company as is reasonably necessary to make such determination.",
        "reference_section": "ARTICLE Article VI COVENANTS AND AGREEMENTS > Section 6.8 CFIUS Approval > (a)"
      },
      {
        "section": "best_efforts",
        "field_name": "effort_scope",
        "answer": "RBE for HSR, CFIUS, and EU filings",
        "summary": "The effort scope includes reasonable best efforts for obtaining necessary approvals and making filings under the HSR Act, CFIUS, and other Regulatory Laws, including EU regulations.",
        "confidence": 0.9,
        "reason": "The clause explicitly mentions the HSR Act, CFIUS, and other Regulatory Laws, including EU regulations, as part of the effort scope.",
        "clause_text": "Subject to the terms and conditions herein provided and without limiting the foregoing, the Company and Sodium shall (i) promptly, but in no event later than fifteen (15) business days after the date hereof (unless a later date is mutually agreed by the parties in writing), make their respective filings under the HSR Act, and (ii) as promptly as practicable, prepare and file all filings, requests, registrations and notices necessary under each other Regulatory Law with respect to the Merger and the other Transactions.",
        "reference_section": "ARTICLE Article VI COVENANTS AND AGREEMENTS > Section 6.7 Regulatory Approvals; Efforts > (b)"
      }
    ],
    "regulatory_fillings_hsr": [
      {
        "section": "best_efforts",
        "field_name": "hsr_required",
        "answer": true,
        "summary": "",
        "confidence": 1.0,
        "reason": "The document explicitly states that the parties are required to make their respective filings under the HSR Act.",
        "clause_text": "Subject to the terms and conditions herein provided and without limiting the foregoing, the Company and Sodium shall (i) promptly, but in no event later than fifteen (15) business days after the date hereof (unless a later date is mutually agreed by the parties in writing), make their respective filings under the HSR Act.",
        "reference_section": "ARTICLE Article VI COVENANTS AND AGREEMENTS > Section 6.7 Regulatory Approvals; Efforts > (b)"
      },
      {
        "section": "best_efforts",
        "field_name": "hsr_filing_deadline_days",
        "answer": 15,
        "summary": "The parties are required to make their respective filings under the HSR Act no later than fifteen business days after the date of the agreement.",
        "confidence": 0.9,
        "reason": "The document specifies a clear deadline for HSR filings.",
        "clause_text": "Subject to the terms and conditions herein provided and without limiting the foregoing, the Company and Sodium shall (i) promptly, but in no event later than fifteen (15) business days after the date hereof (unless a later date is mutually agreed by the parties in writing), make their respective filings under the HSR Act.",
        "reference_section": "ARTICLE Article VI COVENANTS AND AGREEMENTS > Section 6.7 Regulatory Approvals; Efforts > (b)"
      },
      {
        "section": "best_efforts",
        "field_name": "hsr_notes",
        "answer": "Must file within 15 business days of signing; filing required under HSR Act as a condition to closing.",
        "summary": "The parties must make their respective filings under the HSR Act within 15 business days of the agreement date, and these filings are required as a condition to closing.",
        "confidence": 0.9,
        "reason": "The document specifies a 15 business day deadline for HSR Act filings, indicating it as a condition to closing.",
        "clause_text": "Subject to the terms and conditions herein provided and without limiting the foregoing, the Company and Sodium shall (i) promptly, but in no event later than fifteen (15) business days after the date hereof (unless a later date is mutually agreed by the parties in writing), make their respective filings under the HSR Act.",
        "reference_section": "ARTICLE VI – Covenants and Agreements > Section 6.7 – Regulatory Approvals; Efforts > (b)"
      }
    ],
    "regulatory_fillings_cfius": [
      {
        "section": "best_efforts",
        "field_name": "cfius_required",
        "answer": false,
        "summary": "",
        "confidence": 1.0,
        "reason": "The document does not explicitly state that a CFIUS filing is mandatory.",
        "clause_text": "If Sodium determines in its sole and absolute discretion that the CFIUS Approval is required under the DPA or otherwise warranted, each of Sodium and the Company shall, and shall cause their respective Subsidiaries to, use reasonable best efforts to obtain the CFIUS Approval;",
        "reference_section": "ARTICLE Article VI COVENANTS AND AGREEMENTS > Section 6.8 CFIUS Approval > (a)"
      },
      {
        "section": "best_efforts",
        "field_name": "cfius_filing_deadline_days",
        "answer": 10,
        "summary": "The CFIUS notice must be filed no later than ten business days after Sodium conveys to the Company that CFIUS Approval is required.",
        "confidence": 0.9,
        "reason": "The document specifies a deadline of ten business days for filing a CFIUS notice after Sodium's determination.",
        "clause_text": "Such reasonable best efforts shall include, (i) as promptly as practicable, but in no event later than ten (10) business days after the date on which Sodium conveys to the Company, Sodium's determination that CFIUS Approval is required under the DPA or is otherwise warranted (unless a later date is mutually agreed by the parties in writing), jointly filing with CFIUS, either a CFIUS Declaration or a draft CFIUS Notice regarding the Transactions in accordance with the DPA;",
        "reference_section": "ARTICLE Article VI COVENANTS AND AGREEMENTS > Section 6.8 CFIUS Approval > (a)"
      },
      {
        "section": "best_efforts",
        "field_name": "cfius_notes",
        "answer": "If Sodium determines in its sole and absolute discretion that the CFIUS Approval is required under the DPA or otherwise warranted, each of Sodium and the Company shall, and shall cause their respective Subsidiaries to, use reasonable best efforts to obtain the CFIUS Approval; provided, however, that the determination as to whether CFIUS Approval is required under the DPA or is otherwise warranted shall be made within ten (10) business days following the date on which Sodium receives such information from the Company as is reasonably necessary to make such determination.",
        "summary": "CFIUS filing is discretionary and subject to Sodium's determination of necessity under the DPA, with a decision required within ten business days after receiving necessary information.",
        "confidence": 0.9,
        "reason": "The clause specifies that CFIUS Approval is subject to Sodium's discretion and outlines the timeframe for determination.",
        "clause_text": "If Sodium determines in its sole and absolute discretion that the CFIUS Approval is required under the DPA or otherwise warranted, each of Sodium and the Company shall, and shall cause their respective Subsidiaries to, use reasonable best efforts to obtain the CFIUS Approval; provided, however, that the determination as to whether CFIUS Approval is required under the DPA or is otherwise warranted shall be made within ten (10) business days following the date on which Sodium receives such information from the Company as is reasonably necessary to make such determination.",
        "reference_section": "ARTICLE Article VI COVENANTS AND AGREEMENTS > Section 6.8 CFIUS Approval > (a)"
      }
    ],
    "regulatory_fillings_foreign": [
      {
        "section": "best_efforts",
        "field_name": "foreign_filling_notes",
        "answer": "Foreign filings may be required under applicable non-U.S. laws",
        "summary": "The agreement implies that foreign filings may be required under applicable non-U.S. antitrust or merger control laws.",
        "confidence": 0.9,
        "reason": "The definition of 'Regulatory Law' includes all laws designed to regulate monopolization, restraint of trade, or competition, which implies foreign filings may be necessary.",
        "clause_text": "Regulatory Law means the HSR Act, the Sherman Act of 1890, as amended, the Clayton Antitrust Act of 1914, as amended, the Federal Trade Commission Act, CFIUS, and all other Laws that are designed or intended to (A) prohibit, restrict or regulate actions having the purpose or effect of monopolization, restraint of trade or lessening competition through merger or acquisition (including all antitrust, competition, merger control and trade regulation Laws) or (B) protect the national security or the national economy of any nation, or prohibit, restrict or regulate foreign investment.",
        "reference_section": "ARTICLE Article IX MISCELLANEOUS > Section 9.16 Definitions > Regulatory Law"
      },
      {
        "section": "best_efforts",
        "field_name": "foreign_filling_required",
        "answer": true,
        "summary": "",
        "confidence": 1.0,
        "reason": "The agreement references obligations under 'other Regulatory Law,' which includes foreign antitrust or merger control laws.",
        "clause_text": "Subject to the terms and conditions herein provided and without limiting the foregoing, the Company and Sodium shall (i) promptly, but in no event later than fifteen (15) business days after the date hereof (unless a later date is mutually agreed by the parties in writing), make their respective filings under the HSR Act, and (ii) as promptly as practicable, prepare and file all filings, requests, registrations and notices necessary under each other Regulatory Law with respect to the Merger and the other Transactions.",
        "reference_section": "ARTICLE Article VI COVENANTS AND AGREEMENTS > Section 6.7 Regulatory Approvals; Efforts > (b)"
      },
      {
        "section": "best_efforts",
        "field_name": "foreign_filling_deadline_days",
        "answer": "Not found",
        "summary": "",
        "confidence": 1.0,
        "reason": "",
        "clause_text": "",
        "reference_section": ""
      }
    ],
    "divestiture_commitments": [
      {
        "section": "best_efforts",
        "field_name": "divestiture_required",
        "answer": false,
        "summary": "",
        "confidence": 1.0,
        "reason": "The agreement explicitly states that Sodium and its Affiliates are not obligated to propose or agree to any Remedy Actions, such as divestitures, to resolve regulatory objections.",
        "clause_text": "Notwithstanding anything to the contrary contained in this Agreement, nothing contained in this Agreement shall obligate Sodium or its Affiliates, for purposes of resolving any objection that a Governmental Entity may assert under Regulatory Laws with respect to the Transactions, or avoiding or eliminating any impediment under Regulatory Laws that may be asserted by any Governmental Entity with respect to the Transactions, to propose, offer, negotiate, commit to, agree to or effect, by consent decree, hold separate order, or otherwise, (i) the sale, divestiture, license, transfer or other disposition of any businesses, assets, equity interests, product lines or properties of Sodium, the Company or any of their respective Affiliates...",
        "reference_section": "ARTICLE VI – Covenants and Agreements > Section 6.7 – Regulatory Approvals; Efforts > (e)"
      },
      {
        "section": "best_efforts",
        "field_name": "divestiture_cap_target_notes",
        "answer": "Not found",
        "summary": "",
        "confidence": 1.0,
        "reason": "",
        "clause_text": "",
        "reference_section": ""
      },
      {
        "section": "best_efforts",
        "field_name": "divestiture_cap_buyer_notes",
        "answer": "Parent is not required to divest any of its businesses.",
        "summary": "Sodium and its Affiliates are not obligated to propose, offer, negotiate, commit to, agree to or effect any Remedy Action involving divestiture of any businesses, assets, equity interests, product lines, or properties.",
        "confidence": 0.9,
        "reason": "The agreement explicitly states that Sodium is not obligated to take any Remedy Action involving divestiture.",
        "clause_text": "Notwithstanding anything to the contrary contained in this Agreement, nothing contained in this Agreement shall obligate Sodium or its Affiliates, for purposes of resolving any objection that a Governmental Entity may assert under Regulatory Laws with respect to the Transactions, or avoiding or eliminating any impediment under Regulatory Laws that may be asserted by any Governmental Entity with respect to the Transactions, to propose, offer, negotiate, commit to, agree to or effect, by consent decree, hold separate order, or otherwise, (i) the sale, divestiture, license, transfer or other disposition of any businesses, assets, equity interests, product lines or properties of Sodium, the Company or any of their respective Affiliates...",
        "reference_section": "ARTICLE VI – COVENANTS AND AGREEMENTS > Section 6.7 – Regulatory Approvals; Efforts > (e)"
      }
    ],
    "litigation_commitments": [
      {
        "section": "best_efforts",
        "field_name": "litigation_requirement_status",
        "answer": "Explicit Exclusion",
        "summary": "Sodium retains sole discretion in deciding whether to litigate, defend against, or otherwise contest any Action by any Governmental Entity relating to the Transaction.",
        "confidence": 0.9,
        "reason": "The agreement explicitly states that Sodium has sole discretion regarding litigation decisions.",
        "clause_text": "Sodium shall retain sole discretion in deciding whether to litigate, defend against, or otherwise contest any Action by any Governmental Entity relating to the Transaction pursuant to or under the antitrust laws of the United States.",
        "reference_section": "ARTICLE VI – COVENANTS AND AGREEMENTS > Section 6.7 Regulatory Approvals; Efforts > (f)"
      },
      {
        "section": "best_efforts",
        "field_name": "litigation_clause_scope",
        "answer": "Not found",
        "summary": "",
        "confidence": 1.0,
        "reason": "",
        "clause_text": "",
        "reference_section": ""
      },
      {
        "section": "best_efforts",
        "field_name": "required_to_litigate_notes",
        "answer": "Not found",
        "summary": "",
        "confidence": 1.0,
        "reason": "",
        "clause_text": "",
        "reference_section": ""
      }
    ],
    "withdrawal_and_timing_controls_withdrawal": [
      {
        "section": "best_efforts",
        "field_name": "withdrawal_control_type",
        "answer": "buyer_only",
        "summary": "Sodium retains sole discretion in deciding whether to litigate, defend against, or otherwise contest any Action by any Governmental Entity relating to the Transaction pursuant to or under the antitrust laws of the United States.",
        "confidence": 0.9,
        "reason": "The agreement specifies that Sodium has sole discretion over regulatory actions, indicating buyer-only control.",
        "clause_text": "Notwithstanding anything to the contrary in any other provision of this Agreement and other than with respect to obtaining CFIUS Approval (which shall be governed by Section 6.8), Sodium shall retain sole discretion in deciding whether to litigate, defend against, or otherwise contest any Action by any Governmental Entity relating to the Transaction pursuant to or under the antitrust laws of the United States.",
        "reference_section": "ARTICLE Article VI COVENANTS AND AGREEMENTS > Section 6.7 Regulatory Approvals; Efforts > (f)"
      },
      {
        "section": "best_efforts",
        "field_name": "withdrawal_control_type_notes",
        "answer": "Not found",
        "summary": "",
        "confidence": 1.0,
        "reason": "",
        "clause_text": "",
        "reference_section": ""
      }
    ],
    "withdrawal_and_timing_controls_timing": [
      {
        "section": "best_efforts",
        "field_name": "timing_agreement_restriction",
        "answer": false,
        "summary": "",
        "confidence": 1.0,
        "reason": "The agreement does not explicitly state that neither party shall enter into any timing or similar agreement under the HSR Act without the other party’s prior written consent.",
        "clause_text": "Sodium, the Company and their respective Affiliates shall not enter into any timing agreement or similar agreement with any Governmental Entity, or extend any waiting period under any Regulatory Law, if such action would reasonably be expected to delay the consummation of the Transactions beyond the End Date.",
        "reference_section": "ARTICLE VI – Covenants and Agreements > Section 6.7 – Regulatory Approvals; Efforts > (f)"
      },
      {
        "section": "best_efforts",
        "field_name": "timing_agreement_restriction_notes",
        "answer": "Sodium, the Company, and their respective Affiliates shall not enter into any timing agreement or similar agreement with any Governmental Entity, or extend any waiting period under any Regulatory Law, if such action would reasonably be expected to delay the consummation of the Transactions beyond the End Date.",
        "summary": "The agreement restricts entering into timing agreements or extending waiting periods with Governmental Entities if it would delay the transaction beyond the End Date.",
        "confidence": 0.9,
        "reason": "The clause explicitly restricts timing agreements that could delay the transaction beyond the End Date.",
        "clause_text": "Sodium, the Company and their respective Affiliates shall not enter into any timing agreement or similar agreement with any Governmental Entity, or extend any waiting period under any Regulatory Law, if such action would reasonably be expected to delay the consummation of the Transactions beyond the End Date.",
        "reference_section": "ARTICLE VI – Covenants and Agreements > Section 6.7 – Regulatory Approvals; Efforts > (f)"
      }
    ],
    "remedy_actions_other": [
      {
        "section": "best_efforts",
        "field_name": "remedy_definitions_provided",
        "answer": true,
        "summary": "",
        "confidence": 1.0,
        "reason": "The agreement defines remedy-related obligations by describing 'Remedy Actions' and the efforts required to resolve regulatory objections.",
        "clause_text": "Notwithstanding anything to the contrary contained in this Agreement, nothing contained in this Agreement shall obligate Sodium or its Affiliates, for purposes of resolving any objection that a Governmental Entity may assert under Regulatory Laws with respect to the Transactions, or avoiding or eliminating any impediment under Regulatory Laws that may be asserted by any Governmental Entity with respect to the Transactions, to propose, offer, negotiate, commit to, agree to or effect, by consent decree, hold separate order, or otherwise, (i) the sale, divestiture, license, transfer or other disposition of any businesses, assets, equity interests, product lines or properties of Sodium, the Company or any of their respective Affiliates...",
        "reference_section": "ARTICLE VI – Covenants and Agreements > Section 6.7 – Regulatory Approvals; Efforts > (e)"
      },
      {
        "section": "best_efforts",
        "field_name": "remedy_definition_text",
        "answer": "Not found",
        "summary": "",
        "confidence": 1.0,
        "reason": "",
        "clause_text": "",
        "reference_section": ""
      }
    ],
    "transaction_interference": [
      {
        "section": "best_efforts",
        "field_name": "restriction_on_other_transactions",
        "answer": true,
        "summary": "",
        "confidence": 1.0,
        "reason": "The agreement restricts the Company from soliciting or pursuing alternative transactions that could interfere with regulatory approvals.",
        "clause_text": "Except as permitted by this Section 6.4, from the date hereof and prior to the earlier of the Effective Time and the Termination Date, the Company shall not, and shall cause its Subsidiaries and its and their respective directors, officers, employees not to, and shall direct its and their other Representatives acting on its and their behalf not to, directly or indirectly: (i) solicit, initiate, seek or knowingly encourage or knowingly facilitate (including by way of furnishing non-public information) any proposal or offer or any inquiries regarding the making or submission of any proposal or offer, including any proposal or offer to the Company's stockholders, that constitutes, or would reasonably be expected to lead to, a Company Acquisition Proposal;",
        "reference_section": "ARTICLE VI – Covenants and Agreements > Section 6.4 – Company Non-Solicitation; Company Acquisition Proposals; Company Change of Recommendation > (a)"
      },
      {
        "section": "best_efforts",
        "field_name": "interference_clause_text",
        "answer": "sale, divestiture, license, transfer or other disposition of any businesses, assets, equity interests, product lines or properties",
        "summary": "A 'Remedy Action' includes actions such as the sale, divestiture, license, transfer, or other disposition of businesses, assets, equity interests, product lines, or properties.",
        "confidence": 1.0,
        "reason": "",
        "clause_text": "Notwithstanding anything to the contrary contained in this Agreement, nothing contained in this Agreement shall obligate Sodium or its Affiliates, for purposes of resolving any objection that a Governmental Entity may assert under Regulatory Laws with respect to the Transactions, or avoiding or eliminating any impediment under Regulatory Laws that may be asserted by any Governmental Entity with respect to the Transactions, to propose, offer, negotiate, commit to, agree to or effect, by consent decree, hold separate order, or otherwise, (i) the sale, divestiture, license, transfer or other disposition of any businesses, assets, equity interests, product lines or properties of Sodium, the Company or any of their respective Affiliates...",
        "reference_section": "ARTICLE VI COVENANTS AND AGREEMENTS > Section 6.7 Regulatory Approvals; Efforts > (e)"
      }
    ],
    "second_request_certification": [
      {
        "section": "best_efforts",
        "field_name": "second_request_certification_deadline_specified",
        "answer": false,
        "summary": "",
        "confidence": 1.0,
        "reason": "The document does not specify a concrete deadline for certifying compliance with the Second Request under the HSR Act.",
        "clause_text": "The excerpts provided do not contain any specific number of days or exact date tied to Second Request compliance.",
        "reference_section": "ARTICLE Article VI COVENANTS AND AGREEMENTS > Section 6.7 Regulatory Approvals; Efforts"
      },
      {
        "section": "best_efforts",
        "field_name": "second_request_certification_certification_timeline_notes",
        "answer": "as promptly as practicable",
        "summary": "The agreement requires the parties to use reasonable best efforts to make all necessary filings and obtain approvals from Governmental Entities, including under the HSR Act, as promptly as practicable.",
        "confidence": 0.9,
        "reason": "The language 'as promptly as practicable' in the context of regulatory filings and approvals implies a timeline for certifying compliance with a Second Request under the HSR Act.",
        "clause_text": "Subject to the terms and conditions set forth in this Agreement, each of the parties hereto shall use (and shall cause each of its controlled Affiliates to use) its reasonable best efforts to take, or cause to be taken, promptly all actions, and to do, or cause to be done, promptly and to assist and cooperate with the other parties in doing, all things necessary, proper and advisable under applicable Laws to consummate and make effective the Merger and the other Transactions, including using reasonable best efforts to obtain all necessary actions or nonactions, waivers, clearances, expiration or termination of applicable waiting periods, consents and approvals, from Governmental Entities...",
        "reference_section": "ARTICLE VI – Covenants and Agreements > Section 6.7 – Regulatory Approvals; Efforts > (a)"
      },
      {
        "section": "best_efforts",
        "field_name": "second_request_certification_responsibility_party",
        "answer": "Both",
        "summary": "Both Sodium and the Company are required to use reasonable best efforts to comply with regulatory requirements, including the HSR Act, and to cooperate with each other in making necessary filings.",
        "confidence": 0.9,
        "reason": "The agreement specifies that both parties must cooperate and use reasonable best efforts to comply with regulatory requirements, implying joint responsibility.",
        "clause_text": "Subject to the terms and conditions set forth in this Agreement, each of the parties hereto shall use (and shall cause each of its controlled Affiliates to use) its reasonable best efforts to take, or cause to be taken, promptly all actions, and to do, or cause to be done, promptly and to assist and cooperate with the other parties in doing, all things necessary, proper and advisable under applicable Laws to consummate and make effective the Merger and the other Transactions, including using reasonable best efforts to obtain all necessary actions or nonactions, waivers, clearances, expiration or termination of applicable waiting periods, consents and approvals, from Governmental Entities.",
        "reference_section": "ARTICLE VI – Covenants and Agreements > Section 6.7 – Regulatory Approvals; Efforts > (a)"
      }
    ],
    "ftc_warning_letter_handling": [
      {
        "section": "best_efforts",
        "field_name": "ftc_warning_letter_handling_addressed",
        "answer": false,
        "summary": "",
        "confidence": 1.0,
        "reason": "The document does not mention FTC warning letters or similar preliminary regulatory communications.",
        "clause_text": "The document sections provided focus on CFIUS Approval, NYSE Listing, Takeover Statutes, Regulatory Approvals, Public Announcements, Company Financing Cooperation, and Filings, without reference to FTC warning letters.",
        "reference_section": "Multiple sections including ARTICLE VI COVENANTS AND AGREEMENTS > Section 6.7 Regulatory Approvals; Efforts"
      },
      {
        "section": "best_efforts",
        "field_name": "ftc_warning_letter_handling_notes",
        "answer": "Not addressed",
        "summary": "",
        "confidence": 1.0,
        "reason": "",
        "clause_text": "",
        "reference_section": ""
      },
      {
        "section": "best_efforts",
        "field_name": "ftc_warning_letter_handling_effect_on_closing_condition",
        "answer": "Silent",
        "summary": "",
        "confidence": 1.0,
        "reason": "",
        "clause_text": "",
        "reference_section": ""
      },
      {
        "section": "best_efforts",
        "field_name": "ftc_warning_letter_handling_addressed_notes",
        "answer": "Not found",
        "summary": "",
        "confidence": 1.0,
        "reason": "",
        "clause_text": "",
        "reference_section": ""
      }
    ],
    "other_timing_controls": [
      {
        "section": "best_efforts",
        "field_name": "other_timing_controls_deadlines_specified",
        "answer": [
          "Company Stockholder Meeting to be held as promptly as practicable after the Registration Statement is declared effective under the Securities Act, but in no event later than sixty (60) days thereafter.",
          "Proxy Statement/Prospectus to be mailed to each of the Company's stockholders as promptly as reasonably practicable and take such actions to enable such mailing to commence no later than four (4) business days thereafter after the Registration Statement is declared effective under the Securities Act.",
          "Company Stockholder Meeting shall not be adjourned or postponed to a date on or after ten (10) business days prior to the End Date."
        ],
        "summary": "The agreement specifies deadlines for the Company Stockholder Meeting and mailing of the Proxy Statement/Prospectus, including a 60-day limit after Registration Statement effectiveness and a 4-business-day mailing commencement post-effectiveness.",
        "confidence": 1.0,
        "reason": "",
        "clause_text": "The Company shall (ii) cause the Proxy Statement/Prospectus to be mailed to each of the Company's stockholders as promptly as reasonably practicable (and take such actions to enable such mailing to commence no later than four (4) business days thereafter) after the Registration Statement is declared effective under the Securities Act and (iii) take all action necessary in accordance with applicable Laws and the Company Organizational Documents to establish a record date for, duly give notice of, convene and hold the Company Stockholder Meeting, to be held as promptly as practicable after the Registration Statement is declared effective under the Securities Act (but in no event later than sixty (60) days thereafter).",
        "reference_section": "ARTICLE Article VI COVENANTS AND AGREEMENTS > Section 6.5 Filings; Other Actions > (b)"
      }
    ],
    "novel_or_unstructured_regulatory_clauses": [
      {
        "section": "best_efforts",
        "field_name": "novel_or_unstructured_regulatory_clauses_items",
        "answer": [
          {
            "summary": "Sodium has sole discretion to determine if CFIUS Approval is required and is not obligated to propose or agree to any Remedy Action to resolve CFIUS objections.",
            "section": "ARTICLE VI COVENANTS AND AGREEMENTS > Section 6.8 CFIUS Approval",
            "review_required": true
          },
          {
            "summary": "Sodium is not obligated to propose or agree to any Remedy Action that involves divestiture or other significant changes to its or the Company's business to resolve regulatory objections.",
            "section": "ARTICLE VI COVENANTS AND AGREEMENTS > Section 6.7 Regulatory Approvals; Efforts",
            "review_required": true
          }
        ],
        "summary": "",
        "confidence": 1.0,
        "reason": "",
        "clause_text": "",
        "reference_section": ""
      }
    ],
    "prior_approval_commitment": [
      {
        "section": "best_efforts",
        "field_name": "prior_approval_commitment_addressed",
        "answer": false,
        "summary": "",
        "confidence": 1.0,
        "reason": "The document does not explicitly mention an obligation to obtain prior approval from a third party for future actions beyond the merger itself.",
        "clause_text": "The Company shall not, and shall cause its controlled Affiliates not to, propose, offer, negotiate, commit to, agree to, effect or take any Remedy Action without the prior written consent of Sodium, and the Company shall, and shall cause its controlled Affiliates to, propose, offer, negotiate, commit to, agree to, effect or take any Remedy Action if so directed by Sodium; provided, however, that any Remedy Action shall be conditioned upon the Closing.",
        "reference_section": "ARTICLE Article VI COVENANTS AND AGREEMENTS > Section 6.7 Regulatory Approvals; Efforts > (e)"
      },
      {
        "section": "best_efforts",
        "field_name": "prior_approval_commitment_obligations_summary",
        "answer": "Not found",
        "summary": "",
        "confidence": 1.0,
        "reason": "",
        "clause_text": "",
        "reference_section": ""
      }
    ],
    "regulatory_process_control_discretion": [
      {
        "section": "best_efforts",
        "field_name": "regulatory_process_control_discretion",
        "answer": "Parent",
        "summary": "Sodium has control over regulatory process decisions, including the determination of whether CFIUS Approval is required, and retains sole discretion in deciding whether to litigate, defend against, or otherwise contest any Action by any Governmental Entity relating to the Transaction.",
        "confidence": 0.9,
        "reason": "Sodium is granted sole and absolute discretion over CFIUS Approval and retains sole discretion in regulatory matters.",
        "clause_text": "If Sodium determines in its sole and absolute discretion that the CFIUS Approval is required under the DPA or otherwise warranted, each of Sodium and the Company shall, and shall cause their respective Subsidiaries to, use reasonable best efforts to obtain the CFIUS Approval; provided, however, that the determination as to whether CFIUS Approval is required under the DPA or is otherwise warranted shall be made within ten (10) business days following the date on which Sodium receives such information from the Company as is reasonably necessary to make such determination.",
        "reference_section": "ARTICLE Article VI COVENANTS AND AGREEMENTS > Section 6.8 CFIUS Approval > (a)"
      },
      {
        "section": "best_efforts",
        "field_name": "parent_has_sole_discretion_excluding_remedies",
        "answer": true,
        "summary": "",
        "confidence": 1.0,
        "reason": "The agreement explicitly states that Sodium has sole and absolute discretion over determining the necessity of CFIUS Approval, excluding obligations to take or avoid Remedy Actions.",
        "clause_text": "If Sodium determines in its sole and absolute discretion that the CFIUS Approval is required under the DPA or otherwise warranted, each of Sodium and the Company shall, and shall cause their respective Subsidiaries to, use reasonable best efforts to obtain the CFIUS Approval; provided, however, that the determination as to whether CFIUS Approval is required under the DPA or is otherwise warranted shall be made within ten (10) business days following the date on which Sodium receives such information from the Company as is reasonably necessary to make such determination.",
        "reference_section": "ARTICLE Article VI COVENANTS AND AGREEMENTS > Section 6.8 CFIUS Approval > (a)"
      }
    ],
    "no_limitations_on_buyer_remedies": [
      {
        "section": "best_efforts",
        "field_name": "no_limitations_on_buyer_remedies_value",
        "answer": false,
        "summary": "",
        "confidence": 1.0,
        "reason": "The agreement explicitly states that Sodium is not obligated to take any Remedy Action to resolve objections or eliminate impediments asserted by CFIUS or other Governmental Entities.",
        "clause_text": "Notwithstanding anything to the contrary contained in this Agreement, nothing contained in this Agreement shall obligate Sodium or its Affiliates, for purposes of resolving any objection, if any, that CFIUS may assert with respect to the Transactions, or avoiding or eliminating any impediment that may be asserted by CFIUS with respect to the Transactions, to propose, offer, negotiate, commit to, agree to or effect, by consent decree, hold separate order, or otherwise any Remedy Action.",
        "reference_section": "ARTICLE Article VI COVENANTS AND AGREEMENTS > Section 6.8 CFIUS Approval > (b)"
      },
      {
        "section": "best_efforts",
        "field_name": "no_limitations_on_buyer_remedies_inferred_hohw",
        "answer": false,
        "summary": "",
        "confidence": 1.0,
        "reason": "The agreement explicitly states that Sodium is not obligated to take any Remedy Action to resolve objections or eliminate impediments asserted by CFIUS or other Governmental Entities.",
        "clause_text": "Notwithstanding anything to the contrary contained in this Agreement, nothing contained in this Agreement shall obligate Sodium or its Affiliates, for purposes of resolving any objection, if any, that CFIUS may assert with respect to the Transactions, or avoiding or eliminating any impediment that may be asserted by CFIUS with respect to the Transactions, to propose, offer, negotiate, commit to, agree to or effect, by consent decree, hold separate order, or otherwise any Remedy Action.",
        "reference_section": "ARTICLE VI – COVENANTS AND AGREEMENTS > Section 6.8 CFIUS Approval > (b)"
      },
      {
        "section": "best_efforts",
        "field_name": "no_limitations_on_buyer_remedies_explanation",
        "answer": "Not applicable",
        "summary": "",
        "confidence": 1.0,
        "reason": "",
        "clause_text": "",
        "reference_section": ""
      },
      {
        "section": "best_efforts",
        "field_name": "no_limitations_on_buyer_remedies_notes",
        "answer": "Not found",
        "summary": "",
        "confidence": 1.0,
        "reason": "",
        "clause_text": "",
        "reference_section": ""
      },
      {
        "section": "best_efforts",
        "field_name": "no_limitations_on_buyer_remedies_inferred_hohw_notes",
        "answer": "Not found",
        "summary": "",
        "confidence": 1.0,
        "reason": "",
        "clause_text": "",
        "reference_section": ""
      },
      {
        "section": "best_efforts",
        "field_name": "no_limitations_on_buyer_remedies_materiality_basis",
        "answer": "Not found",
        "summary": "",
        "confidence": 1.0,
        "reason": "",
        "clause_text": "",
        "reference_section": ""
      },
      {
        "section": "best_efforts",
        "field_name": "materiality_definition_text",
        "answer": "Not found",
        "summary": "",
        "confidence": 1.0,
        "reason": "",
        "clause_text": "",
        "reference_section": ""
      }
    ],
    "refiling_commitment": [
      {
        "section": "best_efforts",
        "field_name": "refiling_commitment_required",
        "answer": true,
        "summary": "",
        "confidence": 1.0,
        "reason": "The document specifies that the parties shall use reasonable best efforts to make their respective filings under the HSR Act.",
        "clause_text": "Subject to the terms and conditions herein provided and without limiting the foregoing, the Company and Sodium shall (i) promptly, but in no event later than fifteen (15) business days after the date hereof (unless a later date is mutually agreed by the parties in writing), make their respective filings under the HSR Act.",
        "reference_section": "ARTICLE Article VI COVENANTS AND AGREEMENTS > Section 6.7 Regulatory Approvals; Efforts > (b)"
      },
      {
        "section": "best_efforts",
        "field_name": "refiling_commitment_required_notes",
        "answer": "Not found",
        "summary": "",
        "confidence": 1.0,
        "reason": "",
        "clause_text": "",
        "reference_section": ""
      },
      {
        "section": "best_efforts",
        "field_name": "refiling_commitment_max_refiles",
        "answer": "Not found",
        "summary": "",
        "confidence": 1.0,
        "reason": "",
        "clause_text": "",
        "reference_section": ""
      },
      {
        "section": "best_efforts",
        "field_name": "refiling_commitment_max_refiles_notes",
        "answer": "Not found",
        "summary": "",
        "confidence": 1.0,
        "reason": "",
        "clause_text": "",
        "reference_section": ""
      },
      {
        "section": "best_efforts",
        "field_name": "refiling_commitment_max_refiles_specification_status",
        "answer": "Not Specified",
        "summary": "The agreement does not specify a limit on the number of HSR refilings.",
        "confidence": 0.8,
        "reason": "The excerpts provided do not mention any limit or unlimited nature of HSR refilings.",
        "clause_text": "Subject to the terms and conditions set forth in this Agreement, each of the parties hereto shall use (and shall cause each of its controlled Affiliates to use) its reasonable best efforts to take, or cause to be taken, promptly all actions, and to do, or cause to be done, promptly and to assist and cooperate with the other parties in doing, all things necessary, proper and advisable under applicable Laws to consummate and make effective the Merger and the other Transactions, including using reasonable best efforts to obtain all necessary actions or nonactions, waivers, clearances, expiration or termination of applicable waiting periods, consents and approvals, from Governmental Entities...",
        "reference_section": "ARTICLE Article VI COVENANTS AND AGREEMENTS > Section 6.7 Regulatory Approvals; Efforts > (a)"
      }
    ],
    "union_item": [
      {
        "section": "best_efforts",
        "field_name": "union_efforts_required",
        "answer": true,
        "summary": "",
        "confidence": 1.0,
        "reason": "The agreement requires the Company to comply with consultation and bargaining obligations with labor unions or employee representatives in connection with the Transactions.",
        "clause_text": "Prior to the Closing, the Company shall provide any notice, and comply in all material respects, with any applicable information, consultation and bargaining obligations, and shall use reasonable best efforts to satisfy any applicable consent requirements owed to any labor union, works council, labor organization or employee representative, which is representing any employee of the Company and its Subsidiaries, or any applicable labor tribunal, in connection with the Transactions;",
        "reference_section": "ARTICLE VI – Covenants and Agreements > Section 6.6 – Employee Matters > (e)"
      },
      {
        "section": "best_efforts",
        "field_name": "union_consultation_timeframe",
        "answer": "Not found",
        "summary": "",
        "confidence": 1.0,
        "reason": "",
        "clause_text": "",
        "reference_section": ""
      },
      {
        "section": "best_efforts",
        "field_name": "union_agreement_obligation_summary",
        "answer": "The Company is required to provide any notice, comply with applicable information, consultation, and bargaining obligations, and use reasonable best efforts to satisfy any applicable consent requirements owed to any labor union, works council, labor organization, or employee representative in connection with the Transactions.",
        "summary": "The Company must notify, consult, and bargain with labor unions or employee representatives and use reasonable efforts to obtain necessary consents related to the Transactions.",
        "confidence": 0.9,
        "reason": "The document specifies obligations for the Company to engage with labor unions or employee representatives regarding the Transactions.",
        "clause_text": "Prior to the Closing, the Company shall provide any notice, and comply in all material respects, with any applicable information, consultation and bargaining obligations, and shall use reasonable best efforts to satisfy any applicable consent requirements owed to any labor union, works council, labor organization or employee representative, which is representing any employee of the Company and its Subsidiaries, or any applicable labor tribunal, in connection with the Transactions;",
        "reference_section": "ARTICLE Article VI COVENANTS AND AGREEMENTS > Section 6.6 Employee Matters > (e)"
      }
    ],
    "regulatory_strategy_control_rights": [
      {
        "section": "best_efforts",
        "field_name": "regulatory_strategy_control_rights",
        "answer": "Sodium has the right to control the regulatory strategy.",
        "summary": "Sodium shall control, lead and direct all actions, decisions, and strategy for obtaining regulatory approvals and defending against regulatory actions, except for CFIUS Approval.",
        "confidence": 0.9,
        "reason": "Sodium is explicitly granted control over regulatory strategy and litigation decisions.",
        "clause_text": "Sodium shall, upon reasonable consultation with the Company, control, lead and direct all actions, decision and strategy for, and make all final determinations as to the timing and appropriate course of action with respect to, (i) obtaining clearances, expirations or terminations of waiting periods, consents and approvals from Governmental Entities, and all other matters related to Regulatory Laws and related inquiries, negotiations and Actions, in connection with the Transactions, and (ii) responding to and defending any Action by or with any Governmental Entity in connection with the Transactions.",
        "reference_section": "ARTICLE Article VI COVENANTS AND AGREEMENTS > Section 6.7 Regulatory Approvals; Efforts > (f)"
      }
    ],
    "regulatory_delay_control_rights": [
      {
        "section": "best_efforts",
        "field_name": "regulatory_delay_control_rights",
        "answer": "Sodium has the right to control decisions that could delay or extend the regulatory review process.",
        "summary": "Sodium retains sole discretion in deciding whether to litigate, defend against, or otherwise contest any Action by any Governmental Entity relating to the Transaction pursuant to or under the antitrust laws of the United States.",
        "confidence": 0.9,
        "reason": "Sodium is given control over regulatory decisions, including the discretion to litigate or contest actions under antitrust laws.",
        "clause_text": "Sodium shall retain sole discretion in deciding whether to litigate, defend against, or otherwise contest any Action by any Governmental Entity relating to the Transaction pursuant to or under the antitrust laws of the United States.",
        "reference_section": "ARTICLE Article VI COVENANTS AND AGREEMENTS > Section 6.7 Regulatory Approvals; Efforts > (f)"
      }
    ],
    "remedy_consent_required_by_target": [
      {
        "section": "best_efforts",
        "field_name": "remedy_consent_required_by_target",
        "answer": "The Company shall not, and shall cause its controlled Affiliates not to, propose, offer, negotiate, commit to, agree to, effect or take any Remedy Action without the prior written consent of Sodium, and the Company shall, and shall cause its controlled Affiliates to, propose, offer, negotiate, commit to, agree to, effect or take any Remedy Action if so directed by Sodium; provided, however, that any Remedy Action shall be conditioned upon the Closing.",
        "summary": "The agreement requires the Company to obtain prior written consent from Sodium before taking any Remedy Action, and to take such actions if directed by Sodium.",
        "confidence": 0.9,
        "reason": "The clause explicitly states the requirement for the Company's controlled Affiliates to obtain prior written consent from Sodium before taking any Remedy Action.",
        "clause_text": "The Company shall not, and shall cause its controlled Affiliates not to, propose, offer, negotiate, commit to, agree to, effect or take any Remedy Action without the prior written consent of Sodium, and the Company shall, and shall cause its controlled Affiliates to, propose, offer, negotiate, commit to, agree to, effect or take any Remedy Action if so directed by Sodium; provided, however, that any Remedy Action shall be conditioned upon the Closing.",
        "reference_section": "ARTICLE VI COVENANTS AND AGREEMENTS > Section 6.7 Regulatory Approvals; Efforts > (e)"
      }
    ],
    "regulatory_review_discretion_rights": [
      {
        "section": "best_efforts",
        "field_name": "regulatory_review_discretion_rights",
        "answer": "Sodium has discretion authority over CFIUS Approval and other regulatory filings.",
        "summary": "Sodium has sole and absolute discretion to determine if CFIUS Approval is required and control over regulatory filings and procedural decisions related to the Transactions.",
        "confidence": 0.9,
        "reason": "The document explicitly states that Sodium has sole and absolute discretion regarding CFIUS Approval and regulatory filings.",
        "clause_text": "If Sodium determines in its sole and absolute discretion that the CFIUS Approval is required under the DPA or otherwise warranted, each of Sodium and the Company shall, and shall cause their respective Subsidiaries to, use reasonable best efforts to obtain the CFIUS Approval.",
        "reference_section": "ARTICLE Article VI COVENANTS AND AGREEMENTS > Section 6.8 CFIUS Approval > (a)"
      }
    ]
  },
  "termination": {
    "outside_date": [
      {
        "section": "termination",
        "field_name": "primary_date",
        "answer": "April 2, 2025",
        "summary": "The initial 'Outside Date' specified in the agreement is April 2, 2025, which is the earliest date on which either party may terminate the agreement if the merger has not yet closed.",
        "confidence": 1.0,
        "reason": "",
        "clause_text": "by either the Company or Sodium, if the Merger shall not have been consummated on or prior to April 2, 2025 (the \"End Date\");",
        "reference_section": "ARTICLE Article VIII TERMINATION > Section 8.1 Termination or Abandonment"
      }
    ],
    "extension": [
      {
        "section": "termination",
        "field_name": "extension_list",
        "answer": [
          {
            "Extension Length": "6 months",
            "Who Grants the Extension": "automatic",
            "Conditions to Extend": "All conditions to Closing, other than those in Section 7.1(c), Section 7.1(d), or Section 7.3(d) at Sodium's election, must be satisfied or capable of being satisfied.",
            "Termination Restrictions Due to Breach": "Yes, the right to terminate is not available to a party if their material breach caused the failure to close by the outside date."
          }
        ],
        "summary": "The termination date may be automatically extended by 6 months if all conditions to Closing, except certain specified ones, are satisfied or capable of being satisfied. Termination rights are restricted if a party's material breach caused the failure to close.",
        "confidence": 0.95,
        "reason": "The agreement specifies an automatic extension if certain conditions are met and restricts termination rights in case of a party's material breach.",
        "clause_text": "provided, however, that if all of the conditions to Closing, other than any of the conditions set forth in Section 7.1(c), Section 7.1(d) or, at the election of Sodium, Section 7.3(d) (such election, an \"Extension Election\"), shall have been satisfied or shall be capable of being satisfied at such time (other than those conditions that by their nature are to be satisfied at the Closing), the End Date shall automatically be extended to October 2, 2025, which date shall thereafter be deemed to be the End Date; provided, further, that the right to terminate this Agreement pursuant to this Section 8.1(b) shall not be available to a party if the failure of the Closing to occur by such date shall be due to the material breach by such party of any representation, warranty, covenant or other agreement of such party set forth in this Agreement;",
        "reference_section": "ARTICLE Article VIII TERMINATION > Section 8.1 Termination or Abandonment"
      }
    ],
    "termination_fee": [
      {
        "section": "termination",
        "field_name": "termination_fee",
        "answer": "$265,400,000",
        "summary": "The Company Termination Fee is explicitly defined as $265,400,000.",
        "confidence": 1.0,
        "reason": "",
        "clause_text": "Company Termination Fee means $265,400,000.",
        "reference_section": "ARTICLE Article IX MISCELLANEOUS > Section 9.16 Definitions > Company Termination Fee"
      }
    ],
    "reverse_termination_fee": [
      {
        "section": "termination",
        "field_name": "reverse_termination_fee",
        "answer": 326600000,
        "summary": "The agreement specifies that if terminated under certain conditions, Sodium shall pay the Company a Sodium Termination Fee of $326,600,000.",
        "confidence": 0.9,
        "reason": "The Sodium Termination Fee is explicitly defined as $326,600,000 in the agreement.",
        "clause_text": "If this Agreement is terminated...then, in the case of clause (i), (ii) or (iii) Sodium shall pay to the Company, within three (3) business days after the date of termination, the Sodium Termination Fee, by wire transfer of same day federal funds to the account specified by the Company.",
        "reference_section": "ARTICLE Article VIII TERMINATION > Section 8.3 Termination Fees > (d)"
      }
    ],
    "reverse_termination_fee_exist": [
      {
        "section": "termination",
        "field_name": "reverse_termination_fee_exist",
        "answer": true,
        "summary": "",
        "confidence": 1.0,
        "reason": "The agreement includes a provision where Sodium must pay a termination fee to the Company under certain conditions, indicating a reverse termination fee.",
        "clause_text": "If this Agreement is terminated (i) by Sodium or the Company pursuant to Section 8.1(b) [End Date] ... then, in the case of clause (i), (ii) or (iii) Sodium shall pay to the Company, within three (3) business days after the date of termination, the Sodium Termination Fee.",
        "reference_section": "ARTICLE Article VIII TERMINATION > Section 8.3 Termination Fees > (d)"
      }
    ],
    "termination_fee_superior_proposal": [
      {
        "section": "termination",
        "field_name": "termination_fee_superior_proposal_exists",
        "answer": true,
        "summary": "",
        "confidence": 1.0,
        "reason": "The agreement includes a provision requiring the Company to pay a termination fee to Sodium upon accepting a Superior Proposal.",
        "clause_text": "If this Agreement is terminated by Sodium pursuant to Section 8.1(g) [Company Change of Recommendation], then the Company shall pay to Sodium, within three (3) business days after the date of termination, the Company Termination Fee, by wire transfer of same day federal funds to the account specified by Sodium.",
        "reference_section": "ARTICLE Article VIII TERMINATION > Section 8.3 Termination Fees > (b)"
      },
      {
        "section": "termination",
        "field_name": "termination_fee_superior_proposal",
        "answer": "265400000",
        "summary": "The Company must pay a termination fee of $265,400,000 if it terminates the agreement to pursue a Superior Proposal.",
        "confidence": 1.0,
        "reason": "The Company Termination Fee is explicitly defined as $265,400,000.",
        "clause_text": "Company Termination Fee means $265,400,000.",
        "reference_section": "ARTICLE IX MISCELLANEOUS > Section 9.16 Definitions > Company Termination Fee"
      }
    ],
    "termination_fee_company_shareholder_approval": [
      {
        "section": "termination",
        "field_name": "termination_fee_company_shareholder_approval_failure_exists",
        "answer": false,
        "summary": "",
        "confidence": 1.0,
        "reason": "The document does not specify a termination fee triggered solely by the failure to obtain shareholder approval without the involvement of a superior proposal.",
        "clause_text": "If (i) prior to the Company Stockholder Meeting, a Company Acquisition Proposal is publicly disclosed after the date of this Agreement, (ii) this Agreement is terminated by the Company or Sodium, as applicable, pursuant to Section 8.1(b) [End Date], Section 8.1(d) [No Company Stockholder Approval] or Section 8.1(f). [Company Breach of Representation or Failure to Perform Covenant] and the breach giving rise to the right to terminate this Agreement pursuant to Section 8.1(f) [Company Breach of Representation or Failure to Perform Covenant] was the Company's failure to convene and hold the Company Stockholder Meeting in violation of Section 6.5(c) or a breach of the Company's obligations under Section 6.4, (iii) such Company Acquisition Proposal shall not have been withdrawn prior to such termination and (iv) within twelve (12) months after any such termination described in clause (ii), the Company shall have consummated, or shall have entered into an agreement to consummate any Company Acquisition Transaction, which is subsequently consummated (whether before or after such twelve (12)-month period), then the Company shall pay to Sodium an amount equal to the Company Termination Fee, by wire transfer of same day federal funds to the account specified by Sodium, within three (3) business days after the consummation of any such Company Acquisition Transaction.",
        "reference_section": "ARTICLE Article VIII TERMINATION > Section 8.3 Termination Fees > (a)"
      },
      {
        "section": "termination",
        "field_name": "termination_fee_company_shareholder_approval_failure",
        "answer": "Not specified",
        "summary": "The document does not specify a termination fee for the failure to obtain shareholder approval that is not tied to a Superior Proposal or Adverse Recommendation Change.",
        "confidence": 1.0,
        "reason": "",
        "clause_text": "If this Agreement is terminated by Sodium pursuant to Section 8.1(g) [Company Change of Recommendation], then the Company shall pay to Sodium, within three (3) business days after the date of termination, the Company Termination Fee, by wire transfer of same day federal funds to the account specified by Sodium.",
        "reference_section": "ARTICLE Article VIII TERMINATION > Section 8.3 Termination Fees > (b)"
      }
    ],
    "reverse_termination_fee_shareholder_approval": [
      {
        "section": "termination",
        "field_name": "reverse_termination_fee_shareholder_approval_failure_exists",
        "answer": false,
        "summary": "",
        "confidence": 1.0,
        "reason": "There is no provision requiring the Parent to pay a Reverse Termination Fee upon failure to obtain its shareholder approval.",
        "clause_text": "The payment of the Company Termination Fee to Sodium pursuant to this Section 8.3 shall be the sole and exclusive monetary remedy available to Sodium, Sodium US or Merger Sub or any of their Affiliates in connection with this Agreement and the Transactions in any circumstance in which the Company Termination Fee is payable hereunder.",
        "reference_section": "ARTICLE Article VIII TERMINATION > Section 8.3 Termination Fees"
      },
      {
        "section": "termination",
        "field_name": "reverse_termination_fee_shareholder_approval_failure",
        "answer": "Not specified",
        "summary": "The document does not explicitly state the dollar amount, percentage, or formula for a reverse termination fee payable by the Parent due to failure to obtain shareholder approval.",
        "confidence": 1.0,
        "reason": "",
        "clause_text": "If this Agreement is terminated (i) by Sodium or the Company pursuant to Section 8.1(b) [End Date] and at the time of, or prior to, such termination, each of the conditions set forth in Article VII shall have been satisfied (other than the conditions set forth in Section 7.1(c) [Absence of Mutual Legal Restraint] (excluding any Mutual Legal Restraint relating to CFIUS) or Section 7.1(d) [HSR Act and Regulatory Approvals]), (ii) by Sodium or the Company pursuant to Section 8.1(c) [Termination for Mutual Legal Restraint] and at the time of, or prior to, such termination, each of the conditions set forth in Article VII shall have been satisfied (other than the conditions set forth in Section 7.1(c) [Absence of Mutual Legal Restraint] (excluding any Mutual Legal Restraint relating to CFIUS) or Section 7.1(d) [HSR Act and Regulatory Approvals]) or (iii) by Sodium pursuant to Section 8.1(b) if it does not exercise its right to an Extension Election or pursuant to Section 8.1(h), then, in the case of clause (i), (ii) or (iii) Sodium shall pay to the Company, within three (3) business days after the date of termination, the Sodium Termination Fee, by wire transfer of same day federal funds to the account specified by the Company.",
        "reference_section": "ARTICLE Article VIII TERMINATION > Section 8.3 Termination Fees > (d)"
      }
    ],
    "termination_rights": [
      {
        "section": "termination",
        "field_name": "mutual_termination_rights",
        "answer": [
          "by either the Company or Sodium, if the Merger shall not have been consummated on or prior to April 2, 2025 (the 'End Date'); provided, however, that if all of the conditions to Closing, other than any of the conditions set forth in Section 7.1(c), Section 7.1(d) or, at the election of Sodium, Section 7.3(d) (such election, an 'Extension Election'), shall have been satisfied or shall be capable of being satisfied at such time (other than those conditions that by their nature are to be satisfied at the Closing), the End Date shall automatically be extended to October 2, 2025, which date shall thereafter be deemed to be the End Date; provided, further, that the right to terminate this Agreement pursuant to this Section 8.1(b) shall not be available to a party if the failure of the Closing to occur by such date shall be due to the material breach by such party of any representation, warranty, covenant or other agreement of such party set forth in this Agreement",
          "by either the Company or Sodium, if the Closing would violate any final and non-appealable Mutual Legal Restraint; provided, however, that the right to terminate this Agreement under this Section 8.1(c) shall not be available to a party if the failure of such party to perform any of its obligations under this Agreement contributed, in any material respect, to the issuance or continued existence of such Mutual Legal Restraint",
          "by either the Company or Sodium, if the Company Stockholder Meeting (including any adjournments or postponements thereof) shall have concluded, at which a vote upon the adoption of this Agreement was taken and the Company Stockholder Approval was not obtained"
        ],
        "summary": "The agreement may be mutually terminated if the merger is not consummated by the End Date, if the closing violates a final and non-appealable Mutual Legal Restraint, or if the Company Stockholder Approval is not obtained.",
        "confidence": 1.0,
        "reason": "",
        "clause_text": "Notwithstanding anything in this Agreement to the contrary, this Agreement may be terminated and abandoned at any time prior to the Effective Time, whether before or after Company Stockholder Approval has been obtained: (a) by the mutual written consent of the Company and Sodium; (b) by either the Company or Sodium, if the Merger shall not have been consummated on or prior to April 2, 2025 (the 'End Date'); provided, however, that if all of the conditions to Closing, other than any of the conditions set forth in Section 7.1(c), Section 7.1(d) or, at the election of Sodium, Section 7.3(d) (such election, an 'Extension Election'), shall have been satisfied or shall be capable of being satisfied at such time (other than those conditions that by their nature are to be satisfied at the Closing), the End Date shall automatically be extended to October 2, 2025, which date shall thereafter be deemed to be the End Date; provided, further, that the right to terminate this Agreement pursuant to this Section 8.1(b) shall not be available to a party if the failure of the Closing to occur by such date shall be due to the material breach by such party of any representation, warranty, covenant or other agreement of such party set forth in this Agreement; (c) by either the Company or Sodium, if the Closing would violate any final and non-appealable Mutual Legal Restraint; provided, however, that the right to terminate this Agreement under this Section 8.1(c) shall not be available to a party if the failure of such party to perform any of its obligations under this Agreement contributed, in any material respect, to the issuance or continued existence of such Mutual Legal Restraint; (d) by either the Company or Sodium, if the Company Stockholder Meeting (including any adjournments or postponements thereof) shall have concluded, at which a vote upon the adoption of this Agreement was taken and the Company Stockholder Approval was not obtained",
        "reference_section": "ARTICLE Article VIII TERMINATION > Section 8.1 Termination or Abandonment"
      },
      {
        "section": "termination",
        "field_name": "parent_termination_rights",
        "answer": [
          "by Sodium, if the Company shall have breached its representations or warranties or failed to perform its covenants or other agreements contained in this Agreement, which breach or failure to perform (i) if it occurred or was continuing to occur on the Closing Date, would result in a failure of a condition set forth in Section 7.3(a) or Section 7.3(b) and (ii) by its nature, cannot be cured prior to the End Date or, if such breach or failure is capable of being cured by the End Date, is not cured within thirty (30) days following written notice thereof to the Company or by its nature or timing cannot be cured during such period (or, in each case, such fewer days as remain prior to the End Date)",
          "by Sodium, prior to receipt of the Company Stockholder Approval in the event of a Company Change of Recommendation",
          "by Sodium, if the Closing would violate any final and non-appealable Specified Legal Restraint; provided, however, that the right to terminate this Agreement under this Section 8.1(h) shall not be available to Sodium if its failure to perform any of its obligations under this Agreement contributed, in any material respect, to the issuance or continued existence of such Specified Legal Restraint"
        ],
        "summary": "Sodium has the right to terminate the agreement unilaterally if the Company breaches its obligations, if there is a Company Change of Recommendation before stockholder approval, or if the Closing violates a Specified Legal Restraint not caused by Sodium.",
        "confidence": 1.0,
        "reason": "",
        "clause_text": "by Sodium, if the Company shall have breached its representations or warranties or failed to perform its covenants or other agreements contained in this Agreement, which breach or failure to perform (i) if it occurred or was continuing to occur on the Closing Date, would result in a failure of a condition set forth in Section 7.3(a) or Section 7.3(b) and (ii) by its nature, cannot be cured prior to the End Date or, if such breach or failure is capable of being cured by the End Date, is not cured within thirty (30) days following written notice thereof to the Company or by its nature or timing cannot be cured during such period (or, in each case, such fewer days as remain prior to the End Date); by Sodium, prior to receipt of the Company Stockholder Approval in the event of a Company Change of Recommendation; and by Sodium, if the Closing would violate any final and non-appealable Specified Legal Restraint; provided, however, that the right to terminate this Agreement under this Section 8.1(h) shall not be available to Sodium if its failure to perform any of its obligations under this Agreement contributed, in any material respect, to the issuance or continued existence of such Specified Legal Restraint.",
        "reference_section": "ARTICLE Article VIII TERMINATION > Section 8.1 Termination or Abandonment"
      },
      {
        "section": "termination",
        "field_name": "company_termination_rights",
        "answer": [
          "by the Company, if Sodium, Sodium US or Merger Sub shall have breached its representations or warranties or failed to perform its covenants or other agreements contained in this Agreement, which breach or failure to perform (i) if it occurred or was continuing to occur on the Closing Date, would result in a failure of a condition set forth in Section 7.2(a) or Section 7.2(b) and (ii) by its nature, cannot be cured prior to the End Date or, if such breach or failure is capable of being cured by the End Date, is not cured within thirty (30) days following written notice thereof to Sodium or by its nature or timing cannot be cured during such period (or, in each case, such fewer days as remain prior to the End Date)"
        ],
        "summary": "The Company can terminate the agreement if Sodium, Sodium US, or Merger Sub breaches its representations or fails to perform covenants, and such breach cannot be cured by the End Date or within 30 days of notice.",
        "confidence": 1.0,
        "reason": "",
        "clause_text": "by the Company, if Sodium, Sodium US or Merger Sub shall have breached its representations or warranties or failed to perform its covenants or other agreements contained in this Agreement, which breach or failure to perform (i) if it occurred or was continuing to occur on the Closing Date, would result in a failure of a condition set forth in Section 7.2(a) or Section 7.2(b) and (ii) by its nature, cannot be cured prior to the End Date or, if such breach or failure is capable of being cured by the End Date, is not cured within thirty (30) days following written notice thereof to Sodium or by its nature or timing cannot be cured during such period (or, in each case, such fewer days as remain prior to the End Date)",
        "reference_section": "ARTICLE Article VIII TERMINATION > Section 8.1 Termination or Abandonment > (e)"
      }
    ],
    "termination_fee_events": [
      {
        "section": "termination",
        "field_name": "company_termination_fee_events",
        "answer": [
          "Termination of the Agreement by the Company or Sodium pursuant to Section 8.1(b) [End Date], Section 8.1(d) [No Company Stockholder Approval], or Section 8.1(f) [Company Breach of Representation or Failure to Perform Covenant] if a Company Acquisition Proposal is publicly disclosed and not withdrawn prior to termination, and a Company Acquisition Transaction is consummated within twelve months after termination.",
          "Termination by Sodium pursuant to Section 8.1(g) [Company Change of Recommendation]."
        ],
        "summary": "The Company is required to pay a termination fee if the Agreement is terminated under specific conditions related to a Company Acquisition Proposal or a Company Change of Recommendation.",
        "confidence": 1.0,
        "reason": "",
        "clause_text": "If (i) prior to the Company Stockholder Meeting, a Company Acquisition Proposal is publicly disclosed after the date of this Agreement, (ii) this Agreement is terminated by the Company or Sodium, as applicable, pursuant to Section 8.1(b) [End Date], Section 8.1(d) [No Company Stockholder Approval] or Section 8.1(f). [Company Breach of Representation or Failure to Perform Covenant] and the breach giving rise to the right to terminate this Agreement pursuant to Section 8.1(f) [Company Breach of Representation or Failure to Perform Covenant] was the Company's failure to convene and hold the Company Stockholder Meeting in violation of Section 6.5(c) or a breach of the Company's obligations under Section 6.4, (iii) such Company Acquisition Proposal shall not have been withdrawn prior to such termination and (iv) within twelve (12) months after any such termination described in clause (ii), the Company shall have consummated, or shall have entered into an agreement to consummate any Company Acquisition Transaction, which is subsequently consummated (whether before or after such twelve (12)-month period), then the Company shall pay to Sodium an amount equal to the Company Termination Fee, by wire transfer of same day federal funds to the account specified by Sodium, within three (3) business days after the consummation of any such Company Acquisition Transaction. (b) If this Agreement is terminated by Sodium pursuant to Section 8.1(g) [Company Change of Recommendation], then the Company shall pay to Sodium, within three (3) business days after the date of termination, the Company Termination Fee, by wire transfer of same day federal funds to the account specified by Sodium.",
        "reference_section": "ARTICLE Article VIII TERMINATION > Section 8.3 Termination Fees > (a), (b)"
      },
      {
        "section": "termination",
        "field_name": "parent_reverse_termination_fee_events",
        "answer": "Not found",
        "summary": "",
        "confidence": 1.0,
        "reason": "",
        "clause_text": "",
        "reference_section": ""
      }
    ],
    "reimbursement_obligations": [
      {
        "section": "termination",
        "field_name": "target_reimbursement_obligations",
        "answer": "Not found",
        "summary": "",
        "confidence": 1.0,
        "reason": "",
        "clause_text": "",
        "reference_section": ""
      },
      {
        "section": "termination",
        "field_name": "parent_reimbursement_obligations",
        "answer": "Not found",
        "summary": "",
        "confidence": 1.0,
        "reason": "",
        "clause_text": "",
        "reference_section": ""
      }
    ],
    "regulatory_termination_fee": [
      {
        "section": "termination",
        "field_name": "regulatory_termination_fee",
        "answer": "Not found",
        "summary": "",
        "confidence": 1.0,
        "reason": "",
        "clause_text": "",
        "reference_section": ""
      }
    ],
    "failure_to_close_fee": [
      {
        "section": "termination",
        "field_name": "failure_to_close_fee",
        "answer": "Not found",
        "summary": "",
        "confidence": 1.0,
        "reason": "",
        "clause_text": "",
        "reference_section": ""
      }
    ],
    "reverse_termination_fee_regulatory": [
      {
        "section": "termination",
        "field_name": "reverse_termination_fee_regulatory",
        "answer": "Not found",
        "summary": "",
        "confidence": 1.0,
        "reason": "",
        "clause_text": "",
        "reference_section": ""
      }
    ],
    "extend_or_terminate_limitation_due_to_breach": [
      {
        "section": "termination",
        "field_name": "extend_or_terminate_limitation_due_to_breach",
        "answer": "Not found",
        "summary": "",
        "confidence": 1.0,
        "reason": "",
        "clause_text": "",
        "reference_section": ""
      }
    ]
  },
  "ordinary_course": {
    "company_ordinary_course_covenant": [
      {
        "section": "ordinary_course",
        "field_name": "company_conduct_covenant_summary",
        "answer": "The Company is required to conduct its business in the ordinary course and preserve its relationships with significant business partners during the interim period, subject to exceptions for legal requirements, written consent from Sodium, or as required by the Agreement.",
        "summary": "The Company must operate in the ordinary course of business and maintain relationships with key partners, with exceptions for legal requirements, consent from Sodium, or as required by the Agreement.",
        "confidence": 0.95,
        "reason": "The clause explicitly states the requirement for the Company to conduct business in the ordinary course and preserve relationships, with specified exceptions.",
        "clause_text": "From and after the date hereof until the earlier of the Effective Time and the Termination Date, and except (i) as may be required by applicable Law, (ii) as may be consented to in writing by Sodium (which consent shall not be unreasonably withheld, delayed or conditioned), (iii) as contemplated or required by this Agreement or (iv) as set forth in Section 6.1(a) of the Company Disclosure Schedule, the Company shall (A) conduct its business, and cause its Subsidiaries to conduct their business, in each case, in the ordinary course of business, and (B) preserve, and cause its Subsidiaries to preserve, their relationships with clients, customers, suppliers, distributors and creditors and other persons with which such entity has significant business relations, in the case of this clause (B), in all material respects.",
        "reference_section": "ARTICLE VI – Covenants and Agreements > Section 6.1 – Conduct of Business by the Company > (a)"
      }
    ],
    "parent_ordinary_course_covenant": [
      {
        "section": "ordinary_course",
        "field_name": "parent_conduct_covenant_summary",
        "answer": "Not found",
        "summary": "",
        "confidence": 1.0,
        "reason": "",
        "clause_text": "",
        "reference_section": ""
      }
    ]
  },
  "board_approval": {
    "board_approval": [
      {
        "section": "board_approval",
        "field_name": "target_board_approval",
        "answer": true,
        "summary": "",
        "confidence": 1.0,
        "reason": "The merger agreement explicitly states that the Company Board has unanimously authorized and approved the agreement and the transactions.",
        "clause_text": "WHEREAS, the Board of Directors of the Company (the 'Company Board'), at a meeting duly called and held on or prior to the date of this Agreement, has unanimously (a) determined that this Agreement and the consummation of the Merger and the transactions contemplated hereby (collectively, the 'Transactions'), to be fair to and in the best interests of the Company and its stockholders, (b) declared this Agreement and the consummation of the Transactions, including the Merger, to be advisable, (c) authorized and approved this Agreement, including the execution, delivery and performance thereof...",
        "reference_section": "ARTICLE Preamble"
      },
      {
        "section": "board_approval",
        "field_name": "target_board_unanimous",
        "answer": true,
        "summary": "The Company Board unanimously determined that the Agreement and the Transactions are fair and in the best interests of the Company and its stockholders.",
        "confidence": 1.0,
        "reason": "",
        "clause_text": "WHEREAS, the Board of Directors of the Company (the \"Company Board\"), at a meeting duly called and held on or prior to the date of this Agreement, has unanimously (a) determined that this Agreement and the consummation of the Merger and the transactions contemplated hereby (collectively, the \"Transactions\"), to be fair to and in the best interests of the Company and its stockholders...",
        "reference_section": "ARTICLE Preamble"
      },
      {
        "section": "board_approval",
        "field_name": "acquirer_board_approval",
        "answer": true,
        "summary": "",
        "confidence": 1.0,
        "reason": "The merger agreement explicitly states that the Sodium Board has approved the transaction.",
        "clause_text": "The Sodium Board has unanimously (a) determined that it is in the best interests of Sodium and its stockholders, and declared it advisable, to enter into this Agreement, and (b) approved the execution, delivery and performance by Sodium of this Agreement and the Transactions, including the Merger.",
        "reference_section": "ARTICLE Article V REPRESENTATIONS AND WARRANTIES OF SODIUM > Section 5.3 Authority; Noncontravention"
      },
      {
        "section": "board_approval",
        "field_name": "acquirer_board_unanimous",
        "answer": false,
        "summary": "",
        "confidence": 1.0,
        "reason": "There is no mention of unanimous approval by the Parent or Acquirer Board in the provided excerpts.",
        "clause_text": "WHEREAS, the Board of Directors of Sodium (the \"Sodium Board\"), at a meeting duly called and held on or prior to the date of this Agreement, has unanimously (a) determined that the Transactions are advisable and in the best interests of Sodium and its stockholders and (b) approved and declared advisable this Agreement and the Transactions, including the Merger;",
        "reference_section": "ARTICLE Preamble"
      }
    ]
  },
  "party_details": {
    "acquirer": [
      {
        "section": "party_details",
        "field_name": "acquirer",
        "answer": "Schlumberger Limited",
        "summary": "The acquiring entity in the merger is Schlumberger Limited, a Curaçao corporation, referred to as 'Sodium' in the agreement.",
        "confidence": 0.95,
        "reason": "The agreement explicitly names Schlumberger Limited as the acquiring entity initiating the transaction.",
        "clause_text": "This AGREEMENT AND PLAN OF MERGER (this \"Agreement\"), dated as of April 2, 2024, is by and among Schlumberger Limited, a Curaçao corporation (\"Sodium\"), Sodium Holdco, Inc., a Delaware corporation and indirect wholly owned Subsidiary of Sodium, (\"Sodium US\"), Sodium Merger Sub, Inc., a Delaware corporation and direct wholly owned Subsidiary of Sodium US (\"Merger Sub\"), and ChampionX Corporation, a Delaware corporation (the \"Company\").",
        "reference_section": "ARTICLE Preamble"
      },
      {
        "section": "party_details",
        "field_name": "parent_entity_details",
        "answer": "Schlumberger Limited",
        "summary": "Schlumberger Limited is the ultimate parent company of the acquiring entities, with Sodium US being an indirect wholly owned subsidiary and Merger Sub being a direct wholly owned subsidiary of Sodium US.",
        "confidence": 0.95,
        "reason": "The agreement explicitly states the hierarchical relationship among the entities involved in the acquisition.",
        "clause_text": "This AGREEMENT AND PLAN OF MERGER (this \"Agreement\"), dated as of April 2, 2024, is by and among Schlumberger Limited, a Curaçao corporation (\"Sodium\"), Sodium Holdco, Inc., a Delaware corporation and indirect wholly owned Subsidiary of Sodium, (\"Sodium US\"), Sodium Merger Sub, Inc., a Delaware corporation and direct wholly owned Subsidiary of Sodium US (\"Merger Sub\"), and ChampionX Corporation, a Delaware corporation (the \"Company\").",
        "reference_section": "ARTICLE Preamble"
      }
    ],
    "target": [
      {
        "section": "party_details",
        "field_name": "target",
        "answer": "ChampionX Corporation",
        "summary": "The full legal name of the target company being acquired is ChampionX Corporation, as defined in the agreement.",
        "confidence": 1.0,
        "reason": "",
        "clause_text": "This AGREEMENT AND PLAN OF MERGER (this \"Agreement\"), dated as of April 2, 2024, is by and among Schlumberger Limited, a Curaçao corporation (\"Sodium\"), Sodium Holdco, Inc., a Delaware corporation and indirect wholly owned Subsidiary of Sodium, (\"Sodium US\"), Sodium Merger Sub, Inc., a Delaware corporation and direct wholly owned Subsidiary of Sodium US (\"Merger Sub\"), and ChampionX Corporation, a Delaware corporation (the \"Company\").",
        "reference_section": "ARTICLE Preamble"
      }
    ],
    "guarantor": [
      {
        "section": "party_details",
        "field_name": "guarantor_present",
        "answer": false,
        "summary": "",
        "confidence": 1.0,
        "reason": "There is no explicit identification of a separate guarantor distinct from Parent or Merger Sub that guarantees obligations using terms such as 'guarantor', 'guarantees', 'guaranty', or 'backstop'.",
        "clause_text": "The provided excerpts do not contain any mention of a separate guarantor or related terms.",
        "reference_section": "NA"
      },
      {
        "section": "party_details",
        "field_name": "guarantor_details",
        "answer": "Not found",
        "summary": "",
        "confidence": 1.0,
        "reason": "",
        "clause_text": "",
        "reference_section": ""
      }
    ],
    "subsidiaries": [
      {
        "section": "party_details",
        "field_name": "target_subsidiaries_present",
        "answer": false,
        "summary": "",
        "confidence": 1.0,
        "reason": "There is no explicit reference to any subsidiaries of the target company being directly involved in the merger structure.",
        "clause_text": "The obligation of Sodium, Sodium US and Merger Sub to effect the Merger is further subject to the fulfillment (or the waiver by Sodium, to the extent permitted under applicable Law) at or prior to the Effective Time of the following conditions: (a) The representations and warranties of the Company set forth in (i) Article III of this Agreement...",
        "reference_section": "ARTICLE Article VII CONDITIONS TO THE MERGER > Section 7.3 Conditions to Obligation of Sodium, Sodium US and Merger Sub to Effect the Merger"
      },
      {
        "section": "party_details",
        "field_name": "target_subsidiaries",
        "answer": "No target subsidiaries explicitly involved in the merger structure are mentioned.",
        "summary": "The agreement does not explicitly reference any subsidiaries of the target company as being directly involved in the merger structure.",
        "confidence": 0.9,
        "reason": "The provided excerpts do not mention any specific subsidiaries of the target company being involved in the merger mechanics.",
        "clause_text": "Upon the terms and subject to the conditions set forth in this Agreement, at the Effective Time (as defined below), Merger Sub shall be merged with and into the Company in accordance with the requirements of the DGCL, whereupon the separate existence of Merger Sub shall cease, and the Company shall be the surviving corporation in the Merger (the 'Surviving Corporation').",
        "reference_section": "ARTICLE Article I THE MERGER > Section 1.1 The Merger"
      },
      {
        "section": "party_details",
        "field_name": "acquirer_subsidiaries_present",
        "answer": true,
        "summary": "",
        "confidence": 1.0,
        "reason": "The document explicitly references 'Sodium US and Merger Sub' as subsidiaries involved in the merger structure.",
        "clause_text": "The obligation of Sodium, Sodium US and Merger Sub to effect the Merger is further subject to the fulfillment (or the waiver by Sodium, to the extent permitted under applicable Law) at or prior to the Effective Time of the following conditions:",
        "reference_section": "ARTICLE VII CONDITIONS TO THE MERGER > Section 7.3 Conditions to Obligation of Sodium, Sodium US and Merger Sub to Effect the Merger"
      },
      {
        "section": "party_details",
        "field_name": "acquirer_subsidiaries",
        "answer": "No parent subsidiaries explicitly involved in the merger structure are mentioned.",
        "summary": "",
        "confidence": 1.0,
        "reason": "",
        "clause_text": "",
        "reference_section": ""
      }
    ],
    "transaction": [
      {
        "section": "party_details",
        "field_name": "transaction_type",
        "answer": "Reverse Triangular Merger",
        "summary": "The transaction involves Merger Sub merging with and into the Company, with the Company surviving, which is characteristic of a Reverse Triangular Merger.",
        "confidence": 0.95,
        "reason": "The structure described matches the standard definition of a Reverse Triangular Merger.",
        "clause_text": "Upon the terms and subject to the conditions set forth in this Agreement, at the Effective Time (as defined below), Merger Sub shall be merged with and into the Company in accordance with the requirements of the DGCL, whereupon the separate existence of Merger Sub shall cease, and the Company shall be the surviving corporation in the Merger (the 'Surviving Corporation').",
        "reference_section": "ARTICLE Article I THE MERGER > Section 1.1 The Merger"
      },
      {
        "section": "party_details",
        "field_name": "transaction_structure_notes",
        "answer": "Merger Sub shall be merged with and into the Company, with the Company as the surviving corporation. The separate existence of Merger Sub shall cease, and all property, rights, and liabilities of both entities will vest in the Surviving Corporation.",
        "summary": "The transaction involves Merger Sub merging into the Company, with the Company continuing as the surviving corporation, and all assets and liabilities transferring to the Surviving Corporation.",
        "confidence": 0.95,
        "reason": "The document explicitly outlines the merger structure, detailing the roles of Merger Sub and the Company.",
        "clause_text": "Upon the terms and subject to the conditions set forth in this Agreement, at the Effective Time (as defined below), Merger Sub shall be merged with and into the Company in accordance with the requirements of the DGCL, whereupon the separate existence of Merger Sub shall cease, and the Company shall be the surviving corporation in the Merger (the 'Surviving Corporation').",
        "reference_section": "ARTICLE Article I THE MERGER > Section 1.1 The Merger"
      }
    ],
    "merger_sub_details": [
      {
        "section": "party_details",
        "field_name": "merger_sub_details",
        "answer": "Sodium Merger Sub, Inc., a Delaware corporation and direct wholly owned Subsidiary of Sodium US",
        "summary": "The Merger Sub is identified as Sodium Merger Sub, Inc., a Delaware corporation and direct wholly owned Subsidiary of Sodium US.",
        "confidence": 1.0,
        "reason": "The document explicitly states the full legal name, jurisdiction, and ownership relationship of the Merger Sub.",
        "clause_text": "Sodium Merger Sub, Inc., a Delaware corporation and direct wholly owned Subsidiary of Sodium US",
        "reference_section": "ARTICLE Preamble"
      }
    ]
  },
  "closing_mechanics": {
    "target_date": [
      {
        "section": "closing_mechanics",
        "field_name": "target_date",
        "answer": "2 business days after the satisfaction or waiver of the conditions set forth in Article VII",
        "summary": "The closing of the Merger is scheduled to occur on the second business day following the satisfaction or waiver of the conditions outlined in Article VII.",
        "confidence": 0.9,
        "reason": "The closing date is procedurally defined as occurring shortly after the conditions are met, which is a standard practice in M&A agreements.",
        "clause_text": "The closing of the Merger (the \"Closing\") shall take place at the offices of Latham & Watkins LLP, 811 Main Street, Suite 3700, Houston, Texas, 77002, at 10:00 a.m., local time, on the second (2nd) business day after the satisfaction or waiver (to the extent permitted by applicable Law) of the conditions set forth in Article VII...",
        "reference_section": "ARTICLE Article I THE MERGER > Section 1.2 Closing"
      }
    ],
    "marketing_period": [
      {
        "section": "closing_mechanics",
        "field_name": "has_marketing_period",
        "answer": false,
        "summary": "",
        "confidence": 1.0,
        "reason": "The term 'Marketing Period' is not mentioned or explicitly referenced in connection with financing, deliverables, or closing timing in the provided excerpts.",
        "clause_text": "The provided excerpts do not contain any reference to a 'Marketing Period'.",
        "reference_section": "No specific section references 'Marketing Period' in the provided excerpts."
      },
      {
        "section": "closing_mechanics",
        "field_name": "marketing_period_details",
        "answer": "Not found",
        "summary": "",
        "confidence": 1.0,
        "reason": "",
        "clause_text": "",
        "reference_section": ""
      }
    ],
    "inside_date": [
      {
        "section": "closing_mechanics",
        "field_name": "has_inside_date",
        "answer": false,
        "summary": "",
        "confidence": 1.0,
        "reason": "There is no explicit definition or reference to an 'Inside Date' as a deadline or milestone prior to the Outside Date in the provided excerpts.",
        "clause_text": "The excerpts provided do not contain any mention of an 'Inside Date'.",
        "reference_section": "Not applicable as there is no relevant section mentioning 'Inside Date'."
      },
      {
        "section": "closing_mechanics",
        "field_name": "inside_date_details",
        "answer": "Not found",
        "summary": "",
        "confidence": 1.0,
        "reason": "",
        "clause_text": "",
        "reference_section": ""
      }
    ]
  },
  "specific_performance": {
    "specific_performance": [
      {
        "section": "specific_performance",
        "field_name": "specific_performance_available",
        "answer": true,
        "summary": "",
        "confidence": 1.0,
        "reason": "The agreement expressly states that each party is entitled to specific performance as a remedy.",
        "clause_text": "It is accordingly agreed that, in addition to any other remedy that may be available to it at law or in equity, each of the parties shall be entitled to an injunction or injunctions or equitable relief to prevent breaches of this Agreement and to enforce specifically the terms and provisions of this Agreement exclusively in the Delaware Court of Chancery...",
        "reference_section": "ARTICLE Article IX MISCELLANEOUS > Section 9.5 Jurisdiction; Specific Enforcement > (a)"
      },
      {
        "section": "specific_performance",
        "field_name": "specific_performance_parties",
        "answer": "Company",
        "summary": "The Company, acting through the Company Agent, is entitled to seek specific performance in the event of a Willful Breach or Fraud by Sodium, Sodium US, or Merger Sub.",
        "confidence": 0.9,
        "reason": "The clause specifies that the stockholders of the Company, through the Company Agent, can pursue specific performance.",
        "clause_text": "Notwithstanding the foregoing, in the event of Sodium, Sodium US or Merger Sub's Willful Breach of this Agreement or Fraud, then the stockholders of the Company, acting solely through the Company Agent (as defined below), shall be entitled to pursue specific performance as set forth in Section 9.5.",
        "reference_section": "ARTICLE Article IX MISCELLANEOUS > Section 9.13 No Third-Party Beneficiaries; Appointment of Agent > (a)"
      },
      {
        "section": "specific_performance",
        "field_name": "specific_performance_limitations",
        "answer": "The right to seek specific performance is subject to limitations related to Willful Breach or Fraud by Sodium, Sodium US, or Merger Sub. In such cases, the stockholders of the Company, through the Company Agent, may pursue specific performance or damages.",
        "summary": "Specific performance can be pursued in cases of Willful Breach or Fraud by Sodium, Sodium US, or Merger Sub, but only through the Company Agent acting on behalf of the stockholders.",
        "confidence": 0.9,
        "reason": "The agreement specifies that specific performance is available in cases of Willful Breach or Fraud, enforceable only by the Company Agent.",
        "clause_text": "Notwithstanding the foregoing, in the event of Sodium, Sodium US or Merger Sub's Willful Breach of this Agreement or Fraud, then the stockholders of the Company, acting solely through the Company Agent (as defined below), shall be entitled to pursue specific performance as set forth in Section 9.5, or, if specific performance is not sought or granted as a remedy, damages...",
        "reference_section": "ARTICLE IX MISCELLANEOUS > Section 9.13 No Third-Party Beneficiaries; Appointment of Agent > (a)"
      },
      {
        "section": "specific_performance",
        "field_name": "specific_performance_financing_condition",
        "answer": false,
        "summary": "",
        "confidence": 1.0,
        "reason": "There is no explicit language making specific performance conditional upon the availability of debt or equity financing.",
        "clause_text": "The parties agree that irreparable damage, for which monetary damages would not be an adequate remedy, would occur in the event that any of the provisions of this Agreement were not performed, or were threatened to be not performed, in accordance with their specific terms or were otherwise breached.",
        "reference_section": "ARTICLE Article IX MISCELLANEOUS > Section 9.5 Jurisdiction; Specific Enforcement"
      },
      {
        "section": "specific_performance",
        "field_name": "specific_performance_financing_details",
        "answer": "Not found",
        "summary": "",
        "confidence": 1.0,
        "reason": "",
        "clause_text": "",
        "reference_section": ""
      }
    ]
  },
  "confidentiality_and_clean_room": {
    "confidentiality": [
      {
        "section": "confidentiality_and_clean_room",
        "field_name": "confidentiality_exists",
        "answer": true,
        "summary": "",
        "confidence": 1.0,
        "reason": "The agreement explicitly references a confidentiality agreement between the parties.",
        "clause_text": "This Agreement together with the exhibits hereto, schedules hereto, and the Confidentiality Agreement constitute the entire agreement, and supersede all other prior agreements and understandings, both written and oral, between the parties, or any of them, with respect to the subject matter hereof and thereof.",
        "reference_section": "ARTICLE Article IX MISCELLANEOUS > Section 9.10 Entire Agreement"
      },
      {
        "section": "confidentiality_and_clean_room",
        "field_name": "confidentiality_agreement_date",
        "answer": "March 8, 2024",
        "summary": "The confidentiality agreement was signed on March 8, 2024, as referenced in the agreement.",
        "confidence": 1.0,
        "reason": "The confidentiality agreement date is explicitly mentioned in the document.",
        "clause_text": "The parties hereto hereby agree that all information provided to them or their respective officers, directors, employees or Representatives in connection with this Agreement and the consummation of the Transactions shall be governed in accordance with the confidentiality agreement, dated as of March 8, 2024, between the Company and Sodium (the 'Confidentiality Agreement').",
        "reference_section": "ARTICLE VI – Covenants and Agreements > Section 6.3 Mutual Access > (b)"
      },
      {
        "section": "confidentiality_and_clean_room",
        "field_name": "confidentiality_obligation_termination_date",
        "answer": "Not found",
        "summary": "",
        "confidence": 1.0,
        "reason": "",
        "clause_text": "",
        "reference_section": ""
      },
      {
        "section": "confidentiality_and_clean_room",
        "field_name": "confidentiality_amendment_exists",
        "answer": false,
        "summary": "",
        "confidence": 1.0,
        "reason": "There is a statement confirming that no amendments or modifications to the Confidentiality Agreement shall be made without written consent.",
        "clause_text": "The Company Disclosure Schedule and Sodium Disclosure Schedule shall each be delivered as of the entry into this Agreement, and no amendments or modifications thereto shall be made without the written consent of Sodium (in the case of an amendment or modification to the Company Disclosure Schedule) or the Company (in the case of an amendment or modification to the Sodium Disclosure Schedule).",
        "reference_section": "ARTICLE IX MISCELLANEOUS > Section 9.11 Disclosure Schedules"
      },
      {
        "section": "confidentiality_and_clean_room",
        "field_name": "confidentiality_amendment_date",
        "answer": "March 8, 2024",
        "summary": "The confidentiality agreement was dated as of March 8, 2024, between the Company and Sodium.",
        "confidence": 0.9,
        "reason": "The date of the confidentiality agreement is explicitly mentioned in the document.",
        "clause_text": "The parties hereto hereby agree that all information provided to them or their respective officers, directors, employees or Representatives in connection with this Agreement and the consummation of the Transactions shall be governed in accordance with the confidentiality agreement, dated as of March 8, 2024, between the Company and Sodium (the 'Confidentiality Agreement').",
        "reference_section": "ARTICLE VI COVENANTS AND AGREEMENTS > Section 6.3 Mutual Access"
      }
    ],
    "clean_room": [
      {
        "section": "confidentiality_and_clean_room",
        "field_name": "clean_room_exists",
        "answer": false,
        "summary": "",
        "confidence": 1.0,
        "reason": "There is no reference to a Clean Room or Clean Team arrangement in the provided excerpts.",
        "clause_text": "The provided excerpts do not mention a Clean Room or Clean Team arrangement.",
        "reference_section": "Various sections provided, none mention Clean Room or Clean Team."
      },
      {
        "section": "confidentiality_and_clean_room",
        "field_name": "clean_room_signing_date",
        "answer": "Not found",
        "summary": "",
        "confidence": 1.0,
        "reason": "",
        "clause_text": "",
        "reference_section": ""
      },
      {
        "section": "confidentiality_and_clean_room",
        "field_name": "clean_room_start_date",
        "answer": "Not found",
        "summary": "",
        "confidence": 1.0,
        "reason": "",
        "clause_text": "",
        "reference_section": ""
      },
      {
        "section": "confidentiality_and_clean_room",
        "field_name": "clean_room_end_date",
        "answer": "Not found",
        "summary": "",
        "confidence": 1.0,
        "reason": "",
        "clause_text": "",
        "reference_section": ""
      },
      {
        "section": "confidentiality_and_clean_room",
        "field_name": "clean_room_scope_restrictions",
        "answer": "The Clean Room use is subject to several restrictions, including access limitations to prevent unreasonable disruption, violation of agreements, or loss of trade secret protection. Access is also restricted to avoid disclosure of information pertinent to litigation or in violation of applicable laws.",
        "summary": "The Clean Room use is subject to several restrictions, including access limitations to prevent unreasonable disruption, violation of agreements, or loss of trade secret protection. Access is also restricted to avoid disclosure of information pertinent to litigation or in violation of applicable laws.",
        "confidence": 0.9,
        "reason": "The clause outlines specific conditions under which access may be restricted, implying a structured and limited use of the Clean Room.",
        "clause_text": "Notwithstanding the foregoing, neither the Company nor Sodium shall be required to afford such access if it would, in such party's reasonable judgment, reasonably be expected to (1) unreasonably disrupt the operations of such party or any of its Subsidiaries, (2) cause a violation of any agreement to which such party or any of its Subsidiaries is a party, (3) waive or jeopardize any attorney-client or other applicable privilege to such party or any of its Subsidiaries, (4) result in the disclosure of any trade secrets in a manner that would result in any such trade secrets no longer being protected as such under applicable Law following such disclosure, (5) result in the disclosure of information or access that is reasonably pertinent or likely to be reasonably pertinent to a litigation where the Company or any of its Affiliates, on the one hand, and Sodium or any of its Affiliates, on the other hand, are adverse parties or reasonably likely to become adverse parties or (6) constitute a violation of any applicable Law; provided, that in such instances, the party withholding access shall provide written notice to the other party stating that it is withholding such access or such information and stating the justification therefor, and shall use commercially reasonable efforts to provide the applicable information in a way that would not have such effects or otherwise be restricted by this Section 6.3(a).",
        "reference_section": "ARTICLE VI – Covenants and Agreements > Section 6.3 – Mutual Access > (a)"
      },
      {
        "section": "confidentiality_and_clean_room",
        "field_name": "clean_room_protection_clause_present",
        "answer": true,
        "summary": "",
        "confidence": 1.0,
        "reason": "The agreement includes a clause that requires the Company to terminate all physical and electronic data room access previously granted to any person with respect to any Company Acquisition Proposal.",
        "clause_text": "Within one (1) business day following the execution of this Agreement, the Company shall...promptly terminate all physical and electronic data room access previously granted to any such person with respect to any Company Acquisition Proposal.",
        "reference_section": "ARTICLE Article VI COVENANTS AND AGREEMENTS > Section 6.4 Company Non-Solicitation; Company Acquisition Proposals; Company Change of Recommendation > (e)"
      },
      {
        "section": "confidentiality_and_clean_room",
        "field_name": "clean_room_protection_clause_summary",
        "answer": "The agreement contains a provision that requires the Company to request the prompt return or destruction of all non-public information or data previously furnished to any person with respect to any Company Acquisition Proposal, and to terminate all physical and electronic data room access previously granted to such persons.",
        "summary": "The Company must request the return or destruction of non-public information and terminate data room access in connection with a Company Acquisition Proposal.",
        "confidence": 0.9,
        "reason": "The clause explicitly requires the Company to take these actions in response to a Company Acquisition Proposal.",
        "clause_text": "Within one (1) business day following the execution of this Agreement, the Company shall, and shall cause its Subsidiaries and its and their respective officers, directors, and employees to, use its and their reasonable best efforts to cause its and their Representatives acting on its and their behalf to, (i) immediately cease and terminate any discussions existing as of the date of this Agreement between the Company or any of its Subsidiaries or any of its and their respective officers, directors, employees or Representatives acting on its and their behalf and any person (other than Sodium, Merger Sub or any of their respective officers, directors, employees or Representatives) that relate to any Company Acquisition Proposal and (ii) request the prompt return or destruction, to the extent permitted by any confidentiality agreement, of all non-public information or data previously furnished to any such person with respect to any Company Acquisition Proposal and promptly terminate all physical and electronic data room access previously granted to any such person with respect to any Company Acquisition Proposal.",
        "reference_section": "ARTICLE Article VI COVENANTS AND AGREEMENTS > Section 6.4 Company Non-Solicitation; Company Acquisition Proposals; Company Change of Recommendation > (e)"
      }
    ]
  },
  "complex_consideration_and_dividends": {
    "deal_consideration": [
      {
        "section": "complex_consideration_and_dividends",
        "field_name": "deal_consideration_overview",
        "answer": "Each share of Company Common Stock will be converted into the right to receive 0.735 Sodium Shares, with cash provided in lieu of any fractional Sodium Shares.",
        "summary": "Each share of Company Common Stock will be converted into the right to receive 0.735 Sodium Shares, with cash provided in lieu of any fractional Sodium Shares.",
        "confidence": 1.0,
        "reason": "",
        "clause_text": "Each share of Company Common Stock issued and outstanding immediately prior to the Effective Time (other than the Company Excluded Stock) will be converted, without any action on the part of the holder thereof, into the right to receive 0.735 Sodium Shares (such ratio, the \"Exchange Ratio\"), which Sodium Shares will be duly authorized and validly issued in accordance with applicable Laws (the \"Equity Consideration\").",
        "reference_section": "ARTICLE Article II EFFECT OF MERGER; EXCHANGE OF CERTIFICATES > Section 2.1 Conversion of Company Common Stock"
      },
      {
        "section": "complex_consideration_and_dividends",
        "field_name": "deal_consideration_details",
        "answer": "0.735 Sodium Shares per share of Company Common Stock and cash in lieu of fractional Sodium Shares",
        "summary": "The merger consideration consists of 0.735 Sodium Shares per share of Company Common Stock, with cash provided in lieu of any fractional Sodium Shares.",
        "confidence": 0.95,
        "reason": "The document explicitly states the exchange ratio and the provision for cash in lieu of fractional shares.",
        "clause_text": "Each share of Company Common Stock issued and outstanding immediately prior to the Effective Time (other than the Company Excluded Stock) will be converted, without any action on the part of the holder thereof, into the right to receive 0.735 Sodium Shares (such ratio, the \"Exchange Ratio\"), which Sodium Shares will be duly authorized and validly issued in accordance with applicable Laws (the \"Equity Consideration\").",
        "reference_section": "ARTICLE Article II EFFECT OF MERGER; EXCHANGE OF CERTIFICATES > Section 2.1 Conversion of Company Common Stock"
      },
      {
        "section": "complex_consideration_and_dividends",
        "field_name": "is_all_cash_deal",
        "answer": false,
        "summary": "",
        "confidence": 1.0,
        "reason": "The agreement specifies that each share of Company Common Stock will be converted into the right to receive Sodium Shares, indicating a non-cash component.",
        "clause_text": "Each share of Company Common Stock issued and outstanding immediately prior to the Effective Time (other than the Company Excluded Stock) will be converted, without any action on the part of the holder thereof, into the right to receive 0.735 Sodium Shares (such ratio, the 'Exchange Ratio'), which Sodium Shares will be duly authorized and validly issued in accordance with applicable Laws (the 'Equity Consideration').",
        "reference_section": "ARTICLE Article II EFFECT OF MERGER; EXCHANGE OF CERTIFICATES > Section 2.1 Conversion of Company Common Stock"
      }
    ],
    "proration": [
      {
        "section": "complex_consideration_and_dividends",
        "field_name": "proration_exists",
        "answer": false,
        "summary": "",
        "confidence": 1.0,
        "reason": "The document does not mention any proration between different types of consideration such as stock versus cash.",
        "clause_text": "Each share of Company Common Stock issued and outstanding immediately prior to the Effective Time (other than the Company Excluded Stock) will be converted, without any action on the part of the holder thereof, into the right to receive 0.735 Sodium Shares (such ratio, the 'Exchange Ratio').",
        "reference_section": "ARTICLE Article II EFFECT OF MERGER; EXCHANGE OF CERTIFICATES > Section 2.1 Conversion of Company Common Stock"
      },
      {
        "section": "complex_consideration_and_dividends",
        "field_name": "proration_details",
        "answer": "Not found",
        "summary": "",
        "confidence": 1.0,
        "reason": "",
        "clause_text": "",
        "reference_section": ""
      }
    ],
    "election": [
      {
        "section": "complex_consideration_and_dividends",
        "field_name": "election_exists",
        "answer": false,
        "summary": "",
        "confidence": 1.0,
        "reason": "The document does not provide any language indicating that shareholders can elect among different types of consideration.",
        "clause_text": "Each share of Company Common Stock issued and outstanding immediately prior to the Effective Time (other than the Company Excluded Stock) will be converted, without any action on the part of the holder thereof, into the right to receive 0.735 Sodium Shares.",
        "reference_section": "ARTICLE Article II EFFECT OF MERGER; EXCHANGE OF CERTIFICATES > Section 2.1 Conversion of Company Common Stock > (a)"
      },
      {
        "section": "complex_consideration_and_dividends",
        "field_name": "election_details",
        "answer": "No election is permitted and consideration is fixed.",
        "summary": "Shareholders are not allowed to choose the form of consideration; each share of Company Common Stock is converted into the right to receive 0.735 Sodium Shares.",
        "confidence": 0.95,
        "reason": "The agreement specifies a fixed exchange ratio for the conversion of shares, indicating no election is permitted.",
        "clause_text": "Each share of Company Common Stock issued and outstanding immediately prior to the Effective Time (other than the Company Excluded Stock) will be converted, without any action on the part of the holder thereof, into the right to receive 0.735 Sodium Shares (such ratio, the 'Exchange Ratio').",
        "reference_section": "ARTICLE Article II EFFECT OF MERGER; EXCHANGE OF CERTIFICATES > Section 2.1 Conversion of Company Common Stock"
      }
    ],
    "cvr": [
      {
        "section": "complex_consideration_and_dividends",
        "field_name": "cvr_exists",
        "answer": false,
        "summary": "",
        "confidence": 1.0,
        "reason": "There is no mention of a Contingent Value Right (CVR) in the provided document excerpts.",
        "clause_text": "The excerpts provided do not contain any reference to a Contingent Value Right (CVR).",
        "reference_section": "Various sections provided, none mention CVR"
      },
      {
        "section": "complex_consideration_and_dividends",
        "field_name": "cvr_details",
        "answer": "NA",
        "summary": "",
        "confidence": 1.0,
        "reason": "",
        "clause_text": "",
        "reference_section": ""
      }
    ],
    "ticking_fees": [
      {
        "section": "complex_consideration_and_dividends",
        "field_name": "ticking_fees_exists",
        "answer": false,
        "summary": "",
        "confidence": 1.0,
        "reason": "The document does not include any provision for a ticking fee, time-based fee, or incremental increase in consideration payable over time due to delay.",
        "clause_text": "The payment of the Company Termination Fee to Sodium pursuant to this Section 8.3 shall be the sole and exclusive monetary remedy available to Sodium, Sodium US or Merger Sub or any of their Affiliates in connection with this Agreement and the Transactions in any circumstance in which the Company Termination Fee is payable hereunder.",
        "reference_section": "ARTICLE Article VIII TERMINATION > Section 8.3 Termination Fees"
      },
      {
        "section": "complex_consideration_and_dividends",
        "field_name": "ticking_fees_details",
        "answer": "Not found",
        "summary": "",
        "confidence": 1.0,
        "reason": "",
        "clause_text": "",
        "reference_section": ""
      }
    ],
    "contingent_payments": [
      {
        "section": "complex_consideration_and_dividends",
        "field_name": "contingent_payments_exists",
        "answer": false,
        "summary": "",
        "confidence": 1.0,
        "reason": "There is no mention of contingent payments beyond CVRs in the provided excerpts.",
        "clause_text": "The provided document sections do not mention any contingent payments beyond CVRs.",
        "reference_section": "None of the provided sections explicitly mention contingent payments beyond CVRs."
      },
      {
        "section": "complex_consideration_and_dividends",
        "field_name": "contingent_payments_details",
        "answer": "Not found",
        "summary": "",
        "confidence": 1.0,
        "reason": "",
        "clause_text": "",
        "reference_section": ""
      }
    ],
    "company_dividends": [
      {
        "section": "complex_consideration_and_dividends",
        "field_name": "company_dividends_can_pay",
        "answer": false,
        "summary": "",
        "confidence": 1.0,
        "reason": "The merger agreement prohibits the Company from authorizing or paying any dividends on its outstanding equity securities, except for regular quarterly cash dividends not exceeding $0.095 per share per quarter.",
        "clause_text": "The Company shall not and shall cause its Subsidiaries not to... (iii) authorize or pay any dividends on or make any distribution with respect to its outstanding equity securities... other than... regular quarterly cash dividends with customary record and payment dates on the shares of Company Common Stock not in excess of $0.095 per share per quarter;",
        "reference_section": "ARTICLE VI – Covenants and Agreements > Section 6.1 – Conduct of Business by the Company > (b) > (iii)"
      },
      {
        "section": "complex_consideration_and_dividends",
        "field_name": "company_dividends_details",
        "answer": "Not found",
        "summary": "",
        "confidence": 1.0,
        "reason": "",
        "clause_text": "",
        "reference_section": ""
      }
    ],
    "parent_dividends": [
      {
        "section": "complex_consideration_and_dividends",
        "field_name": "parent_dividends_can_pay",
        "answer": false,
        "summary": "",
        "confidence": 1.0,
        "reason": "The merger agreement does not expressly permit the parent company to declare or pay dividends prior to closing.",
        "clause_text": "Sodium shall not, and shall cause its Subsidiaries not to: (iii) authorize or pay any dividends on or make any distribution with respect to the outstanding equity securities of Sodium (whether in cash, assets, capital stock or other securities of Sodium), except regular quarterly cash dividends on Sodium Shares consistent with past practice (including any historical increases in such cash dividends);",
        "reference_section": "ARTICLE VI – COVENANTS AND AGREEMENTS > Section 6.2 Conduct of Business by Sodium, Sodium US and Merger Sub > (b) > (iii)"
      },
      {
        "section": "complex_consideration_and_dividends",
        "field_name": "parent_dividends_details",
        "answer": "Regular quarterly cash dividends on Sodium Shares consistent with past practice are allowed.",
        "summary": "The merger agreement permits the parent to pay regular quarterly cash dividends on Sodium Shares consistent with past practice.",
        "confidence": 0.9,
        "reason": "The clause explicitly allows regular quarterly cash dividends consistent with past practice.",
        "clause_text": "Sodium shall not, and shall cause its Subsidiaries not to...authorize or pay any dividends on or make any distribution with respect to the outstanding equity securities of Sodium (whether in cash, assets, capital stock or other securities of Sodium), except regular quarterly cash dividends on Sodium Shares consistent with past practice (including any historical increases in such cash dividends);",
        "reference_section": "ARTICLE Article VI COVENANTS AND AGREEMENTS > Section 6.2 Conduct of Business by Sodium, Sodium US and Merger Sub > (b) > (iii)"
      }
    ],
    "collar": [
      {
        "section": "complex_consideration_and_dividends",
        "field_name": "collar_exists",
        "answer": false,
        "summary": "",
        "confidence": 1.0,
        "reason": "The document describes a fixed exchange ratio without any mention of a collar provision that adjusts consideration based on stock price movement.",
        "clause_text": "Each share of Company Common Stock issued and outstanding immediately prior to the Effective Time (other than the Company Excluded Stock) will be converted, without any action on the part of the holder thereof, into the right to receive 0.735 Sodium Shares (such ratio, the 'Exchange Ratio').",
        "reference_section": "ARTICLE Article II EFFECT OF MERGER; EXCHANGE OF CERTIFICATES > Section 2.1 Conversion of Company Common Stock"
      },
      {
        "section": "complex_consideration_and_dividends",
        "field_name": "collar_details",
        "answer": "Not found",
        "summary": "",
        "confidence": 1.0,
        "reason": "",
        "clause_text": "",
        "reference_section": ""
      }
    ],
    "exchange_ratio": [
      {
        "section": "complex_consideration_and_dividends",
        "field_name": "exchange_ratio_exists",
        "answer": true,
        "summary": "",
        "confidence": 1.0,
        "reason": "The agreement explicitly defines an exchange ratio for the merger consideration.",
        "clause_text": "Each share of Company Common Stock issued and outstanding immediately prior to the Effective Time (other than the Company Excluded Stock) will be converted, without any action on the part of the holder thereof, into the right to receive 0.735 Sodium Shares (such ratio, the 'Exchange Ratio').",
        "reference_section": "ARTICLE Article II EFFECT OF MERGER; EXCHANGE OF CERTIFICATES > Section 2.1 Conversion of Company Common Stock"
      },
      {
        "section": "complex_consideration_and_dividends",
        "field_name": "exchange_ratio_summary",
        "answer": "Each Company share will be exchanged for 0.735 Sodium Shares",
        "summary": "Each share of Company Common Stock will be converted into the right to receive 0.735 Sodium Shares as part of the merger consideration.",
        "confidence": 1.0,
        "reason": "The document explicitly states the exchange ratio and the conversion of Company shares into Sodium Shares.",
        "clause_text": "Each share of Company Common Stock issued and outstanding immediately prior to the Effective Time (other than the Company Excluded Stock) will be converted, without any action on the part of the holder thereof, into the right to receive 0.735 Sodium Shares (such ratio, the 'Exchange Ratio').",
        "reference_section": "ARTICLE Article II EFFECT OF MERGER; EXCHANGE OF CERTIFICATES > Section 2.1 Conversion of Company Common Stock"
      }
    ],
    "exchange_ratio_adjustment": [
      {
        "section": "complex_consideration_and_dividends",
        "field_name": "exchange_ratio_adjustment_exists",
        "answer": true,
        "summary": "",
        "confidence": 1.0,
        "reason": "The agreement provides for an adjustment to the Exchange Ratio based on events such as stock splits or stock dividends.",
        "clause_text": "If at any time during the period between the date of this Agreement and the Effective Time, any change in the outstanding shares of Company Common Stock or outstanding Sodium Shares shall occur as a result of any reclassification, stock split (including a reverse stock split) or combination, exchange or readjustment of shares, or any stock dividend or stock distribution with a record date during such period, the Equity Consideration, the Exchange Ratio and any other similarly dependent items shall be equitably adjusted.",
        "reference_section": "ARTICLE II – EFFECT OF MERGER; EXCHANGE OF CERTIFICATES > Section 2.1 Conversion of Company Common Stock > (c) Adjustments"
      },
      {
        "section": "complex_consideration_and_dividends",
        "field_name": "exchange_ratio_adjustment",
        "answer": "The exchange ratio will be adjusted if there are changes in the outstanding shares due to reclassification, stock split, or similar events.",
        "summary": "The exchange ratio will be equitably adjusted to maintain the same economic effect if there are changes in the outstanding shares due to reclassification, stock split, or similar events.",
        "confidence": 0.9,
        "reason": "The clause specifies adjustments to the exchange ratio in response to changes in outstanding shares to maintain economic equivalence.",
        "clause_text": "If at any time during the period between the date of this Agreement and the Effective Time, any change in the outstanding shares of Company Common Stock or outstanding Sodium Shares shall occur as a result of any reclassification, stock split (including a reverse stock split) or combination, exchange or readjustment of shares, or any stock dividend or stock distribution with a record date during such period, the Equity Consideration, the Exchange Ratio and any other similarly dependent items shall be equitably adjusted to provide to Sodium, Sodium US, Merger Sub and the holders of shares of Company Common Stock the same economic effect as contemplated by this Agreement prior to such action...",
        "reference_section": "ARTICLE II – Effect of Merger; Exchange of Certificates > Section 2.1 – Conversion of Company Common Stock > (c) Adjustments"
      }
    ],
    "dividend_adjustment_mechanism": [
      {
        "section": "complex_consideration_and_dividends",
        "field_name": "dividend_adjustment_mechanism_exists",
        "answer": true,
        "summary": "",
        "confidence": 1.0,
        "reason": "The merger consideration adjusts based on stock dividends or stock distributions prior to closing.",
        "clause_text": "If at any time during the period between the date of this Agreement and the Effective Time, any change in the outstanding shares of Company Common Stock or outstanding Sodium Shares shall occur as a result of any reclassification, stock split (including a reverse stock split) or combination, exchange or readjustment of shares, or any stock dividend or stock distribution with a record date during such period, the Equity Consideration, the Exchange Ratio and any other similarly dependent items shall be equitably adjusted...",
        "reference_section": "ARTICLE Article II EFFECT OF MERGER; EXCHANGE OF CERTIFICATES > Section 2.1 Conversion of Company Common Stock > (c)"
      },
      {
        "section": "complex_consideration_and_dividends",
        "field_name": "dividend_adjustment_mechanism",
        "answer": "The merger consideration will be equitably adjusted if any stock dividend or stock distribution occurs with a record date during the period between the date of the Agreement and the Effective Time.",
        "summary": "The merger consideration will be equitably adjusted if any stock dividend or stock distribution occurs with a record date during the period between the date of the Agreement and the Effective Time.",
        "confidence": 0.9,
        "reason": "The clause specifies adjustments for stock dividends or distributions, implying consideration adjustments for dividends.",
        "clause_text": "If at any time during the period between the date of this Agreement and the Effective Time, any change in the outstanding shares of Company Common Stock or outstanding Sodium Shares shall occur as a result of any reclassification, stock split (including a reverse stock split) or combination, exchange or readjustment of shares, or any stock dividend or stock distribution with a record date during such period, the Equity Consideration, the Exchange Ratio and any other similarly dependent items shall be equitably adjusted...",
        "reference_section": "ARTICLE II – EFFECT OF MERGER; EXCHANGE OF CERTIFICATES > Section 2.1 Conversion of Company Common Stock > (c) Adjustments"
      }
    ]
  },
  "law_and_jurisdiction": {
    "governing_law": [
      {
        "section": "law_and_jurisdiction",
        "field_name": "governing_law_exists",
        "answer": true,
        "summary": "",
        "confidence": 1.0,
        "reason": "The agreement explicitly states that it shall be governed by and construed in accordance with the laws of the State of Delaware.",
        "clause_text": "This Agreement, and all claims or causes of action (whether at Law, in contract or in tort or otherwise) that may be based upon, arise out of or relate to this Agreement or the negotiation, execution or performance hereof, shall be governed by and construed in accordance with the laws of the State of Delaware, without giving effect to any choice or conflict of law provision or rule (whether of the State of Delaware or any other jurisdiction) that would cause the application of the laws of any jurisdiction other than the State of Delaware.",
        "reference_section": "ARTICLE Article IX MISCELLANEOUS > Section 9.4 Governing Law"
      },
      {
        "section": "law_and_jurisdiction",
        "field_name": "governing_law_jurisdiction",
        "answer": "Delaware",
        "summary": "The agreement specifies that it shall be governed by and construed in accordance with the laws of the State of Delaware.",
        "confidence": 1.0,
        "reason": "The governing law jurisdiction is explicitly stated as the State of Delaware.",
        "clause_text": "This Agreement, and all claims or causes of action (whether at Law, in contract or in tort or otherwise) that may be based upon, arise out of or relate to this Agreement or the negotiation, execution or performance hereof, shall be governed by and construed in accordance with the laws of the State of Delaware, without giving effect to any choice or conflict of law provision or rule (whether of the State of Delaware or any other jurisdiction) that would cause the application of the laws of any jurisdiction other than the State of Delaware.",
        "reference_section": "ARTICLE Article IX MISCELLANEOUS > Section 9.4 Governing Law"
      }
    ],
    "incorporation_details": [
      {
        "section": "law_and_jurisdiction",
        "field_name": "parent_incorporation_details",
        "answer": "a Curaçao corporation",
        "summary": "Schlumberger Limited, referred to as 'Sodium', is incorporated as a Curaçao corporation.",
        "confidence": 1.0,
        "reason": "The document explicitly states the incorporation details of the Parent entity, Schlumberger Limited, as a Curaçao corporation.",
        "clause_text": "AGREEMENT AND PLAN OF MERGER (this \"Agreement\"), dated as of April 2, 2024, is by and among Schlumberger Limited, a Curaçao corporation (\"Sodium\"), Sodium Holdco, Inc., a Delaware corporation and indirect wholly owned Subsidiary of Sodium, (\"Sodium US\"), Sodium Merger Sub, Inc., a Delaware corporation and direct wholly owned Subsidiary of Sodium US (\"Merger Sub\"), and ChampionX Corporation, a Delaware corporation (the \"Company\").",
        "reference_section": "ARTICLE Preamble"
      },
      {
        "section": "law_and_jurisdiction",
        "field_name": "company_incorporation_details",
        "answer": "a Delaware corporation",
        "summary": "The Company is identified as a Delaware corporation in the preamble of the agreement.",
        "confidence": 1.0,
        "reason": "The preamble explicitly states the Company's incorporation details.",
        "clause_text": "ChampionX Corporation, a Delaware corporation (the \"Company\").",
        "reference_section": "ARTICLE Preamble"
      }
    ],
    "mae_interpretation_jurisdiction": [
      {
        "section": "law_and_jurisdiction",
        "field_name": "mae_interpretation_jurisdiction_exists",
        "answer": false,
        "summary": "",
        "confidence": 1.0,
        "reason": "There is no specific language stating that the interpretation of Material Adverse Effect (MAE) is to be construed under a specific jurisdiction or legal standard.",
        "clause_text": "Company Material Adverse Effect means any event, change, effect, development or occurrence that has had, or would be reasonably expected to have, either individually or in the aggregate, a material adverse effect on the business, property, assets, financial condition or results of operations of the Company and its Subsidiaries, taken as a whole...",
        "reference_section": "ARTICLE Article IX MISCELLANEOUS > Section 9.16 Definitions > Company Material Adverse Effect"
      },
      {
        "section": "law_and_jurisdiction",
        "field_name": "mae_interpretation_jurisdiction",
        "answer": "Not found",
        "summary": "",
        "confidence": 1.0,
        "reason": "",
        "clause_text": "",
        "reference_section": ""
      }
    ],
    "financing_jurisdiction": [
      {
        "section": "law_and_jurisdiction",
        "field_name": "financing_jurisdiction_exists",
        "answer": true,
        "summary": "",
        "confidence": 1.0,
        "reason": "The agreement specifies that any legal action or proceeding relating to or arising out of the agreement shall be brought exclusively in the Delaware Court of Chancery or other courts within the State of Delaware.",
        "clause_text": "Each of the parties hereto irrevocably agrees that any legal action or proceeding relating to or arising out of this Agreement and the rights and obligations hereunder... shall be brought and determined exclusively in the Delaware Court of Chancery and any state appellate court therefrom within the State of Delaware...",
        "reference_section": "ARTICLE Article IX MISCELLANEOUS > Section 9.5 Jurisdiction; Specific Enforcement > (b)"
      },
      {
        "section": "law_and_jurisdiction",
        "field_name": "financing_jurisdiction",
        "answer": "Not found",
        "summary": "",
        "confidence": 1.0,
        "reason": "",
        "clause_text": "",
        "reference_section": ""
      }
    ],
    "arbitration_clause": [
      {
        "section": "law_and_jurisdiction",
        "field_name": "arbitration_clause_exists",
        "answer": false,
        "summary": "",
        "confidence": 1.0,
        "reason": "The agreement specifies that legal actions or proceedings shall be brought exclusively in the Delaware Court of Chancery, indicating no mandate for arbitration.",
        "clause_text": "Each of the parties hereto irrevocably agrees that any legal action or proceeding relating to or arising out of this Agreement and the rights and obligations hereunder, or for recognition and enforcement of any judgment relating to or arising out of this Agreement and the rights and obligations hereunder brought by the other party hereto or its successors or assigns, shall be brought and determined exclusively in the Delaware Court of Chancery.",
        "reference_section": "ARTICLE Article IX MISCELLANEOUS > Section 9.5 Jurisdiction; Specific Enforcement > (b)"
      },
      {
        "section": "law_and_jurisdiction",
        "field_name": "arbitration_clause",
        "answer": "Not found",
        "summary": "",
        "confidence": 1.0,
        "reason": "",
        "clause_text": "",
        "reference_section": ""
      }
    ]
  },
  "financing": {
    "committed_financing": [
      {
        "section": "financing",
        "field_name": "committed_financing_present",
        "answer": false,
        "summary": "",
        "confidence": 1.0,
        "reason": "The document does not mention committed financing or equity support such as a debt commitment letter or equity commitment agreement.",
        "clause_text": "Financing means the debt financing incurred or intended to be incurred in connection with the Transactions by Sodium or its Subsidiaries, including the offering or private placement of debt securities.",
        "reference_section": "ARTICLE IX MISCELLANEOUS > Section 9.16 Definitions > Financing"
      },
      {
        "section": "financing",
        "field_name": "committed_financing_summary",
        "answer": "Not found",
        "summary": "",
        "confidence": 1.0,
        "reason": "",
        "clause_text": "",
        "reference_section": ""
      }
    ],
    "financing_efforts_summary": [
      {
        "section": "financing",
        "field_name": "financing_efforts_summary",
        "answer": "Sodium is obligated to use reasonable best efforts to obtain financing, with the Company providing commercially reasonable cooperation.",
        "summary": "Sodium is obligated to use reasonable best efforts to obtain financing, with the Company providing commercially reasonable cooperation.",
        "confidence": 0.9,
        "reason": "The clause outlines the Company's obligation to cooperate with Sodium in obtaining financing, implying Sodium's obligation to pursue financing.",
        "clause_text": "Prior to the Closing, the Company shall use commercially reasonable efforts to provide to Sodium cooperation (and to cause its Subsidiaries and its and their respective affiliates, officers, directors, employees or Representatives to use their respective commercially reasonable efforts to provide such cooperation) reasonably requested by Sodium that is reasonably necessary in connection with the Financing...",
        "reference_section": "ARTICLE Article VI COVENANTS AND AGREEMENTS > Section 6.17 Company Financing Cooperation > (a)"
      }
    ],
    "substitute_financing_notice_and_efforts": [
      {
        "section": "financing",
        "field_name": "substitute_financing_notice_and_efforts",
        "answer": "Not found",
        "summary": "",
        "confidence": 1.0,
        "reason": "",
        "clause_text": "",
        "reference_section": ""
      }
    ]
  },
  "proxy_statement": {
    "proxy_statement_filing_timing": [
      {
        "section": "proxy_statement",
        "field_name": "proxy_statement_filing_timing",
        "answer": "As promptly as reasonably practicable following the date of this Agreement",
        "summary": "The proxy statement or Form F-4 must be filed as promptly as reasonably practicable following the date of the agreement.",
        "confidence": 0.9,
        "reason": "The clause specifies that the Registration Statement, including the Proxy Statement/Prospectus, should be prepared and filed as promptly as reasonably practicable.",
        "clause_text": "As promptly as reasonably practicable following the date of this Agreement, Sodium and the Company shall jointly prepare the Registration Statement, including the Proxy Statement/Prospectus, and Sodium shall file with the SEC the Registration Statement.",
        "reference_section": "ARTICLE Article VI COVENANTS AND AGREEMENTS > Section 6.5 Filings; Other Actions > (a)"
      }
    ],
    "f4_effectiveness": [
      {
        "section": "proxy_statement",
        "field_name": "f4_effectiveness_efforts",
        "answer": "reasonable best efforts",
        "summary": "The parties must use reasonable best efforts to have the Registration Statement declared effective under the Securities Act as promptly as reasonably practicable after filing.",
        "confidence": 0.9,
        "reason": "The clause explicitly states the use of 'reasonable best efforts' to achieve effectiveness.",
        "clause_text": "Each of Sodium and the Company shall use reasonable best efforts to have the Registration Statement declared effective under the Securities Act as promptly as reasonably practicable after such filing and to keep the Registration Statement effective until the earlier of the Effective Time and the Termination Date.",
        "reference_section": "ARTICLE Article VI COVENANTS AND AGREEMENTS > Section 6.5 Filings; Other Actions > (a)"
      },
      {
        "section": "proxy_statement",
        "field_name": "f4_effectiveness_target_date",
        "answer": "Not found",
        "summary": "",
        "confidence": 1.0,
        "reason": "",
        "clause_text": "",
        "reference_section": ""
      }
    ],
    "shareholder_meeting": [
      {
        "section": "proxy_statement",
        "field_name": "shareholder_meeting_timing",
        "answer": "The shareholder meeting is expected to be held as promptly as practicable after the Registration Statement is declared effective under the Securities Act, but in no event later than sixty (60) days thereafter.",
        "summary": "The shareholder meeting is expected to be held as promptly as practicable after the Registration Statement is declared effective under the Securities Act, but in no event later than sixty (60) days thereafter.",
        "confidence": 0.9,
        "reason": "The document specifies the timing of the shareholder meeting in relation to the effectiveness of the Registration Statement.",
        "clause_text": "The Company shall ... convene and hold the Company Stockholder Meeting, to be held as promptly as practicable after the Registration Statement is declared effective under the Securities Act (but in no event later than sixty (60) days thereafter).",
        "reference_section": "ARTICLE Article VI COVENANTS AND AGREEMENTS > Section 6.5 Filings; Other Actions > (b)"
      },
      {
        "section": "proxy_statement",
        "field_name": "shareholder_meeting_deadline",
        "answer": "60 days",
        "summary": "The Company Stockholder Meeting must be held as promptly as practicable after the Registration Statement is declared effective under the Securities Act, but in no event later than sixty (60) days thereafter.",
        "confidence": 0.9,
        "reason": "The document specifies a clear deadline for holding the shareholder meeting after the Registration Statement is declared effective.",
        "clause_text": "The Company shall ... convene and hold the Company Stockholder Meeting, to be held as promptly as practicable after the Registration Statement is declared effective under the Securities Act (but in no event later than sixty (60) days thereafter).",
        "reference_section": "ARTICLE Article VI COVENANTS AND AGREEMENTS > Section 6.5 Filings; Other Actions > (b)"
      },
      {
        "section": "proxy_statement",
        "field_name": "shareholder_vote_efforts",
        "answer": "reasonable best efforts",
        "summary": "The company is required to use reasonable best efforts to solicit proxies in favor of the adoption of the agreement and to obtain shareholder approval.",
        "confidence": 0.9,
        "reason": "The clause explicitly states the use of 'reasonable best efforts' to solicit proxies and obtain shareholder approval.",
        "clause_text": "Subject to a Company Change of Recommendation in accordance with Section 6.4, the Company shall include the Company Recommendation in the Proxy Statement/Prospectus and use reasonable best efforts to solicit from its stockholders proxies in favor of the adoption of this Agreement.",
        "reference_section": "ARTICLE Article VI COVENANTS AND AGREEMENTS > Section 6.5 Filings; Other Actions > (b)"
      },
      {
        "section": "proxy_statement",
        "field_name": "shareholder_meeting_postponment",
        "answer": "Not Found",
        "summary": "",
        "confidence": 1.0,
        "reason": "",
        "clause_text": "",
        "reference_section": ""
      }
    ],
    "parent_shareholder_meeting": [
      {
        "section": "proxy_statement",
        "field_name": "parent_shareholder_meeting_timing",
        "answer": "Not found",
        "summary": "",
        "confidence": 1.0,
        "reason": "",
        "clause_text": "",
        "reference_section": ""
      },
      {
        "section": "proxy_statement",
        "field_name": "parent_shareholder_meeting_deadline",
        "answer": "Not found",
        "summary": "",
        "confidence": 1.0,
        "reason": "",
        "clause_text": "",
        "reference_section": ""
      },
      {
        "section": "proxy_statement",
        "field_name": "parent_shareholder_vote_efforts",
        "answer": "Not found",
        "summary": "",
        "confidence": 1.0,
        "reason": "",
        "clause_text": "",
        "reference_section": ""
      },
      {
        "section": "proxy_statement",
        "field_name": "parent_shareholder_meeting_postponment",
        "answer": "Not found",
        "summary": "",
        "confidence": 1.0,
        "reason": "",
        "clause_text": "",
        "reference_section": ""
      }
    ],
    "proxy_summary_notes": [
      {
        "section": "proxy_statement",
        "field_name": "proxy_summary_notes",
        "answer": "The agreement contains notable terms related to proxy or shareholder voting, including the requirement for the Company to submit a proposal for the adoption of the agreement at the Company Stockholder Meeting, with no other proposals allowed without Sodium's consent. The Company must also use reasonable best efforts to solicit proxies in favor of the agreement and may adjourn the meeting to ensure sufficient votes or quorum.",
        "summary": "The agreement mandates the Company to submit a proposal for adoption at the Stockholder Meeting, restricts other proposals without consent, and requires efforts to solicit proxies in favor. The meeting can be adjourned for vote solicitation or quorum.",
        "confidence": 0.9,
        "reason": "The language specifies the Company's obligations regarding the Stockholder Meeting and proxy solicitation, implying notable terms for shareholder voting.",
        "clause_text": "The Company shall (i) submit to its stockholders a proposal for the adoption of this Agreement at the Company Stockholder Meeting and shall not submit any other proposal to the Company's stockholders in connection with the Company Stockholder Meeting (other than a non-binding, advisory vote to approve the compensation that may be received by Company executive officers in connection with the Merger and a customary proposal regarding adjournment of the Company Stockholder Meeting) without the prior written consent of Sodium, which consent shall not be unreasonably withheld, delayed or conditioned, (ii) cause the Proxy Statement/Prospectus to be mailed to each of the Company's stockholders as promptly as reasonably practicable...",
        "reference_section": "ARTICLE Article VI COVENANTS AND AGREEMENTS > Section 6.5 Filings; Other Actions > (b)"
      }
    ],
    "dissenting_shares_cap": [
      {
        "section": "proxy_statement",
        "field_name": "dissenting_shares_cap",
        "answer": "NA",
        "summary": "",
        "confidence": 1.0,
        "reason": "",
        "clause_text": "",
        "reference_section": ""
      }
    ]
  },
  "timeline": {
    "agreement_signing_date": [
      {
        "section": "timeline",
        "field_name": "agreement_signing_date",
        "answer": "April 2, 2024",
        "summary": "The Agreement and Plan of Merger was signed on April 2, 2024, as indicated in the preamble of the document.",
        "confidence": 1.0,
        "reason": "The date is explicitly stated in the preamble of the Agreement and Plan of Merger.",
        "clause_text": "This AGREEMENT AND PLAN OF MERGER (this \"Agreement\"), dated as of April 2, 2024, is by and among Schlumberger Limited, a Curaçao corporation (\"Sodium\"), Sodium Holdco, Inc., a Delaware corporation and indirect wholly owned Subsidiary of Sodium, (\"Sodium US\"), Sodium Merger Sub, Inc., a Delaware corporation and direct wholly owned Subsidiary of Sodium US (\"Merger Sub\"), and ChampionX Corporation, a Delaware corporation (the \"Company\").",
        "reference_section": "ARTICLE Preamble"
      }
    ],
    "confidentiality_agreement_signing_date": [
      {
        "section": "timeline",
        "field_name": "confidentiality_agreement_signing_date",
        "answer": "March 8, 2024",
        "summary": "The confidentiality agreement related to the merger was signed on March 8, 2024, as specified in the document.",
        "confidence": 1.0,
        "reason": "",
        "clause_text": "The parties hereto hereby agree that all information provided to them or their respective officers, directors, employees or Representatives in connection with this Agreement and the consummation of the Transactions shall be governed in accordance with the confidentiality agreement, dated as of March 8, 2024, between the Company and Sodium (the \"Confidentiality Agreement\").",
        "reference_section": "ARTICLE Article VI COVENANTS AND AGREEMENTS > Section 6.3 Mutual Access > (b)"
      }
    ],
    "announcement_date": [
      {
        "section": "timeline",
        "field_name": "announcement_date",
        "answer": "Not found",
        "summary": "",
        "confidence": 1.0,
        "reason": "",
        "clause_text": "",
        "reference_section": ""
      }
    ],
    "proxy_filing_deadline": [
      {
        "section": "timeline",
        "field_name": "proxy_filing_deadline",
        "answer": "As promptly as reasonably practicable",
        "summary": "The preliminary proxy statement and/or registration statement on Form F-4 must be filed as promptly as reasonably practicable following the signing of the agreement.",
        "confidence": 0.9,
        "reason": "The clause specifies that the filing should occur 'as promptly as reasonably practicable' after the agreement date.",
        "clause_text": "As promptly as reasonably practicable following the date of this Agreement, Sodium and the Company shall jointly prepare the Registration Statement, including the Proxy Statement/Prospectus, and Sodium shall file with the SEC the Registration Statement.",
        "reference_section": "ARTICLE Article VI COVENANTS AND AGREEMENTS > Section 6.5 Filings; Other Actions > (a)"
      }
    ],
    "shareholder_vote_deadline": [
      {
        "section": "timeline",
        "field_name": "shareholder_vote_deadline",
        "answer": "sixty (60) days",
        "summary": "The shareholder vote must occur no later than sixty (60) days after the Registration Statement is declared effective under the Securities Act.",
        "confidence": 0.9,
        "reason": "The document specifies that the Company Stockholder Meeting must be held no later than sixty (60) days after the Registration Statement is declared effective.",
        "clause_text": "The Company shall ... convene and hold the Company Stockholder Meeting, to be held as promptly as practicable after the Registration Statement is declared effective under the Securities Act (but in no event later than sixty (60) days thereafter).",
        "reference_section": "ARTICLE Article VI COVENANTS AND AGREEMENTS > Section 6.5 Filings; Other Actions > (b)"
      }
    ],
    "outside_date": [
      {
        "section": "timeline",
        "field_name": "outside_date",
        "answer": "April 2, 2025",
        "summary": "The initial 'Outside Date' specified in the agreement is April 2, 2025, which is the earliest date on which either party may terminate the agreement if the merger has not yet closed.",
        "confidence": 1.0,
        "reason": "",
        "clause_text": "by either the Company or Sodium, if the Merger shall not have been consummated on or prior to April 2, 2025 (the \"End Date\");",
        "reference_section": "ARTICLE Article VIII TERMINATION > Section 8.1 Termination or Abandonment"
      },
      {
        "section": "timeline",
        "field_name": "outside_date_extension_list",
        "answer": "1. Extension Length – 6 months; Who Grants the Extension – Automatic; Conditions to Extend – All conditions to Closing, other than those in Section 7.1(c), Section 7.1(d), or at Sodium's election, Section 7.3(d), must be satisfied or capable of being satisfied; Termination Restrictions Due to Breach – Yes, the right to terminate is not available if the party's material breach caused the failure to close.",
        "summary": "The Outside Date may be automatically extended by 6 months if all conditions to Closing, except certain specified ones, are satisfied or capable of being satisfied. Termination rights are restricted if a party's material breach caused the failure to close.",
        "confidence": 1.0,
        "reason": "",
        "clause_text": "provided, however, that if all of the conditions to Closing, other than any of the conditions set forth in Section 7.1(c), Section 7.1(d) or, at the election of Sodium, Section 7.3(d) (such election, an \"Extension Election\"), shall have been satisfied or shall be capable of being satisfied at such time (other than those conditions that by their nature are to be satisfied at the Closing), the End Date shall automatically be extended to October 2, 2025, which date shall thereafter be deemed to be the End Date; provided, further, that the right to terminate this Agreement pursuant to this Section 8.1(b) shall not be available to a party if the failure of the Closing to occur by such date shall be due to the material breach by such party of any representation, warranty, covenant or other agreement of such party set forth in this Agreement;",
        "reference_section": "ARTICLE Article VIII TERMINATION > Section 8.1 Termination or Abandonment"
      }
    ],
    "hsr_filing_deadline": [
      {
        "section": "timeline",
        "field_name": "hsr_filing_deadline",
        "answer": "15 business days after the date hereof",
        "summary": "The deadline for submitting initial filings under the HSR Act is no later than fifteen (15) business days after the date of the agreement, unless a later date is mutually agreed upon by the parties in writing.",
        "confidence": 0.95,
        "reason": "The document explicitly states the deadline for HSR Act filings.",
        "clause_text": "Subject to the terms and conditions herein provided and without limiting the foregoing, the Company and Sodium shall (i) promptly, but in no event later than fifteen (15) business days after the date hereof (unless a later date is mutually agreed by the parties in writing), make their respective filings under the HSR Act.",
        "reference_section": "ARTICLE Article VI COVENANTS AND AGREEMENTS > Section 6.7 Regulatory Approvals; Efforts > (b)"
      }
    ],
    "second_request_deadline": [
      {
        "section": "timeline",
        "field_name": "second_request_deadline",
        "answer": "Not found",
        "summary": "",
        "confidence": 1.0,
        "reason": "",
        "clause_text": "",
        "reference_section": ""
      }
    ],
    "cfius_filing_deadline": [
      {
        "section": "timeline",
        "field_name": "cfius_filing_deadline",
        "answer": "Not found",
        "summary": "",
        "confidence": 1.0,
        "reason": "",
        "clause_text": "",
        "reference_section": ""
      }
    ],
    "marketing_period_dates": [
      {
        "section": "timeline",
        "field_name": "marketing_period_dates",
        "answer": "Not found",
        "summary": "",
        "confidence": 1.0,
        "reason": "",
        "clause_text": "",
        "reference_section": ""
      }
    ],
    "inside_date": [
      {
        "section": "timeline",
        "field_name": "inside_date",
        "answer": "Not found",
        "summary": "",
        "confidence": 1.0,
        "reason": "",
        "clause_text": "",
        "reference_section": ""
      }
    ],
    "closing_date": [
      {
        "section": "timeline",
        "field_name": "closing_date",
        "answer": "second business day after the satisfaction or waiver of the conditions set forth in Article VII",
        "summary": "The closing of the Merger is scheduled to occur on the second business day following the satisfaction or waiver of specified conditions.",
        "confidence": 0.9,
        "reason": "The document explicitly states the closing date formula based on the satisfaction or waiver of conditions.",
        "clause_text": "The closing of the Merger (the \"Closing\") shall take place at the offices of Latham & Watkins LLP, 811 Main Street, Suite 3700, Houston, Texas, 77002, at 10:00 a.m., local time, on the second (2nd) business day after the satisfaction or waiver (to the extent permitted by applicable Law) of the conditions set forth in Article VII...",
        "reference_section": "ARTICLE Article I THE MERGER > Section 1.2 Closing"
      }
    ],
    "conditions_satisfaction_end_date": [
      {
        "section": "timeline",
        "field_name": "conditions_satisfaction_end_date",
        "answer": "April 2, 2025",
        "summary": "The agreement specifies that the merger must be consummated on or prior to April 2, 2025, unless extended under certain conditions.",
        "confidence": 0.9,
        "reason": "The document explicitly states the End Date for the merger, which serves as the deadline for satisfying all conditions.",
        "clause_text": "by either the Company or Sodium, if the Merger shall not have been consummated on or prior to April 2, 2025 (the \"End Date\"); provided, however, that if all of the conditions to Closing, other than any of the conditions set forth in Section 7.1(c), Section 7.1(d) or, at the election of Sodium, Section 7.3(d) (such election, an \"Extension Election\"), shall have been satisfied or shall be capable of being satisfied at such time (other than those conditions that by their nature are to be satisfied at the Closing), the End Date shall automatically be extended to October 2, 2025, which date shall thereafter be deemed to be the End Date;",
        "reference_section": "ARTICLE Article VIII TERMINATION > Section 8.1 Termination or Abandonment"
      }
    ]
  }
}